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Abstract 
Nicotinamide adenine dinucleotide (NAD+) is both an essential redox coenzyme and 
a substrate for NAD+-consuming enzymes, such as the sirtuins, which adapt 
transcriptional programmes to increase energy availability. Skeletal muscle is a 
major regulator of energy metabolism and its function is impaired with ageing. 
Uncovering the key routes regulating NAD+ availability may provide valuable insight 
into novel aspects of skeletal muscle metabolic health. Data presented here 
identifies a limited set of enzymes important for skeletal muscle NAD+-biosynthesis 
namely; nicotinamide phosphoribosyltransferase (NAMPT) and nicotinamide riboside 
kinases (NMRK) 1 and 2, which salvage vitamin B3s nicotinamide (NAM) and 
nicotinamide riboside (NR) to NAD+. NAMPT was confirmed vital for recycling of 
NAM, with NAD+ depleted in myotubes following NAMPT inhibition.  Single and 
double NMRK knockout mouse models found NMRK activity non-essential for 
maintaining basal NAD+, with activity restricted by NR availability. Exogenous NR 
delivery enhanced NAD+ and recovered the effects of NAD+ depletion following 
NAMPT inhibition. NMRK2 was determined highly muscle-specific; although energy 
signalling was mostly unperturbed in NMRK2KOs, in vivo data indicated impaired 
metabolic flexibility following high fat diet. While the muscle-specific role of NMRK2 
requires further investigation, this thesis identifies NMRK1/2 as important therapeutic 
targets for enhancing NAD+ by NR supplementation.     
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Chapter 1 General Introduction 
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1.1 Skeletal muscle metabolism 
Skeletal muscle is an essential contractile tissue made up of myofibres and 
connective tissue, integrated with neural and vascular networks [1]. As the largest 
organ by mass, accounting for around 40% of a healthy adult’s total body mass, 
maintaining muscle health and function is vital for preserving systemic 
homeostasis [1].     
1.1.1 Skeletal muscle structure 
 
Figure 1.1 Skeletal muscle structure 
Individual myofibres are surrounded by connective tissue (endomysium). They are 
bundled into fascicles and held by further connective tissue (perimysium). 
Fascicles are grouped together to form muscle tissue and coated by an outer 
membrane (epimysium). 
 
Skeletal muscle is one of three main muscle types (skeletal, cardiac and smooth 
muscle) [2] characterised by its multinucleated, long and cylindrical shaped cells 
and is under the voluntary control of the somatic nervous system (SNS) [1]. These 
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multinucleated cells are known as myofibres, which are individually coated with a 
layer of connective tissue called the endomysium. Muscle fibres are bundled 
together by further connective tissue, the perimysium, to form muscle fascicules 
and the entire muscle is surrounded by the epimysium, an outer layer of 
connective tissue (figure 1.1) [3, 4].  
Myofibres are composed of filamentous bundles, known as myofibrils, which 
extend across the whole length of the fibre [5].  Actin and myosin are the two main 
myofilaments in muscle but troponin and tropomyosin also play an important role. 
The filaments are grouped by appearance into thin (actin, troponin and 
tropomyosin) and thick filaments (myosin) [6]. The arrangement of thick and thin 
myofilaments within individual myofibrils is known as a sarcomere; the striated 
appearance of skeletal muscle is a result of repeated alignment of sarcomeres 
within myofibres. Individual sarcomere regions were originally described due to 
their appearance and named using alphabetical letters. The dark anisotropic 
region of the sarcomere refracts polarised light and is known as the A band, in 
contrast the lighter isotropic region does not refract polarised light and is termed 
the I band. The line dividing the I band is called the Z line and one Z line to the 
next makes up one sarcomere unit (figure 1.2) [7].          
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Figure 1.2 Structure of individual myofibres 
Different levels of myofibre structure. Myofibrils are packed into a multinucleated 
myotubes (top). The sarcomere unit of Individual myofibrils consists of aligned 
myofilaments (bottom).  
 
1.1.2 Myogenesis 
During mammalian embryonic development skeletal muscle of the vertebrate 
mostly originates from lateral plate and paraxial somatic mesoderm [8]. Following 
somite segmentation, the dermomyotome is formed and involution of these cells 
gives rise to the myotome. The process of skeletal myogenesis is a 2-step process 
which firstly requires the commitment of mesodermal cells to myoblasts and then 
terminal differentiation of myoblasts to myotubes. Both steps are highly regulated 
by a number of myogenic regulatory factors (MRFs) including Myf5, MyoD, 
myogenin and MRF4. Myf5 is the earliest MRF to be expressed during muscle 
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development [9], and is thought to be an important muscle commitment factor, 
followed by MyoD, MRF4 and myogenin; the latter three are thought to play a role 
in terminal differentiation (figure 1.3 demonstrates a simplified example of 
myogenesis). Importantly, numerous single and combined loss of function studies 
show incredible redundancy of these MRFs during muscle development and their 
roles are not limited to either stage of myogenesis [10].   
 
Figure 1.3 Myogenesis 
A simplified outline of skeletal muscle myogenesis. This highly regulated process 
involves several MRFs allowing progenitor cell commitment to myoblasts and 
differentiation into multinucleated myotubes which are then arranged into 
myofibres. 
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As myotubes are post-mitotic, the highly regenerative capacity of muscle is 
coordinated by a unique subset of cells known as satellite cells. Satellite cells are 
myogenic precursor cells, with stem-cell like properties, that are located on the 
surface of terminally differentiated myotubes [11].  In sedentary adult muscle they 
typically remain quiescent, expressing the transcription factor paired box 7(Pax-7). 
In response to physiological (exercise) and pathological (muscle cell death or 
injury) stimuli, satellite cells are taken out of quiescence by the upregulation of 
Myf5 and MyoD [12]. Activation of satellite cells allows muscle regeneration 
through cell proliferation, myogenic commitment, and differentiation; in a process 
regulated by MRFs akin to embryonic muscle development (figure 1.3). Differential 
expression of these myogenic factors, alongside extensive intracellular and 
extracellular signalling cascades induced by muscle injury (e.g. downregulation of 
notch signalling and upregulation of Wnt signalling), subsequently drives 
activation, proliferation, and differentiation [12].  
1.1.3 Skeletal muscle function 
Skeletal muscle typically coincides alongside bone and connective tissue to form 
the musculoskeletal system crucial for stability, locomotion of the body and 
physiological respiration [13, 14]. These vital physiological processes are 
coordinated through excitation-contraction coupling in response to motor neuron 
signalling with tension generated by muscle contraction. Following somatic neural 
stimulation, an action potential is fired leading to calcium (Ca2+) release from the 
sarcoplasmic reticulum (SR) into the sarcoplasm of muscle cells. A surge in free 
Ca2+ leads to reformation of the complex formed by actin, troponin and 
tropomyosin filaments; whereby troponin binds to free Ca2+ and changes position. 
This allows actin to interact with the head groups of myosin filaments. Binding of 
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adenosine triphosphate (ATP) to myosin heads leads to dissociation from actin 
filaments and subsequent hydrolysis of ATP causes a change in to angle of the 
myosin head and results in movement along the actin filament and shortening of 
the sarcomere. This process is repeated with further ATP, and as the filaments 
appear to slide over each other this interaction was termed the ‘sliding filament 
theory’ (figure 1.4) [15-17]. Although skeletal muscle is both structurally and 
functionally distinct from cardiac and smooth muscle, the actin-myosin driven 
contractile process between the three different muscle types remains similar.   
 
Figure 1.4 The sliding filament theory 
(1) ATP hydrolysis by myosin heads leads to a conformational change (2) allowing 
the myosin heads to bind actin filaments and form crossbridges. (3) Through a 
‘powerstroke’, myosin heads move towards the middle of the sarcomere and (4) 
then binding of ATP to the myosin heads leads to dissociation of crossbridges 
ready for the cycle to start again.  
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1.1.4 Skeletal muscle fibre types 
Muscle fibre composition is heterogeneous. The three muscle fibre types in 
mammalians are type 1, type 2A and type 2X (humans or 2B rodents), determined 
by the expression of different myosin heavy chain isoforms (MYH7, MYH2 and 
MYH1 (or MYH4) respectively) [18, 19]. Type 1 and 2A are typically more 
oxidative while type 2X fibres are glycolytic [20]. Although in most cases fibre type 
composition is mixed, the distribution of different fibre types that make up an 
individual muscle mostly depends on the activity the muscle is intended to do. 
Muscles important for endurance or low intensity activity, such as maintaining 
posture, are predominantly composed of oxidative (slow-twitch) fibres, whereas 
muscles intended for high intensity exercise such as weightlifting are mostly 
composed of glycolytic (fast-twitch) fibres [21]. Table 1.1 demonstrates some of 
the key differences between the muscle fibre types [19, 22]. For example, 
oxidative fibres have a good blood supply to deliver fuel and oxygen, they resist 
fatigue and are abundant in mitochondria allowing a high oxidative capacity. On 
the other hand, glycolytic fibres typically, generate strong force, have lower levels 
of mitochondria and myoglobin due to their preference of non-oxidative 
metabolism. Further factors that influence fibre type composition include age, 
metabolic health and exercise training [23-25].  
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 Type 1  Type 2A  Type 2X  Type 2b  
Activity Oxidative / 
aerobic 
Oxidative-glycolytic / 
mostly aerobic 
Glycolytic / 
anaerobic 
Glycolytic / 
anaerobic 
Fatigue resistance High Fairly high intermediate Low 
Contraction time Slow Moderately fast Fast Very fast 
Myosin heavy chain MYH7 MYH2 MYH1 MYH4 
Force production Weak Moderate Strong Very strong 
Blood supply Good Good Poor Poor 
Mitochondria Rich Rich Poor Poor 
Myoglobin content  Rich Rich Poor Poor 
Oxidative capacity Very high High Low Low 
Glycolytic capacity Low Intermediate High High 
Main fuel storage Triglycerides Creatine phosphate, 
glycogen, 
triglycerides 
Creatine 
phosphate, 
glycogen 
Creatine 
phosphate, 
glycogen 
Table 1.1 – Muscle fibre properties in humans and rodents [19, 22] 
 
1.1.5 Skeletal muscle energy metabolism 
Further to physical movement, skeletal muscle plays a crucial role in energy 
metabolism and nutrient storage [26, 27]. As the largest organ by mass, skeletal 
muscle is the body’s major site of glycogen storage and acts as an energy 
reservoir to sustain systemic energy homeostasis and deal with perturbations 
following metabolic stresses like physical activity, food intake or fasting by 
modulating glucose uptake and glycogen breakdown [28, 29].  During metabolic 
stress, muscle demonstrates high plasticity through its ability to metabolically 
adapt both acutely and chronically in response to environmental cues, intrinsic 
hormonal signals and myokines to meet changing energy requirements [30, 31]. 
Metabolic adaptations include modulating mitochondrial biogenesis and function, 
myogenesis or atrophy, glucose mobilisation, fuel substrate use, blood flow, fibre-
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type composition and fibre size [23, 32]. However, the adaptive response of 
muscle can be compromised in numerous disease states including diabetes, 
cancer cachexia and chronic obstructive pulmonary disease (COPD) with muscle 
wasting and impaired energy homeostasis common [33-35].    
The primary fuel source used in muscle to produce ATP is dependent on the type 
of muscle activity and energy demand. The main fuels stored in muscle tissue are 
glycogen, creatine phosphate, and triglycerides (figure 1.5) [36, 37]. Creatine 
phosphate provides a rapid short-term energy source that is metabolised to 
creatine, whilst donating a phosphate group to ADP in the process [37]. 
Alternatively, glycogen stores can be broken down to glucose and used to fuel 
sustained activity [38]. During anaerobic glycolysis a chain of enzymatic reactions 
generate ATP through the breakdown of glucose to pyruvate [39]. For endurance 
activities, a much greater supply of energy is required and under aerobic 
conditions pyruvate enters the mitochondria and is converted to acetyl Coenzyme 
A (acetyl CoA).  Acetyl CoA is oxidised in the Krebs cycle and importantly results 
in the reduction of NAD+ to NADH; an essential reducing agent for driving 
oxidative phosphorylation and leading to larger scale ATP production [39, 40]. 
Finally, fatty acids can be broken down to provide an alternative source of acetyl 
CoA and ultimately generate ATP. Triglycerides stored in adipose tissue are 
broken down by lipolysis to glycerol and free fatty acids. The fatty acids can then 
be transported to other cells where they react with coenzyme A (CoA) to produce 
acyl-CoA, which finally undergoes β-oxidation resulting in acetyl-CoA to fuel the 
Krebs cycle [41].  
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Figure 1.5 The important fuel sources for skeletal muscle energy production 
Skeletal muscle acts as a major energy fuel store. For acute activity, it can use 
creatine phosphate to generate ATP and creatine. Muscle also stores glycogen 
that can be broken down to glucose and used for glycolysis. For sustained activity, 
oxidative metabolism is required to produce larger quantities of ATP. In 
oxygenated conditions, pyruvate from glycolysis can enter the TCA cycle. Fatty 
acids can be transported through the circulation to the muscle and β-oxidation 
leads to acetyl-CoA production. During starvation muscle protein can be broken 
down providing amino acids which can be used to assemble substrates for the 
TCA cycle (e.g. pyruvate).  
 
 
Alternatively, when muscle energy stores are depleted (typically in starvation) 
amino acids from muscle protein itself can be used to generate ATP. Muscle 
degradation releases amino acids such as alanine for hepatic gluconeogenesis or 
in some cases (mostly leucine, isoleucine, and valine) in the muscle. This allows 
the building of substrates for energy production including pyruvate and 
intermediates of the TCA cycle [42, 43]. However, the use of amino acids from 
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muscle for energy is limited as excessive breakdown of muscle protein can lead to 
muscle atrophy if protein degradation exceeds protein synthesis [44].  
1.1.6 Metabolic adaptation to exercise 
Adaptive changes that manifest in muscle during metabolic stress demonstrate its 
plasticity in response to scenarios that may otherwise threaten energy 
homeostasis, including exercise, food consumption and fasting. For example, 
contracting muscle during exercise leads to a surge in ATP consumption [45]. 
Thus, widespread metabolic adaptation is necessary for the muscle to meet the 
increased energy requirements during the bout of exercise as well as improving 
muscle performance and endurance during repeated bouts of exercise. A large 
array of genomic, proteomic and metabolic changes are stimulated in skeletal 
muscle during and following exercise. Contraction induced cues (including 
posttranslational modifications and changes to metabolite levels) selectively 
activate transcription factors central to regulating metabolic genes; permitting 
molecular reprogramming. Some of the many important adaptive response targets 
include forkhead transcription factor (FOXO1), cyclic AMP response element 
binding protein (CREB), histone deacetylase (HDAC), Myogenic regulatory factors 
(MRFs), peroxisome proliferator-activated receptor gamma coactivator-1-alpha 
(PGC1α), mitochondrial transcription factor A (Tfam), nuclear respiratory factor 
(NRF) and glucose transporter 4 (GLUT4) [46]. Important targets of metabolic 
adaptations include energy production pathways (oxidative phosphorylation and 
carbohydrate metabolism), myogenesis, lipid mobilisation, increased blood flow 
and mitochondrial biogenesis to support mitochondrial metabolism and ATP 
generation (figure 1.6). Metabolic reprogramming intends to maximise substrate 
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delivery and in turn enhance glycolytic activity and/or mitochondrial oxidative 
capacity; allowing improved performance and resistance to fatigue on repeat [46].  
 
 
 
Figure 1.6 Pathways and responses involved in metabolic adaptation 
An overview of important pathways targeted during the adaptive response to 
exercise and the desired outcomes. Metabolic and transcription reprogramming 
results in both systemic and local adaptations. Systemic changes include 
increased blood flow and delivery of substrates (lipids, glucose). Local adaptations 
include the release of growth factors and myokines to act upon cell receptors and 
induce cellular signalling cascades. Intrinsic changes induced by contacting 
muscle such as, substrate depletion, hypoxia and lactate accumulation combine 
with local and systemic signalling to drive metabolic adaptation [30].     
 
The specific adaptations seen in response to exercise are dependent on the type 
of exercise performed [46]. Table 1.2 demonstrates some of the common skeletal 
muscle metabolic adaptations following high intensity and endurance exercise. 
Metabolic adaptation following high intensity exercise mostly leads to muscle 
hypertrophy with an increase in protein synthesis and muscle strength; whereas 
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adaptations following endurance activity target oxidative performance through 
enhanced mitochondrial function [46-48].  
 Table 1.2 – Skeletal muscle metabolic adaptations following exercise ([+] is an 
increase, [=] is unchanged and [ ̶ ]  is a decrease, +++ is high, ++ is intermediate, 
+ small and + / = is a slight change).  
 
Exercise training also results in adaptations to systemic metabolism including; 
elevated bone mineral density, increased insulin sensitivity, lower percentage 
body fat, reduced inflammatory markers and increased basal metabolic rate [49-
52]. Together, these systemic and muscle specific adaptations demonstrate the 
globally beneficial health effects of physical activity and highlights the importance 
of understanding the key interactions and regulators involved in metabolic 
adaptation.  
1.1.7 Mitochondrial biogenesis and metabolism 
Mitochondria are distinct double membraned organelles with their own circular 
genome at around 16 Kb in size and can divide independently from the cell [53, 
 High intensity Endurance 
Muscle mass + + + = 
Mitochondrial biogenesis + + + + 
Myofibrillar protein synthesis + + + + / = 
Mitochondrial protein 
synthesis = / + + + 
Contractile force + + + = /  ̶ 
Capillarisation = + + 
Endurance capacity = / + + + + 
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54]. They evolved by endosymbiosis from bacteria residing in larger cells and still 
share some characteristics with bacteria [55].  Mitochondria are known as the 
‘powerhouses’ of cells; providing ATP by oxidative phosphorylation and are 
therefore abundant in skeletal muscle, particularly in slow-twitch fibres, to ensure 
energy production meets demand [22, 40]. Mitochondrial biogenesis is a process 
that results in the growth and division of mitochondria and is essential for 
maintaining function. Studies have shown disruption to mitochondrial biogenesis 
during ageing – associated with a reduction in activity of mitochondrial regulatory 
proteins such as AMP-activated protein kinase (AMPK) – results in reduced 
mitochondrial function [56]. There are numerous contributory factors regulating 
mitochondrial biogenesis including physical activity, calorie restriction, oxidative 
stress, cold temperatures, cell regeneration, cell differentiation, age and disease 
[57-59]. Mitochondrial biogenesis is normally coordinated in parallel to an increase 
in mitochondrial size and mass; collectively resulting in enhanced mitochondrial 
capacity. PGC1α is the principal coordinator of mitochondrial biogenesis, and on 
activation by deacetylation it activates cohorts of mitochondrial transcription 
factors, including nuclear respiratory factor (NRF) 1 and 2, uncoupling protein 2 
(UCP2) and mitochondrial transcription factor A (TFAM), required for the 
transcription and replication of mitochondrial DNA [57-59].  
As a master regulator of mitochondrial biogenesis, PGC1α is highly modulated by 
upstream energy sensing proteins such as AMPK [56]. AMPK acts as an energy 
sensor within the cell to ensure ATP consumption and generation are tightly 
regulated. When ATP levels drop, such as during exercise, a rise in AMP or ADP 
leads to the activation of AMPK [31], which coordinates the reprogramming of 
cellular energy pathways to enhance energy production and inhibit consumption 
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[60, 61]. Importantly, AMPK can directly phosphorylate PGC1α and upregulate 
expression of metabolic genes (including GLUT4, Cytochrome C, UCP2 and 
UCP3) to stimulate mitochondrial biogenesis and ultimately enhance ATP 
production [62]. Another notable regulator of PGC1α is the NAD+-dependent 
enzyme Sirtuin1 (SIRT1), which responds to an increase in NAD+ levels during 
metabolic stress and activates PGC1α by deacetylation [31, 63]. Together, these 
reversible post-translational modifications to PGC1α allow rapid and highly 
sensitive modulation of mitochondrial biogenesis.  
1.2 NAD+: History and classic functions 
The coenzyme NAD+ is a vital cellular signalling intermediate first identified more 
than a century ago as a cofactor in yeast fermentation and now widely known for 
its essential role in energy production [64-66]. It consists of a nicotinamide and an 
adenine nucleotide joined by respective phosphate groups to form a dinucleotide 
and exists in both an oxidised (NAD+) and reduced (NADH) forms (figure 1.7). 
Oxidised NAD+ accepts electrons from molecules and is thereby reduced to 
NADH; this transfer of electrons allows oxidoreductase enzymes to catalyse 
transhydrogenase reactions. Otto Warburg further determined the importance of 
NAD+ as a cofactor and it is now well recognised that NAD(H) in both its oxidised 
and reduced form is essential to many fundamental cellular processes [67]. 
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Figure 1.7 NAD(H) as a coenzyme  
Reversible hydride transfer by NAD redox reactions. During oxidation NAD+ 
accepts electrons and is reduced to NADH. NADH may then act as a reducing 
agent by donating electrons.    
 
Although not limited to energy production, the vital role of NAD+ as a redox 
cofactor for rate limiting enzymes in pathways that generate ATP, such as 
glycolysis and oxidative phosphorylation, is well demonstrated [68] . NADH can be 
generated from the reduction of NAD+ in glycolysis, whereby NAD+ acts as an 
essential cofactor for glyceraldehyde-3-phosphate dehydrogenase activity, 
converting glyceraldehyde-3-phosphate to 1,3-biphosphoglycerate [69]. Under 
oxidative conditions pyruvate, ultimately produced from glycolysis can be 
metabolised to acetyl CoA by pyruvate dehydrogenase with NAD+ concurrently 
reduced to NADH [70].  Alternatively, fatty acid oxidation and oxidation of ketone 
bodies can also produce acetyl CoA and both processes also feature enzymes 
that require NAD+ as a cofactor (e.g. long-chain 3-hydroxyacyl-CoA 
dehydrogenase, hydroxyacyl-CoA dehydrogenase and D-β-hydroxybutyrate 
dehydrogenase) [71, 72]. The TCA cycle hosts further NAD+ redox enzymes 
(isocitrate dehydrogenase, α-ketoglutarate dehydrogenase and malate 
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dehydrogenase) [73]. The reduction of NAD+ to NADH by these enzymes is 
essential to drive the electron transport chain (with FAD+ to FADH) by donating 
electrons to acceptors (figure 1.8) [72]. Depletion of cellular NAD+ has been shown 
to impede glycolysis and oxidative phosphorylation, ultimately leading to a loss in 
cellular ATP and cell death; demonstrating the importance of redox signalling 
pathways [74-76].    
Notably, NAD+ can also be phosphorylated by NAD kinase (NADK) to NADP+ and 
similarly this also exists in its reduced form NADPH. NADPH acts as an important 
reducing agent aiding many anabolic pathways including nucleic acid and lipid 
biosynthesis [77]. NADPH can be generated by the pentose phosphate pathway 
through glucose-6-phosphate dehydrogenase and phosphogluconate 
dehydrogenase redox activity where by ribose-5-phospate can be also produced 
for nucleotide and nucleic acid synthesis [78, 79]. NADPH also plays an important 
role is alleviating oxidative stress following an increase in the production of 
reactive oxygen species by acting as an essential reducing factor for antioxidants 
such as glutathione that remove hydrogen peroxide, a downstream product of 
ROS [80]. 
Beyond its redox role, NAD+ was later proposed to have additional important 
functions owing to its high turnover rate with the majority of NAD+ synthesised 
later consumed and only a small proportion maintaining the NAD+ pool [81]. 
Further evidence was provided when the half-life of NAD+ in enucleated cell types 
was extended to 10 hours from an average of ~ 1 hour in nucleated cells [81, 82]. 
It has since been established that NAD+ is an important cellular signalling 
molecule [83-86]. 
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Figure 1.8 NAD+ as a cofactor in energy production 
NAD+ is an essential cofactor that features in the energy production pathways of 
glycolysis, fatty acid oxidation, oxidation of ketone bodies, tricarboxylic acid cycle 
(TCA) and the electron transport chain. 
 
More recently, NAD+ has been identified as a signalling molecule. During these 
signalling events, NAD+ is consumed by numerous enzymes including sirtuins 
(SIRTs), poly (ADP-ribose) polymerases (PARPs) and cADP-ribose synthases. 
The discovery of these NAD+ driven enzymatic reactions has since recognised 
NAD+ as an important modulator of metabolism and energy homeostasis as well 
as DNA repair and calcium signalling [87-90].  
 
 
20 
 
More specifically, the new found metabolic regulatory role of NAD+ is 
predominantly exerted through its ability to activate SIRTs, NAD+ ‘sensing’ 
proteins, which act downstream to modulate energy metabolism [91]. SIRT activity 
is NAD+ dependent; thus to prevent cellular NAD+ depletion upon consumption by 
SIRTs, and other NAD+ signalling enzymes such as PARPs [92], NAD+ 
biosynthesis and salvage pathways are critical for replenishing NAD+ in order to 
preserve vital signalling processes and support NAD(P)(H) dependent reactions. 
Although currently not fully understood due to technical limitations, organelle 
specific expression of NAD+ generating and consuming enzymes indicates the 
presence of distinct subcellular pools of NAD+ in the mitochondria, nucleus and 
cytoplasm [93, 94] (figure 1.9). Recent technical advances using an NAD+ 
fluorescent biosensor supports this notion and shows that nucleic and cytosolic 
NAD+ levels appear interchangeable whereas mitochondrial NAD+ independently 
fluctuates [94]. These individual NAD+ pools allow for tightly regulated and 
compartment specific NAD/NADH redox reactions and signalling. NAD+ can pass 
freely through the pores of the nuclear membrane and thus nuclear NAD+ is 
thought to be comparable to cytoplasmic; whereas NAD+ and NADH are 
impermeable to the mitochondrial membrane.  The size of compartmental NAD+ 
pools also differ between tissues, for example cardiac myocytes were previously 
shown to have a much higher percentage of mitochondrial NAD+ compared to the 
cytosolic yet other cell types including astrocytes and hepatocytes have a larger 
cytosolic pool [95]. These differences are likely to be related to the oxidative 
capacity and function of the individual cell. Further evidence for a distinct 
mitochondrial pool was identified by mitochondrial resistance to NAD+ decline 
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following pharmacological cellular depletion of NAD+ [96]; allowing for continued 
oxidative phosphorylation and protecting from cell death for over 24 hours [96].  
Figure 1.9 Subcellular NAD+ compartmentation 
Graphical representation of different cellular NAD+ pools and localisation of NAD+ 
generating (Nampt, Nmnat, Nmrk) and consuming enzymes (PARPs, SIRTs and 
CD38/CD157). NAD+ can freely move through nuclear pores from the cytoplasm; 
with nucleic and cytosolic levels thought to be comparable.  The mitochondrial 
membrane in impermeable to NAD+ and NADH and therefore relies on shuttles 
including glyceraldehyde-3-phosphate (G3P) or malate-aspartate (MA) shuttles to 
transfer electrons across the mitochondrial membrane. Enzymatic reactions 
involving the same shuttles leads to NAD+ generation and replenishes cytosolic 
NAD+.    
 
Despite compartmentalisation of NAD+ pools, and although the mitochondrial 
membrane is impermeable to NAD+ and NADH, there is still vital crosstalk 
between compartments (figure 1.9). For example, pyruvate and NADH derived 
from glycolysis in the cytosol are important reducing factors for the tricarboxylic 
acid cycle (TCA) and the electron transport chain (ETC). Electrons from cytosolic 
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NADH are shuttled into the mitochondria by glyceraldehyde-3-phosphate (G3P) or 
malate-aspartate shuttles [97] and NAD+ released into the cytosol. Therefore, 
cytosolic NAD+ content is an important determinant of mitochondrial NADH flux; 
with substantial drops in NAD+, particularly in cells using glucose as a principal 
fuel source, leading to a loss of cell viability [97].  
1.3 NAD+ signalling and consumption 
Since NAD+ has been acknowledged for its integral role as a consumed substrate 
in multiple cellular signalling pathways, understanding the importance and 
regulation of cellular NAD+ levels and availability is imperative. NAD+ consumption 
during signalling is mostly attributed to the activity of three enzyme families: 
SIRTS, PARPs and cyclic ADP-ribose synthases [98-100]. The relative amount 
these enzymes contribute to NAD+ consumption may have an important influence 
on the activity of the other enzymes through changes to NAD+ availability; 
highlighting the important need to consider crosstalk between these distinct 
signalling pathways.       
1.3.1 Sirtuins 
The SIRT proteins are a family of seven NAD+ dependent deacetylases, known as 
SIRT1-7, which act as metabolic sensors within the cell [101]. They are 
homologous to Sir2 in yeast, thought to mediate cellular longevity post calorie 
restriction [102], and work by reversing acetylated lysine residues on proteins such 
as histones [103]. However more recent research, standardising for the genetic 
background of Caenorhabditis elegans and Drosophila melanogaster models 
through outcrossing, showed that Sir2 overexpression did not impact on lifespan 
and in fact differences previously seen were explained by alternative genetic 
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mutations [104].  On activation, the SIRTs can induce metabolic adaptations 
through the regulation of downstream metabolic transcriptional targets.  During 
SIRT-mediated deacetylation, NAD+ is consumed and the products nicotinamide 
(NAM) and O-acetyl-ADP-ribose (OAADPr) are released (figure 1.10) [105, 106]. 
The seven SIRT homologs are ubiquitously expressed and share a core 275 
amino acid sequence attributing to their catalytic activity [107]. The different SIRT 
enzymes can be further grouped by their organelle specific expression (although 
expression is not completely compartment exclusive).  SIRT1, SIRT6 and SIRT7 
are mostly localised in the nuclei and are able to easily access and modulate 
nuclear transcription factors and chromatin remodelling proteins [108]. SIRT2 is 
predominantly cytoplasmic and can regulate transcription factors that reside in the 
cytoplasm when inactive [109]. Finally, SIRT3, SIRT4 and SIRT5 are mainly 
localised in the mitochondria and are thought to play critical roles sensing the 
cellular redox state and inducing appropriate metabolic responses [107, 110].  
Together the SIRT proteins cover a vast range of cellular processes from cell 
cycle control to regulation of DNA repair processes [111, 112]. 
From a metabolic perspective, SIRT1 and SIRT3 have provided the most interest 
to date [113]. SIRT1 is typically activated during metabolic stress, for example, in 
response to periods of exercise and fasting, when there is a concurrent increase in 
NAD+ levels [84]. SIRT1 works to modulate energy homeostasis by modifying the 
acetylation status of transcription factors associated with metabolic regulation and 
mitochondrial biogenesis including the forkhead box class O (FOXO) proteins, 
peroxisome proliferator-activated receptor γ (PPARγ), and PPAR γ coactivator-1α 
(PGC-1α) [84, 114, 115]. To illustrate the role of SIRT1 in mice, during fasting 
there is more than a two fold increase in liver NAD+ content with an associated 
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increase in SIRT1 activity leading to deacetylation and activation of PGC1α which 
promotes gluconeogenesis [116]. Reduction in SIRT1 expression has also been 
shown to decrease fasting hyperglycaemia and hepatic glucose production 
through increased acetylation of SIRT1 substrates including PGC1a and FOXO1, 
implicating SIRT1 activity as a potential regulator of type 2 diabetes and a possible 
therapeutic target [117, 118].   
 In skeletal muscle SIRT1 activity is also upregulated with a concomitant increase 
in AMPK activity; together activating and upregulating the expression of PGC1α to 
reprogram transcription profiles in favour of mitochondrial fatty acid oxidation [63]. 
SIRT3 has also been linked to energy homeostasis through regulation of 
mitochondrial expressed genes. Recent work by Jing et al. in skeletal muscle has 
shown that through deacetylation of pyruvate dehydrogenase (PDH), which 
converts pyruvate to Acetyl CoA, SIRT3 can coordinate energy metabolism and 
acts as a metabolic switch by altering energy substrate choice. Postprandial, 
SIRT3 activity is increased and therefore it pushes metabolism in favour of 
glucose metabolism whereas during fasting SIRT3 activity is reduced resulting in 
hyperacetylation of PDH and a switch to fatty acid metabolism [119].  
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Figure 1.10 Sirtuin and PARP signalling 
Sirtuin (SIRT) deacetylation of proteins is an NAD+ dependent process with 
nicotinamide (NAM) and oAADPr released (left). PARP signalling is induced by 
DNA damage and results in poly-ADP-ribosylation of proteins, NAD+ is consumed 
by signalling and NAM released (right).    
 
1.3.2 PARP 
The PARP family of proteins are ADP-ribosyl transferases. Currently 17 PARPs 
have been discovered with PARP-1 the best understood.  PARP activity leads to 
post translational modification of proteins by poly-ADP-ribosylation using NAD+ as 
a substrate. During this reaction, ADP-ribose groups can be linked to an amino 
acid receptor with NAM released [120, 121] (figure 1.10).  Unlike SIRTs, they are 
not necessarily dependent on NAD+ for their activity; they are in fact mostly 
regulated by binding to breaks in DNA with activity remaining low in the absence 
of DNA damage [87, 121-123].  Despite this, it is thought that PARPs are the 
major NAD+ consumers within the cell and their activity has a substantial impact 
on cellular NAD+ availability [92, 124-126]. Inhibition of PARP activity has been 
shown to increase cellular NAD+ [92, 127].  This means that sufficient salvage and 
synthesis of NAD+ is continuously required to maintain pools and metabolic 
homeostasis [125].  
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Although PARPs are involved in a diverse range of processes such as apoptotic 
and epigenetic signalling, the primary role of PARPs is to maintain DNA integrity 
within the cell [122]. PARPs are highly responsive to DNA damage, especially 
DNA strand breaks, and work to induce DNA strand repair by recruitment of 
proteins and formation of repair complexes [87, 120, 123]. Additionally, a role for 
PARPs has also been outlined in modulating metabolism. For example, high 
PARP activity during DNA damage can cause a repression of SIRT activity 
through NAD+ consumption [128] whereas inhibition of PARP-1 leads to an 
increase in SIRT activity and metabolic adaptations including enhanced muscle 
mitochondrial content and energy expenditure [92]. Moreover, PARP-2 has been 
identified as a direct repressor of the SIRT1 promoter, with PARP-2 deficiency 
resulting in an increase of SIRT1 activity through enhanced expression rather than 
increased NAD+ availability [129]. The interplay between SIRTs and PARPs and 
the great influence they exert on their respective enzyme activity demonstrates the 
importance of continually balancing NAD+ consumption and biosynthesis to 
maintain homeostasis.  
1.3.3 Cyclic ADP-Ribose Synthases  
The highly conserved cADP-ribose synthases, also known as CD38 and CD157, 
are ectoenzymes that consume NAD+ and produce second messengers to 
coordinate numerous processes [130]. For example, they can generate cADP-
riboses which act as central modulators of intracellular calcium signalling [98]. 
Importantly, studies have revealed that CD38 requires a large amount of NAD+ to 
generate cADP-ribose with a 100:1 ratio of NAD+ substrate for every cADP-ribose 
molecule [131]. Thus, even during low activity, CD38 is a central modulator of 
cellular NAD+. Further research by Aksoy et al highlighted this using a CD38 KO 
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mouse model, which exhibited a 10-20 fold increase in intracellular NAD+ content 
and with this they demonstrated enhanced SIRT activity [85, 131].       
1.4 NAD+ Biosynthesis  
As previously described in section 1.3, the consumption of NAD+, as part of 
numerous signalling pathways, necessitates continuous re-synthesis to maintain 
cellular NAD+ levels. The significance of replenishing NAD+ was first delineated by 
the disease pellagra. Pellagra is characterised by the triad of symptoms; 
dermatitis, diarrhoea and dementia caused most commonly by malnutrition – more 
specifically a deficiency in vitamin B3 NAD+ precursors. Dietary replacement of 
NAD+ precursors can successfully treat pellagra [132, 133]. In mammalian cells, 
numerous NAD+ synthesis pathways have since been identified. Without these 
biosynthesis pathways the high turnover of NAD+ means cellular levels would 
deplete within hours and ultimately lead to cell death [134, 135].  
1.4.1 De novo synthesis 
NAD+ can be synthesised de novo, predominantly from the dietary amino acid L-
tryptophan. Briefly, as demonstrated in figure 1.11, biosynthesis begins with the 
conversion of tryptophan to N-formylkynurenine by the rate limiting enzyme 
indoleamine 2,3-dioxygenase (IDO) or alternatively tryptophan2,3-dioxygenase 
(TDO). Following this, 4 enzymatic reactions convert N-formylknurenine to α-
amino-β-carboxymuconate-ε-semialdehyde (ACMS) [136]. ACMS can undergo 
complete oxidation or spontaneous cyclization producing quinolinic acid. 
Quinolinate phosphoribosyl-transferase (QPRT) catalyses the conversion of 
quinolinic acid to nicotinic acid mononucleotide (NAMN) which is subsequently 
converted by the ubiquitously expressed enzyme nicotinamide mononucleotide 
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adenylyltransferase (NMNAT) to nicotinic acid adenine dinucleotide (NAAD)[136]. 
Finally NAAD undergoes ATP dependent amidation via glutamine-dependent 
NAD+ synthase (NADS) activity to produce NAD+ [137]. 
 
Figure 1.11 NAD+ biosynthesis pathways 
NAD+ can be generated through multistep de novo synthesis from L-tryptophan or 
through the salvage of NAD+ precursors; nicotinic acid (NA), nicotinamide (NAM) 
and nicotinamide riboside (NR). Replenishment of NAD+ allows continued 
signalling by enzymes including SIRTs and PARPs and released NAM can be 
recycled back to NAD+. 
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1.4.2 Vitamin B3 Salvage pathways 
Despite de novo biosynthesis being a major route to NAD+ in the liver [138, 139], it 
is thought that the majority of cellular NAD+ content in other tissues is attributed to 
salvage pathways. Illustrated in figure 1.11, these pathways resynthesise NAD+ 
from vitamin B3 precursor molecules nicotinic acid (NA), nicotinamide (NAM) and 
nicotinamide riboside (NR), found in the diet or as consumed NAD+ metabolites, 
with similar chemical structures to NAD+ (figure 1.12) [140-142]. 
Figure 1.12 Structure of NAD+ and NAD+ precursors 
NAD+ and precursors NAM, NR and NMN all share a common nicotinamide 
moiety (adapted from Bogan et al. 2014) [143].  
 
 It is thought that NAM is the preferred NAD+ precursor over NA; this was 
illustrated by only transient increases of NAD+ after intraperitoneal injection with 
NA as opposed to stable increases following NAM administration [144]. Despite 
the growing interest in NAD+ metabolism, particularly since NAD+ dependent SIRT 
proteins have been acknowledged for their central metabolic regulatory role [63, 
145], it is still unclear how these different biosynthesis and salvage pathways 
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interact. The relative importance and tissue specificity of the different precursor 
molecules in NAD+ replenishment in vivo remains unclear.  
1.4.3 Preiss – Handler pathway 
NA is converted into NA mononucleotide (NAMN) in the Preiss-Handler pathway; 
the reaction is catalysed by NA phosphoribosyltransferase (NAPT) with 5-
phospho-α-ᴅ-ribose-1-diphosphate as its substrate [146]. Following this initial step 
this pathway undergoes a similar route to the de novo biosynthesis pathway, 
where NAMN is converted to NAAD by NMNAT and finally to NAD+ by NADS 
[146].  
Mammalian, NADS is a homohexameric cytosolic protein that uses co-substrates 
ATP and glutamine to convert NAAD to NAD+ and releasing AMP, PPi and 
glutamic acid in the process [147].  As the final step of both the de novo and 
Preiss-Handler pathway, NADS activity is rate-limiting for NAD+ generation by 
either of these routes. The importance of NADS activity for NAD+ generation has 
been shown to be organism and tissue specific. Some bacteria such as 
mycobacterium tuberculosis are dependent on NADS for NAD+ synthesis, making 
it a potential antibacterial target, whereas others make NAD+ independent of 
NADS [148, 149]. The rate of NADS enzyme activity differs across tissues, with 
highest levels of activity demonstrated in liver and kidney tissue. Activity is 
undetectable in lung and skeletal muscle tissues and very low in brain 
homogenates, indicating NAD+ production via the de novo and Press-Handler 
pathways is limited in these tissues [147]. 
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1.4.4 NAMPT salvage pathway  
Alternatively, NAM can replenish NAD+ pools by the nicotinamide 
phosphoribosyltransferase (NAMPT) pathway [150]. Here, NAMPT acts as the 
rate-limiting enzyme and catalyses the conversion of NAM and 5’-phosphoribosyl-
1-pyrophosphate (PRPP) to nicotinamide mononucleotide (NMN) in an ATP 
dependent reaction. NMN is then converted to NAD+ by NMNAT enzyme activity 
[151]. As NAM is a product of SIRT and PARP mediated NAD+ signalling, salvage 
by NAMPT provides a direct NAD+ recycling mechanism. This pathway also allows 
for tight regulation of NAD+ levels with NAMPT expression shown to be regulated 
by cellular NAD+ levels and SIRT activity negatively regulated by NAM levels 
[152].  
NAMPT is a dimeric, type II phosphoribosyltransferase [153].  It was initially 
thought to be a cytokine termed pre-B cell colony enhancing factor (PBEF) [154]; 
but was later redefined as a hormonal factor, named visfatin, with alleged insulin 
mimetic effects [155] (now found to be unsupported [156]), before a universal 
name of NAMPT was assigned. NAMPT is highly conserved from prokaryotes to 
humans and expressed in almost all the tissues and cells that have been 
examined highlighting a necessity for NAMPT activity in normal cell function [157]. 
It exists both intracellularly, predominantly in the cytosol and nucleus, and 
extracellularly [158, 159]. Intracellular NAMPT activity has proved critical for 
maintaining cellular NAD+ and redox pathways through salvage of NAM to NAD+. 
Inhibition of enzyme activity with the potent NAMPT inhibitor FK866 leads to a 
reduction in NAD+ over time and ultimately leads to cell death [134, 150].  The role 
of extracellular NAMPT (eNAMPT) is still unclear but activity has been associated 
with cell pathology whereby cell death results in a release of ATP and PRPP into 
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the circulation (both normally have low plasma concentrations), which then drive 
enzyme activity [157, 160]. Proinflammatory responses, such as the induction of 
inducible nitric oxide synthase, have also been associated with eNAMPT activity in 
diabetes [161]. Moreover, eNAMPT is also believed to promote macrophage 
survival whilst muting T-cell responses through non-enzymatic actions in some 
disease states including chronic lymphocytic leukaemia [162, 163].  
1.4.5 NMRK salvage pathway 
In addition to these long-established salvage pathways, a new route to NAD+ has 
been more recently recognised since the identification of the nicotinamide riboside 
kinase 1 and 2 (NMRK1 and NMRK2) enzymes. The NMRKs phosphorylate the 
vitamin B3 nicotinamide riboside  (NR) to NMN [164] which is then subsequently 
converted to NAD+ by NMNAT1 [142].   
Initial identification of the NMRK enzymes stemmed from the finding of NR as a 
novel NAD+ precursor with the ability to extend lifespan of yeast via enhanced 
NAD+ dependent Sir2 signalling [142]. Although NMRK1 and 2 are close 
paralogues, both with a high affinity for NR, their substrate specificity differs. 
NMRK1 has a Km (substrate required for half maximal enzyme rate) for NR of 
0.088 mM whereas NMRK2 has a Km of 0.19 mM [164]. Moreover, NMRK1 can 
use ATP or GTP (guanosine triphosphate) as a substrate to phosphorylate NR to 
NMN yet NMRK2 exhibits ATP specific activity [164, 165]. There is currently little 
understanding regarding the roles NMRK1 and 2 play in endogenous NAD+ 
biosynthesis – or beyond NAD+ metabolism – with only recent findings showing 
that loss of NMRK1 function is not critical to basal NAD+ signalling [166]. However, 
in hepatocytes NMRK1 is an essential component for NAD+ biosynthesis following 
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exogenous NR and NMN supplementation [166]. Understanding the function of 
NMRK2 is also of great interest since it was found to be the most upregulated 
NAD+ biosynthetic gene (by over 20-fold) following injury to dorsal root ganglion 
neurons, despite expression normally absent or low in the nervous system [167]. 
1.4.6 NAD+ biosynthesis in skeletal muscle 
Metabolic profiling of tissue enzyme activity has revealed NADS activity to be 
negligible in muscle whereas enzyme activity of NMNAT1 through the amidated 
routes (thus via NAMPT and NMRK) was detected to a much greater extent [147]. 
This data already indicates that the de novo and Preiss-Handler routes to NAD+ 
may be limited in skeletal muscle. The NAMPT salvage pathway has previously 
been demonstrated to be a critical determinant of NAD+ content across many 
tissues including liver, skeletal muscle and adipose [76, 168-170] . Conversely, 
due to the infancy of research surrounding the NMRKs, the extent to which they 
contribute to the maintenance of skeletal muscle NAD+ pools is unknown. The 
NMRKs are highly conserved in all eukaryotes [142] and although NMRK1 is 
ubiquitously expressed [166], NMRK2 is thought to be specifically expressed in 
skeletal muscle but has not been well characterised in this regard [171]. 
NMRK2 and its orthologs have been implicated in coordinating muscle 
differentiation and improving dystrophic muscle function in zebrafish. Previously Li 
et al. have defined a role for muscle-specific β1 integrin binding protein (MIBP), a 
186 amino acid protein which they believe to be a splice variant of NMRK2, in 
regulating muscle differentiation where by MIBP expression may repress terminal 
differentiation in muscle [172]. Furthermore, research in zebrafish has associated 
Nrk2b, believed to be the zebrafish orthologue of MIBP, with NAD+ mediated 
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amelioration of muscular dystrophy through activation of downstream targets such 
as paxillin [173].    
1.5 NAD+ metabolism in health and disease 
The important role NAD+ plays in metabolic health is now widely acknowledged 
and can be well demonstrated during exercise. As previously described, physical 
activity enhances NAD+ turnover in muscle, results in changes to NAD+ redox and 
induces metabolic adaptation [174]. The key regulatory response to exercise that 
allows these signalling events to occur is the AMPK induction of NAMPT 
expression [145]. Upregulation of NAMPT leads to an increase in NAD+ turnover 
through enhanced recycling of NAM. The consequent rise in NAD+ allows for an 
increase in SIRT activity and rapid salvage of NAM to NAD+ preventing NAM 
inhibition of SIRTs (figure 1.13) [31, 175].  
The perturbations to skeletal muscle NAD+, NADH and NAD+/NADH ratio following 
exercise allow for increased ATP production by glycolysis and oxidative 
phosphorylation to tightly maintain ATP levels during muscle contraction [145]. 
Metabolic adaptation by SIRT signalling is equally important for enhancing 
oxidative capacity, fuel utilisation and improving metabolic performance on repeat 
activity.  Notably, metabolic adaptation and mitochondrial biogenesis can be 
induced following just a single bout of exercise [176, 177]; demonstrating the 
acute positive health effects of enhancing NAD+ signalling.  
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Figure 1.13 Metabolic signalling in skeletal muscle following metabolic 
stress 
Metabolic stresses such as exercise lead to a depletion in available ATP, this 
stimulates metabolic sensors such as AMPK which can induce a surge in NAD+ 
content to drive SIRT activity and reprogram metabolic pathways to replete ATP.  
 
However, NAD+ signalling can be perturbed in disease and a drop in cellular NAD+ 
content has been associated with numerous pathophysiological states, examples 
of which include diabetes, neuronal degeneration, non-alcoholic fatty liver disease 
and noise-induced hearing loss [100, 169, 178-180]. In these examples, depleted 
 
 
36 
 
NAD+ levels are thought to be - at least in part - a consequence of hyper-activation 
of PARPs by oxidative stress induced DNA damage and thereby resulting in 
excessive NAD+ consumption [100, 180]. Reduced NAD+ availability is then 
associated with a decline in SIRT activity [89]. 
Importantly, restoration of NAD+ signalling through repletion of NAD+ in these 
diseases has demonstrated positive outcomes. Brown et al. demonstrated that NR 
supplementation protected against noise-induced hearing loss by restoring NAD+ 
levels and SIRT3 activity [179]. Remarkably, studies have also shown NR 
repletion of NAD+ improved the metabolic phenotype of high fat diet (HFD) 
induced diabetes in mice with reduced weight gain, insulin resistance and hepatic 
steatosis [178]. Alternatively, PARP mutation strategies, to limit excessive NAD+ 
consumption during DNA damage, led to increased NAD+ availability and 
protection from neurodegeneration in drosophila models of Parkinson’s disease 
[180]. Finally, primary cardiac-myocytes taken from mouse models of heart failure 
were also shown to be protected from cell death induced by excessive PARP1 
mediated NAD+ consumption following repletion of NAD+ [128].  
1.6  NAD+ in Ageing and Sarcopenia 
More recently there has been a major focus on ageing research due to growing 
ageing populations and the need to improve health span which continues to lag 
behind lifespan. During ageing, cells typically have increased levels of DNA 
damage, a reduction in mitochondrial function and consequently a reduction in 
cellular ATP turnover [181].  
In terms of muscle health and metabolism, a major problem during ageing is 
sarcopenia – defined as a degenerative loss of muscle mass and function [182]. 
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Sarcopenia characteristically manifests with muscle weakness, loss of strength, 
frailty and immobility; with a decline in muscle health also negatively impacting on 
whole body metabolism. Although sarcopenia is mostly associated with ageing, 
physical inactivity and metabolic diseases also drive muscle loss [183]. It is now 
thought of as a multifactorial process with several factors involved including 
nutrition, hormone changes, muscle catabolic imbalance, chronic disease states 
and inflammation [182-184]. The pathophysiological processes of sarcopenia have 
shown sex-specific differences with malnutrition thought to be a major reversible 
factor aside from physical activity [185].    
Reduced NAD+ availability is commonly featured in aged muscle and associated 
morbidities including insulin resistance, obesity and cardiovascular disease [89, 
128, 170, 181, 186]. Physical inactivity drives sarcopenia progression but can also 
be a resulting outcome due to muscle loss and weakness [183]. With metabolic 
adaptation and NAD+ signalling highly regulated by exercise it is difficult to 
delineate whether a drop in cellular NAD+ contributes to the progression of 
sarcopenia or a consequence of muscle wasting and metabolic decline (figure 
1.14). Accumulation of reactive oxygen species (ROS) in sarcopenic muscle has 
been associated with activation of PARP1, providing an initial mechanism for 
NAD+ decline and reduced SIRT activity [187].  Additionally, vitamin B3 nutrient 
availability appears important for NAD+ signalling and malnutrition is a key factor 
for driving sarcopenia [185]; thus, nutrient replenishment may be valuable strategy 
for reversing or impeding sarcopenia progression, particularly when physical 
activity is limited due to muscle weakness and disability.  
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Figure 1.14 Factors associated with sarcopenia 
An illustration of the key factors involved in sarcopenia and the consequential 
outcomes that drive further progression. A potential role for NAD+ is highlighted by 
an associated decline with a number of sarcopenic factors.  
 
Since an age-related reduction of NAD+ availability in some tissues has been 
identified, the impact of NAD+ signalling in ageing has been investigated. NAMPT 
protein expression has been shown to be downregulated in aged rats concomitant 
with a decline in muscle NAD+ content [174]. Muscle from exercised aged rats 
however, displayed increased NAMPT expression and NAD+ content similar to 
that of unexercised young rats. This demonstrates some degree of ‘reversal’ of 
age-related NAD+ decline; yet the aged cohort was still unable to upregulate 
NAMPT to the same extent as young rats following exercise [174]. This highlights 
the importance of NAD+ salvage mechanisms in response to exercise and 
identifies aberrant NAMPT activity as a possible driver of age-related metabolic 
decline.  
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1.7 Strategies to boost NAD+ signalling 
The implications of perturbed NAD+ signalling in disease and ageing clearly 
demonstrate the criticality of NAD+ signalling for energy metabolism and beyond. 
This has driven current research to develop new therapeutic strategies based on 
restoring NAD+ levels and metabolic signalling (figure 1.15).  PARP inhibitors, to 
prevent excessive NAD+ consumption, have been shown to not only increase 
NAD+ availability and drive SIRT1 mediated mitochondrial metabolism but also act 
as effective anti-cancer agents [92, 188]. Alternatively, SIRT activators, such as 
derivatives of resveratrol and SRT1720, can potently stimulate SIRT1 activity and 
exert widespread metabolic effects [189-191]. These include; protection from diet 
induced obesity and insulin resistance through enhanced fatty acid oxidation 
signalling, improved endothelial function and enhanced mitochondrial content and 
function [189-191]. Although these strategies have promising therapeutic potential 
in regards to metabolic disease, more recently there has been a major focus on 
vitamin B3 supplementation strategies. As naturally bioavailable ‘nutraceuticals’, 
that have also been synthetically established, they potentially provide a relatively 
inexpensive approach with low toxicity and limited side-effects [139, 171, 192].  
1.7.1 Vitamin B3 supplementation 
From a clinical perspective, NA supplementation is the most therapeutically 
characterised. The hypolipidemic effects of NA and its derivatives were first 
described in the 1950’s and have since been used to treat hyperlipidaemia and 
associated cardiovascular diseases. NA supplementation reduces plasma 
triglycerides and low density lipoprotein (LDL) whilst also elevating circulating high 
density lipoprotein (HDL) [193, 194]. However, activation of the nicotinic acid 
receptor GPR109A following NA treatment results in severe cutaneous 
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vasodilation, known as flushing, in a large majority of patients leading to poor 
compliance [195]. More recently, short-term clinical studies have shown that the 
NA derivative acipimox can also enhance mitochondrial respiration in skeletal 
muscle and elevate ATP content [196]. Importantly, the study also identified 
unwanted effects with acipimox treatment causing an increase in plasma non-
esterified fatty acids (NEFA) and reduced insulin sensitivity [196]. This along with 
the adverse flushing has limited the use of NA as a nutraceutical to enhance NAD+ 
signalling and metabolism in skeletal muscle. Nonetheless, the health benefits 
demonstrated by NA were a major driving factor towards the ongoing research 
investigating the therapeutic potential of alternative vitamin B3 NAD+ precursors.    
NAM supplementation as a strategy to boost NAD+ signalling and energy 
metabolism is also limited due to the inhibitory effects of NAM on SIRT activity 
[197]. However, in some cases NAM supplementation may still be useful. For 
example, during cerebral ischaemia NAD+ levels diminish, altering the cells 
bioenergetic state and leading to excitoxicity [198]. Short-term NAM 
supplementation can both replete cellular NAD+ and inhibit PARP and SIRT 
activity to reduce NAD+ consumption; restoring the bioenergetic state and 
protecting against excitotoxic shock and neuron death [198]. 
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Figure 1.15 Strategies to boost NAD+ signalling in aged muscle 
An illustration of current understanding of basic NAD+ signalling in young (top) and 
aged (middle) muscle. Aged muscle exhibits reduced basal NAD+ availability, 
thought to be in part due to perturbed NAD+ biosynthesis and enhanced 
consumption by PARPs as a response to increases DNA damage. The therapeutic 
strategies (bottom) that are currently being investigated in human and mouse 
models of metabolic decline are shown including NAD+ precursor 
supplementation, PARP inhibitors and SIRT activating compounds. 
 
Currently NMN and NR supplementation are the most therapeutically promising 
approaches in regards to metabolic health. Both have been shown to significantly 
elevate NAD+ levels without inhibiting SIRT activity or causing flushing through the 
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activation of the GPR109A receptor [166, 199, 200]. Although limited, human and 
animal studies have yet to identify major side effects of NR or NMN 
supplementation [170, 200, 201], however considerably larger cohorts and longer 
term supplementation is required to establish any harmful effects. Importantly, 
recent studies have quantified NR and NMN in foods such as milk (NR and NMN) 
and vegetables (NMN), identifying a possible dietary source for both [192, 202, 
203].  Thus the value of NMN and NR supplementation is currently being 
extensively studied in a wide range of disease contexts.   
Short-term NMN supplementation has already shown promise in animal models of 
obesity, neuropathy and ageing. NMN supplementation (17 days) led to an 
improved metabolic phenotype of high fat diet (HFD) fed obese mice with 
enhanced NAD+ detected in liver and muscle tissue and improved glucose 
tolerance [200]. In mouse models of Alzheimer’s, NMN supplementation (10 days) 
recovered neuronal NAD+ levels and mitochondrial respiratory function leading to 
repletion of ATP, reduced reactive oxygen species and attenuation of neuronal 
cell death [204, 205]. In studies of age-related pathologies NMN supplementation 
(8 weeks) could restore vascular function of aged mice through a SIRT1-mediated 
reduction in oxidative stress [206], and NMN (10-11 days) was able to improve 
glucose intolerance and lipid profiles of mice with age-induced type 2 diabetes 
(T2D) [170]. Remarkably, aged mice treated daily with NMN for one week had 
restored mitochondrial function to the same level as a young mouse through 
NAD+-induced SIRT1 dependent signalling [181]. More recently, long term NMN 
supplementation (1 year) through dietary supplementation has been investigated 
in mice in terms of ageing. Here NMN was shown to be orally bioavailable and 
able to alleviate some of the effects associated with age-related metabolic decline 
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including reduced weight gain associated with ageing, improved insulin sensitivity, 
enhanced energy expenditure and increased maximal mitochondrial respiration 
[203].  
Equally, NR supplementation has also demonstrated great therapeutic potential 
across a range of metabolic pathologies [178, 179, 199, 207]. Since the discovery 
of the NMRK enzymes there has been considerable interest in the importance of 
the NR salvage pathway to NAD+.  Initial studies in yeast identified that NR 
salvage was essential for calorie-restriction lifespan extension via NAD+-
dependent Sir2 deacetylase [208]. Numerous positive effects of NR 
supplementation on mammalian metabolic health were subsequently 
demonstrated by Canto et al. in HFD fed mice [199]. NR supplementation (for the 
entire HFD period) increased NAD+ in key metabolic tissues including muscle and 
liver; leading to increased SIRT1 and 3 activity detected by deacetylation of 
FOXO1 and induction of downstream gene expression. NR treated HFD mice 
exhibited an improved metabolic phenotype with reduced weight gain and fat 
mass from increased energy expenditure, improved insulin sensitivity and reduced 
total cholesterol compared to control HFD mice. Furthermore, analysis of muscle 
tissue identified upregulation of mitochondrial genes and proteins and enhanced 
oxidative performance [199].   
More recent studies have shown NR supplementation to protect against noise 
induced hearing loss [179], diet-induced T2D [178] (both described in section 1.5), 
as well as mitochondrial myopathy [207]. In mouse models of progressive adult-
onset mitochondrial myopathy, dietary NR treatment (16 weeks) significantly 
delayed disease progression and protected against mitochondrial structural 
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abnormalities as well as sustaining mitochondrial biogenesis, mitochondrial DNA 
copy number and oxidative capacity; all of which deteriorated more rapidly in 
untreated mice [207]. An alternative model of mitochondrial myopathy 
characterised by cytochrome c oxidase (COX) deficiency and exercise intolerance 
also demonstrated the beneficial effects of NR treatment on mitochondrial health 
in muscle. Here, NR supplementation (4 weeks) enhanced skeletal muscle NAD+ 
and upregulated SIRT1 activity. In addition, treated mice displayed enhanced 
expression of mitochondrial oxidative phosphorylation genes and proteins, 
upregulated mitochondrial respiratory chain enzyme activities and improved 
endurance exercise performance [99].  
Despite the large amounts of evidence supporting the notion that increasing NAD+ 
levels may be beneficial in a range of disease settings, there may be some 
scenarios where NAD+ supplementation may be potentially detrimental. For 
example, studies have shown a reduction of NAD+ via inhibition of NAMPT may 
be beneficial under some circumstances including tumorigenesis and autoimmune 
disease. In terms of cancer, studies have shown reduction of NAD+ to limit 
glycolytic flux, ATP levels and inhibition of further cancer cell or tumour growth [74, 
75, 209-211]. Furthermore, upregulation of NAMPT has been identified in patients 
with inflammatory diseases such as rheumatoid arthritis [212]. Inhibition of NAMPT 
has been shown to have anti-inflammatory effects, with reduced circulating TNFα, 
decreased NAD+ in inflammatory cells and a reduction in ROS [213, 214].      
Clinical studies involving vitamin B3 supplementation remain in their infancy; but 
the first controlled human study of NR supplementation determined that oral 
delivery could significantly elevate peripheral blood mononuclear cell (PBMC) 
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NAD+ [201]. Although no major adverse effects were reported, this was a short-
term study based on a small cohort of 12 healthy subjects and therefore larger 
scale investigations are necessary to determine potential adverse events.  
Together these examples demonstrate the potential of vitamin B3 
supplementation as a therapeutic strategy for treating metabolic diseases. 
However, there are still large knowledge gaps to be addressed surrounding 
vitamin B3s in order to determine their true potential as nutraceuticals. These 
include tissue specific substrate preference, substrate delivery to the target tissue, 
substrate stability and dose. Previously studies, particularly with NMN 
supplementation, have often used Intraperitoneal (I.P) injections over oral 
supplementation due to concerns with long-term stability in food and water, 
uncertainty of stability in the gut and the use of large doses [170, 181, 200]. 
Although, NR has been shown to be orally bioavailable in humans (and mice) 
[201], questions remain regarding whether NR can bypass breakdown by the 
bacteria of the gut and be delivered to target tissues in sufficient quantities.  
1.8 Project rationale 
The importance of NAD+ as a signalling molecule has now been well established 
and outlined in this chapter. Its central role in regulating important processes such 
as energy metabolism, DNA repair and calcium signalling has put NAD+ and its 
metabolism into the spotlight in many research fields [32, 66, 86]. Understanding 
how NAD+ and its metabolites are generated, their interactions and downstream 
signalling is now critical to establish new therapeutic strategies scoping from 
metabolism to cancer. Extensive studies, many that have been discussed, have 
already begun to demonstrate the beneficial potential of enhancing NAD+ 
 
 
46 
 
availability across different tissues and diseases yet the underlying signalling 
mechanisms are still unclear. A better understanding of how NAD+ is generated 
and metabolised, and how changes to this impact on signalling in tissues and 
pathophysiological states is essential. This knowledge will help elucidate whether 
‘boosting’ NAD metabolism can provide beneficial health outcomes and, if so, how 
can these beneficial outcomes be maximised.  
This project focusses on understanding the importance of NAD+ biosynthetic 
pathways in regulating energy metabolism specifically in skeletal muscle. A 
demonstration of the potential metabolic impact that enhancing NAD+ availability 
and signalling may have on ageing muscle health is demonstrated in figure 1.16. 
Despite increasing interest in vitamin B3 NAD+ precursor supplementation as a 
novel strategy to enhance NAD+ and improve metabolism, the pathways and 
precursors important to skeletal muscle NAD+ metabolism remain ill-defined. Thus, 
defining these pathways will not only provide a better insight to muscle specific 
NAD+ signalling pathways but also delineate the best therapeutic targets.     
 
 
47 
 
Figure 1.16 Time line of metabolic muscle health 
An outline of physiological changes that contribute to muscle decline during 
ageing (blue box). Interventions that may protect against metabolic decline (green) 
and the positive metabolic outcomes these interventions may induce (orange).     
 
1.9 Hypothesis 
NAD+ availability is a central determinant of skeletal muscle health and during 
metabolic decline NAD+ levels decrease. Driving NAD+ biosynthesis enzyme 
activity through vitamin B3 precursor supplementation can enhance NAD+ 
availability and negate the effects of metabolic decline in skeletal muscle.  
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1.10  Project Aims  
To characterise the important NAD+ biosynthesis and salvage pathways for NAD+ 
turnover in skeletal muscle (Chapter 3). 
 
Using in vitro models of skeletal muscle, investigate the therapeutic potential of 
the different vitamin B3 precursors in muscle and determine the effects of 
supplementation on cellular NAD+ metabolism and downstream signalling 
(Chapter 3). 
 
Establish the effects of NAD+ biosynthesis enzyme depletion on NAD+ metabolism 
and NAD+ related cellular signalling through knockout mouse models and 
chemical enzyme inhibition (Chapter 4).  
 
Determine the effects of NMRK2 deficiency on energy homeostasis in vivo using 
NMRK2 knock out (NMRK2KO) mouse models (Chapter 5).   
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Chapter 2 Materials and Methods  
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Unless stated otherwise, all reagents were obtained from Sigma-Aldrich Chemical 
Company (Poole, Dorset, UK) and all cell culture plasticware was obtained from 
Corning (Artington, Surrey, UK). 
2.1 C2C12 cell line growth and maintenance   
All tissue culture was performed under sterile conditions in a Class I biological 
safety cabinet (Holten LaminAir) using sterile tissue culture flasks and reagents. 
All cells were incubated at 37 ˚C in 5% CO2/95% air.  
2.1.1 C2C12 cell line  
The murine C2C12 myoblast cell line was purchased from the European 
Collection of Cell Cultures (Salisbury, UK). The cell line is a well-recognised 
skeletal muscle cell model, sub-cloned from serially passaged C2 myoblasts 
originally isolated from thigh muscles of C3H mice 70 hours after a crush injury 
[215, 216].   Following serum removal C2C12 myoblasts can rapidly differentiate 
into contractile myotubes and exhibit comparable expression of muscle proteins to 
normal muscle cells [217].    
2.1.2 Proliferation 
C2C12 cells were cultured in 75 cm³ tissue culture flasks in growth media (GM) - 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal 
calf serum (FCS), 2 mM L-glutamine and 1% (v/v) penicillin/streptomycin (P/S) 
and 4.5 g/L glucose. Before reaching 60-70% confluence cells were split by 
removing media and washing with sterile phosphate buffered saline (PBS), 1 ml of 
TrypLETM Express trypsin enzyme (GibcoTM, UK) was added to the flask and 
incubated for 5 minutes at 37 ˚C. Fresh DMEM was added to detached cells and a 
proportion of cells were added to a new flask or alternatively, for experiments, 
 
 
51 
 
cells were seeded into 6 or 12-well tissue culture plates at the desired density. GM 
was replaced every 48 hours.         
2.1.3  Differentiation  
At 70-80% confluence C2C12 myoblasts were induced to begin differentiating by 
replacing GM with DMEM supplemented with 5% (v/v) horse serum (HS). Over a 
period of days C2C12 myoblasts begin to fuse and extend into multinucleated 
myotubes as illustrated in figure 2.1.   Differentiation media was replaced every 48 
hours.    
 
Figure 2.1 C2C12 differentiation 
C2C12 myoblasts (left) are induced to differentiate with low serum media, 
myoblasts begin to fuse with surrounding myoblasts (centre) and finally fully 
extend into multinucleated myotubes (right). 
 
2.1.4 Cryopreservation 
Cryopreservation of C2C12 cells allowed for long term storage and prevented high 
cell passage numbers. C2C12s were detached from 75 cm³ flasks using trypsin 
(described in 2.1.2), transferred to a falcon tube and pelleted by centrifugation. 
Supernatant was removed and the cells were re-suspended in 10 ml of freezing 
media - GM supplemented with 20% (v/v) FCS and 5% (v/v) DMSO. The re-
suspended cells were aliquoted into 1 ml cryotubes, placed in a pre-cooled Mr 
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FrostyTM freezing container (Sigma, UK) overnight at -80°C and then stored at -
160˚C in liquid nitrogen tanks.  
To start new C2C12 cultures from the cryopreserved cells, the cells were quickly 
thawed in a water bath at 37˚C and added to 10 ml of DMEM. Cells were pelleted 
by centrifugation and freezing media was replaced with fresh growth media.    
2.2 Primary muscle cell isolation and culture 
Primary myotubes were cultured from mice by isolating satellite cells from single 
muscle fibres following an adapted protocol by Rosenblatt et al [218]. Primary 
cultures provided a more physiologically representative model of muscle and 
allowed for longer differentiation periods to ensure full myotube formation before 
treatment. C2C12 myotubes begin to detach once fully differentiated making 24-
72 hour treatments post differentiation difficult. In addition, isolating primary 
myotubes from mouse models allowed direct in vitro analysis of genetic 
interventions. All cells were incubated at 37 ˚C in 5% CO2/95% air. 
2.2.1  Primary murine satellite cell isolation 
Gastrocnemius, extensor digitorum longus (EDL), tibialis anterior (TA) or soleus 
(Sol) muscles were dissected from 10-12 week old mice and digested for 2 hours 
in DMEM with 0.2% (w/v) type I collagenase at 37°C. The digested muscles were 
washed and then placed in fresh DMEM in horse serum (HS) coated cell culture 
plates to equilibrate for 1 hour at 37°C. The muscles were moved into adjacent 
wells with fresh DMEM and using serum-coated glass pipettes, media was 
expelled vigorously onto the muscle to allow single myofibres to detach. Cell 
culture plates were pre-coated in Matrigel (BD biosciences) and left to set for 3 
hours in the incubator. Once set, plating media was added, consisting of DMEM 
 
 
53 
 
supplemented with 30 % (v/v) FCS, 10% (v/v) HS, 1% (v/v) P/S, 2mM L-glutamine, 
1% (v/v) Chick embryo extract (CEE) (Seralab, UK) and 10 ng/ml of fibroblast 
growth factor-basic (bFGF) (Peprotech, UK), and single myofibres were 
transferred into the wells and left for 72 hours at 37°C to allow satellite cells to 
migrate from the myofibres.  
2.2.2 Proliferation  
Following satellite cell migration, plating media was replaced with proliferation 
media (DMEM with 10% (v/v) HS, 1% (v/v) P/S and 0.5% (v/v) CEE). Proliferation 
media was replaced every 48 hours until satellite cell derived myoblasts were 
around 70% confluent.  
Figure 2.2 Primary myotube differentiation 
Satellite cells migrate from isolated myofibres and on activation become 
proliferating myoblasts (left). Primary myoblasts are induced to differentiate with 
low serum media, where myotubes fuse and extend into multinucleated myotubes 
(right). 
 
2.2.3 Differentiation     
Differentiation of primary myoblasts was initiated once the cells reached around 
70% confluence. Proliferation media was changed to differentiation media 
consisting of DMEM supplemented with 2% (v/v) HS, 0.5% (v/v) CEE and 1% (v/v) 
X10 X10 
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P/S. Cells were left to differentiate until they formed fully fused and elongated 
tubes with fresh differentiation media applied every 48 hours (figure 2.2). 
2.3 C2C12 and primary myotube treatments  
Unless otherwise specified, following 5 (C2C12) or 6 (primary muscle) days of 
differentiation myotubes were treated with 100 nM FK866 for 24, 48 or 72 hours. 
Myotubes were also supplemented with vitamin B3 NAD+ precursors, including NR 
(ChromaDex, USA), NAM, NMN and nicotinic acid riboside (NaR) at 0.5 mM 
unless otherwise stated (0.5 mM is a standard dose used in literature and NR is 
thought to give a maximal NAD+ response in C2C12s at this concentration [199]). 
All experiments were performed with vehicle controls (DMSO for FK866 (0.001% 
(v/v) final volume) and sterile water for vitamin B3 experiments.   
2.4 siRNA transfections 
Transfecting cells with siRNA enabled transient silencing of target genes in vitro. 
Primary myotubes seeded in 6 well plates were grown to confluence. On day 3 
and 5 of differentiation 0.5 µg/µl Nmrk1 siRNA (MSS212930, Invitrogen, UK) or 
negative (scrambled ) siRNA medium GC duplex control (Invitrogen, UK)  was 
added to a final volume of 250 µl of OptiMem per sample whilst, in a separate 
tube, 4 µl of Lipofectamine 2000 was added to 246 µl of OptiMem. Each tube was 
incubated at room temperature (RT) for 5 minutes and then mixed gently together 
and incubated for a further 30 minutes at RT. Cells were washed twice with sterile 
PBS and 1 ml of antibiotic and serum free DMEM was added to cells. Finally, 500 
µl of transfection solution was added to each well and left overnight. Media was 
then changed back to normal differentiation media until cells were harvested.     
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2.5 Polymerase chain reaction (PCR)  
Conventional PCR is used to amplify deoxyribonucleic acid (DNA). Double 
stranded DNA is denatured to single strands at 95°C, and at a reduced 
temperature  ̴ 60°C (primer dependent), primers complimentary to the gene of 
interest anneal to the template DNA and at an increased temperature (72°C) the 
oligonucleotides can be extended by Taq DNA polymerase activity. 
 DNA samples were amplified using 2x BioMix Red (Bioline, UK) and the relevant 
primers listed in appendix A. 19 µl of the PCR mastermix, described in table 2.1, 
was added to a PCR Eppendorf tube with 1 µl of DNA and samples were then 
placed into a thermocycler set to 3 minutes at 95°C, then 35 cycles of [30 seconds 
95°C, 30 seconds 60°C and 30 seconds 72°C] followed by 3 minutes at 72 °C and 
left indefinitely at 4 °C. Samples were assessed qualitatively by electrophoresis at 
100 V using 1.8% agarose gels in TBE buffer (89 mM Tris (pH 7.6), 89 mM boric 
acid and 2 mM EDTA) supplemented with 10,000x GelRed nucleic acid gel stain 
(Biotium, USA). Separated bands were visualised using a G Box Syngene UV 
transilluminator (Syngene, UK). Fragments were identified by size by comparing to 
a 100 base pair DNA ladder (New England Biolabs, UK).   
 
Per sample (µl) 
2 x BioMix Red 10 
Primers  0.5  
Nuclease free water (NFW)  9 – (0.5 * No. of primers) 
 Table 2.1 – PCR mastermix 
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2.6 Ribonucleic acid (RNA) extraction and analysis 
RNA was extracted and prepared to complimentary DNA (cDNA) from tissues and 
cells for the analysis of cellular messenger RNA (mRNA) levels as a measurement 
of gene expression.     
2.6.1  RNA extraction 
Cells were harvested in 0.5 ml of TRIzol (Invitrogen, UK) per well, cells were 
scraped from the well surface, pipetted up and down to maximise lysis and 
transferred to an Eppendorf tube. For tissues, samples were harvested in 1 ml of 
TRIzol and manually homogenised. Once in TRIzol, all samples were left at room 
temperature for 5 minutes and from this point both cell and tissue samples were 
treated the same with all concurrent reagent volumes described per 1 ml of 
TRIzol. 200 µl of chloroform was added to samples. Samples were briefly vortexed 
and then incubated for 5 minutes at room temperature. Samples were centrifuged 
at 4°C at 12,000 revolutions per minute (rpm) for 5 minutes and the top aqueous 
fraction of each sample was transferred to a new Eppendorf tube. 500 µl of 
isopropanol (propan-2-ol) was then added to each sample and tubes were then 
inverted 5 times to gently mix before leaving samples to precipitate at -20˚C for 30 
minutes. Samples were centrifuged at 4°C for 10 minutes at 12,000 rpm to pellet 
RNA and supernatant was discarded. Pellets were washed by resuspension in 1 
ml of 70% (v/v) ethanol and pelleted again by centrifugation at 4°C for 10 minutes 
at 12,000 rpm and the ethanol was removed. Samples were left at room 
temperature for 5 minutes to dry and resuspended in 30 µl of nuclease free water 
(NFW). RNA samples were stored at -80˚C and thawed on ice before use.       
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2.6.2 RNA sample quantification 
RNA concentration was determined using the NanoDrop (ND, Labtech 
international). 1 µl of NFW was applied to the NanoDrop sample detection arm 
and measured to use as a blank sample. The detection arm was cleaned and 1 µl 
of RNA sample was added to the detector and measured. RNA with a 260/280 nm 
ratio between 1.7 - 2 was deemed of sufficient quality. RNA quality was confirmed 
by running samples in 6x DNA loading buffer (30% (v/v) glycerol, 0.25% (w/v) 
bromophenol blue and 0.25% (w/v) xylene cyanol) on a 1.8% agarose gel. Two 
clear bands of ribosomal 28 and 18 subunits (28S and 18S) can be visualised 
following the same process as in section 2.5 with smearing of bands suggesting 
RNA degradation.  
2.6.3 Reverse transcription (RT) 
Reverse transcription (RT) converts single stranded RNA to more stable double 
stranded cDNA for amplification and analysis. RNA samples were made up to a 1 
µg concentration in NFW with a final volume of 10 µl per sample. Using the High 
capacity cDNA reverse transcription kit (Applied Biosystems, USA) a RT master 
mix was made with the reagent quantities listed in table 2.2. 10 µl of the RT 
master mix was added to each 10 µl RNA sample (1 µg) and samples were placed 
in the thermal cycler set to: 10 minutes at 25°C, 120 minutes at 37°C, 5 minutes at 
85°C and then continuously at 4°C. Following RT cDNA was stored at 4°C.   
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Per sample (µl) 
RT buffer 2 
Random primers 2 
MultiScribe® Reverse Transcriptase 1 
RNase inhibitor 1 
Deoxynucleotide (dNTP) mix  0.8 
Nuclease free water 3.2 
Table 2.2 – High capacity cDNA reverse transcription master mix  
2.6.4 Real-time PCR (qPCR) 
Real-time PCR (qPCR) allows highly sensitive quantification of target genes using 
TaqMan probes with complimentary 5’-3’ regions to the gene of interest. The 
probes consist of a fluorophore and quencher attached to 5’ and 3’ ends 
respectively. Primer hybridisation and extension of target DNA leads to cleavage 
of the probe by Taq polymerase 5’ to 3’ exonuclease activity. This releases the 
fluorophore from the quencher and results in fluorescence. Fluorescence is 
proportional to the amount of DNA template in the sample and the number of 
amplifications for the fluorescent signal to reach the threshold is given as cycle 
threshold (Ct) values. TaqMan primers of interest (Appendix B) (Life Technologies, 
UK) were thawed on ice and protected from light. A separate master mix for each 
primer probe was made as follows - 3.5 µl NFW, 0.5 µl TaqMan primer probe and 
5 µl 2x qPCR master mix (Life Technologies, UK) – per sample. 1 µl of cDNA 
sample was added to a well of a 96 or 384 well PCR plate followed by 9 µl of the 
gene probe master mix. All samples were run in duplicate or triplicate. Plates were 
sealed with film and spun briefly before they were loaded onto the ABI 7500 Real-
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time-PCR machine using the pre-set PCR program settings: 95°C for 10 minutes 
then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Data were collected 
as Ct values (figure 2.3) and normalised with the housekeeping gene 18s rRNA 
(VIC) (Life Technologies, UK) by subtraction of the samples 18s Ct value from the 
gene of interest Ct value to give deltaCt (dCt) values [219].    
 
Figure 2.3 Real-time PCR amplification plot 
An example amplification plot of samples analysed by qPCR, with data given as 
the cycle number that the signal reaches the set cycle threshold at a linear part of 
the curve.    
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2.7 Protein analysis 
Protein, extracted from both cells and tissue, was quantified and analysed by 
immunoblotting to assess cellular protein expression.  
2.7.1 Protein extraction  
For cells, media was removed from wells and cells were washed with ice cold PBS 
before adding 75 µl of radioimmunoprecipitation assay (RIPA) lysis and extraction 
buffer (50 mM Trizma hydrochloride (Tris HCl) [pH 8], 150 mM sodium chloride 
(NaCl), 1% (w/v) Nonidet P-40 (NP-40), 0.5% (w/v) sodium deoxycholate 0.1% 
(w/v) sodium dodecyl sulfate (SDS), 1 mM ethylenediaminetetraacetic acid 
(EDTA)). Each 10 ml RIPA stock was supplemented with 100 µl of phosphatase 
inhibitor, 1 Pierce protease inhibitor tablet (Life Technologies, UK) and, to inhibit 
histone deacetylase (HDAC) enzymes, 10 mM nicotinamide and 1 µM of 
trichostatin A (TSA). Using a scraper cells were removed from the well surface in 
RIPA and pipetted up and down to maximise lysis. Lysates were transferred to 
Eppendorf tubes on ice and underwent two freeze thaw cycles to further enhance 
lysis. Samples were centrifuged at 12000 rpm for 10 minutes to pellet debris and 
the supernatant was transferred to a new Eppendorf. For tissues, previously snap 
frozen tissues were placed immediately into 150 µl of ice cold RIPA buffer and 
manually homogenised. Samples were also freeze thawed twice and followed the 
same extraction process as cell lysates from this point.   
2.7.2 Quantification 
The Bio-Rad DCTM protein assay kit was used to measure protein lysate 
concentration. 5 µl of protein samples, and serially diluted bovine serum albumin 
(BSA) protein standards (of known concentrations in RIPA), were added to a 96 
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well plate in duplicate.  200 µl of Bio-Rad protein assay reagent B was added to 
each well followed by 25 µl of Bio-Rad protein assay reagent A (supplemented 
with 20 µl of reagent S per 1 ml of reagent A). Samples were incubated at room 
temperature for 5 minutes and then plates were read using the Victor3 1420 
multilabel plate reader (PerkinElmer, USA) at 595 nm. Standards were plotted on 
a scatter graph and sample concentrations were extrapolated from the standard 
curve (see figure 2.4 for an example standard curve). 
Figure 2.4 BSA standard curve 
Following the Bradford assay a BSA standard curve was plotted using the 
absorbance of BSA at known concentrations. The concentration of samples was 
then determined by extrapolating absorbance values to the standard curve.  
 
2.7.3 Immunoblotting  
Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to separate proteins based on their molecular weight. 10% (v/v) acrylamide 
gels were made in Bio-Rad SDS-PAGE apparatus using ProtoGel reagents 
(national diagnostics, UK). Firstly, 10 ml resolving gels were made (3.33 ml of 30% 
acrylamide, 2.5 ml of 4x resolving buffer, 0.5 ml 1.5% (w/v) ammonium persulfate, 
y = 0.0316x + 0.0946 
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3.67 ml distilled water and 10 µl tetramethylethylenediamine (TEMED)) and 
poured into the gel apparatus and left until set. Following this, stacking gels were 
made (0.6 ml of 30% acrylamide, 1.25 ml of stacking buffer, 0.2 ml 1.5% (w/v) 
ammonium persulfate, 2.6 ml distilled water and 15 µl TEMED) and poured on top 
of set resolving gel. 10 well combs were added to the top of the stacking gel and 
then left to set. Once set gels were transferred into Bio-Rad SDS-PAGE tanks and 
running buffer (0.1 M Tris [pH 7.4], 0.1 M glycine and 0.1% (w/v) SDS) was added.      
Protein samples were made up to 20 µg/µl in distilled water and 2x Laemmli 
sample buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% 
bromophenol blue and 0.125 M Tris HCl [pH approx. 6.8]) was added in a 1:1 
ratio. Samples were boiled for 3-5 minutes before loading.  
Combs were removed from the gels, wells were washed with running buffer and 5 
µl of PAGE-Ruler plus prestained protein ladder was added to the first well to 
mark specific molecular weights. Then protein samples were added to the 
remaining wells. The Bio-Rad tank was filled with running buffer and the gels were 
electrophoresed at 120 V for 1.5 hours or until the dye front reached the end of the 
gel. Gels were removed and transferred onto nitrocellulose membranes using the 
iBlot (Invitrogen, UK). Ponceau S stain was added to membranes to confirm even 
transfer and then membranes were washed briefly in PBS. Membranes were 
blocked in 5% (w/v) milk or 5% (w/v) BSA in PBS with 0.1% (v/v) Tween (PBS-T) 
for 1 hour rocking at room temperature. Membranes were briefly washed in PBS-T 
and then primary antibody (in 5% milk or BSA in PBS-T) was added to 
membranes and left rocking overnight at 4°C. Membranes were washed in PBS-T 
for 5 minutes 3 times and then secondary antibody (in 5% milk or BSA in PBS-T) 
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was added to membranes for 1-2 hours rocking at room temperature (see 
Appendix C for antibody details). Membranes were washed for 15 minutes 4 times 
in PBS-T and then 1 ml of electrochemiluminescence (ECL) luminance substrate 
(Bio-Rad, UK) was added to each membrane and left at room temperature for 5 
minutes. Membranes were placed into a developing cassette and covered with 
seran wrap; then in darkness a blue-x-ray film (GE Healthcare Life Sciences, UK) 
was placed in the cassette and left for the required exposure time. Films were 
removed and developed in the Xograph compact X4 developer (Xograph 
healthcare, UK). 
2.8 NAD+ measurements  
2.8.1 NAD+ cycling assay 
To measure cellular NAD/NADH content we used reagents provided in the 
NAD/NADH quantification colorimetric kit (BioVision, USA). NAD cycling enzyme 
activity results in sample colour intensity proportional to the amount of NAD/NADH 
present; providing both specific and sensitive detection. 
 
Figure 2.5 NAD/NADH assay principals 
The two key steps to detect NADH using the NAD/NADH colorimetric cycling 
assay. Step 1 converts all of the sample NAD+ to NADH and step 2 involves the 
addition of a colorimetric probe to develop colour intensity proportional to NADH 
content 
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Samples were kept on ice unless otherwise stated.  Cells were differentiated in 12 
well plates for 6 days and washed twice with ice cold PBS. 400 µl of extraction 
buffer was added to each well, cells were scraped from the well surface and 
transferred to an Eppendorf tube. Cells were freeze thawed twice on dry ice to 
maximise lysis and vortexed for 10 seconds. Samples were centrifuged at 14000 
rpm to pellet debris and supernatant was split between two new tubes (200 µl in 
each), labelled as total NAD and NADH. The NADH samples were then heated for 
30 minutes at 60˚C to allow NAD+ decomposition. 50 µl of each sample was 
added to a 96 well plate in duplicate. In addition, a set of NADH standards of 
known concentrations (0-100 pmol) were also set up in duplicate and made up to 
50 µl in extraction buffer. A mix of NAD cycling enzyme in NAD cycling buffer was 
made with 2 µl enzyme and 98 µl buffer per sample. 100 µl of the mix was added 
to each well and plates were mixed gently and left to incubate at room 
temperature for 5 minutes. 10 µl of NADH developer was then added to each well 
and the plate was left for 1 – 4 hours at room temperature for the cycling reaction 
to take place (reaction principals represented in figure 2.5).  
Plates were read using Victor3 1420 multilabel plate reader (PerkinElmer, USA) at 
optical density (OD) 450 nm. Using the known standard values a standard curve 
was plotted (demonstrated in figure 2.6) and sample concentrations were 
extrapolated. NAD+ content was determined by subtraction of NADH from total 
NAD.    
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Figure 2.6 NAD/NADH cycling assay standard curve 
Following the NAD/NADH cycling assay an NADH standard curve was plotted 
using the absorbance of NADH at known concentrations. Sample concentrations 
were determined by extrapolating absorbance values to the standard curve. 
 
2.8.2 High performance liquid chromatography (HPLC) NAD+ 
measurement 
HPLC was used as an alternative technique to measure NAD+ content in tissues. 
Tissue samples were analysed by Dr Antje Garten at the University of Leipzig 
using their established HPLC protocol [220]. Frozen muscle tissue was pulverized 
and then extracted in 1 M perchloric acid. Samples were neutralized in 3 M 
potassium carbonate on ice and centrifuged at 13,000 rpm for 10 minutes at 4°C. 
The supernatant was filtered and loaded onto the column. HPLC analysis was 
performed with the Chromaster Purospher STAR RP-18 endcapped 3 mm Hibar 
RT 150-3 HPLC column (Merck). To measure NAD+, the HPLC was run at a flow 
rate of 0.4 ml/min with 100% buffer A (50 mM dipotassium phosphate,  pH 7.0) 
from 0–5 min, a linear gradient to 95% Buffer A/5% Buffer B (100% methanol) 
from 5–6 min, 95% Buffer A/5% Buffer B from 6–11 min, a linear gradient to 85% 
Buffer A/15% Buffer B from 11–12 min, 85% Buffer A/15% Buffer B from 12–16 
min, and a linear gradient to 100% Buffer A from 16–17 min. NAD+ was eluted as 
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R² = 0.9966 
0.0
0.5
1.0
1.5
2.0
0 20 40 60 80 100 120 140 160A
b
s
o
rb
a
n
c
e
 (
a
t 
4
5
0
 n
m
) 
 
NADH (pmol) 
NADH standard curve 
 
 
66 
 
a sharp peak at 15 min and quantitated by peak area relative to a standard curve 
and normalised to tissue weight.  
2.9 Cell viability 
Cellular viability and apoptotic activity were both determined using the ApoLive-
GloTM Multiplex assay (Promega, USA). As the aim of this experiment was to 
determine cell viability upon changing NAD+ content this assay was specifically 
chosen because the reactions are not NAD+ dependent.  
Cells were seeded into 96 well plates at a density of 15,000 per well and 
differentiated for 6 days, before cells were treated with the relevant compounds for 
24, 48 or 72 hours with a final well volume of 100 µl. Hydrogen peroxide (1 mM 
and 100 µM) and ionomycin (100 µM) were added as controls to induce cell death. 
Firstly, cell viability was measured; 10 µl of glycyl-phenylalanyl-amino 
fluorocoumarin (GF-AFC) substrate – cleaved by protease activity limited to viable 
cells - was added to 2 ml of assay buffer provided to make viability reagent. Then 
20 µl of the reagent was added to each well and the plate was mixed using an 
orbital shaker at 300 rpm for 30 seconds. The plate was incubated for 30 minutes 
at 37°C. Fluorescence was measured at 400EX/505EM with the signal proportional 
to the number of viable cells (see step 1 figure 2.7 for viability reaction). 
Secondly, induction of apoptosis in cells was determined by measuring the activity 
of the apoptotic marker caspase-3/7. 100 µl of the Caspase-Glo® was added to 
each well and mixed using an orbital shaker at 300 rpm for 30 seconds. The plate 
was incubated for 30 minutes at room temperature and then luminescence was 
measured with an increase in signal proportional to caspase-3/7 activity (step 2 
figure 2.7).    
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Figure 2.7 Cell viability and apoptosis assay 
Key principals of the ApoLive- GloTM Multiplex assay (Promega). Cell viability (step 
1) can be determined by addition of the glycyl-phenylalanyl-amino fluorocoumarin 
(GF-AFC) substrate which can cross cell membranes and can be cleaved by live 
cell protease activity to release fluorescent AFC (live cell protease is inactive in 
membrane compromised cells). Cellular apoptotic activity (step 2) can be 
determined by caspase-3/7 activity. Luminogenic substrate is added to cells and 
upon caspase-3/7 activity aminoluciferin is released, which is a substrate for the 
UltraGloTMluciferase enzyme and ultimately leads to production of light.  
 
2.10 Bioinformatics 
Online bioinformatic databases were used to investigate protein and nucleotide 
sequences of genes of interest. To maximise reliability numerous sequence 
database sites were used including PubMed (https://www.ncbi.nlm.nih.gov/gene), 
Ensembl (http://www.ensembl.org/index.html) and Z-Fin (https://zfin.org) and cross 
examined. Sequences were aligned using multiple sequence alignment software 
ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) using on an adaption to the 
Myers and Miller alignment algorithm and scored on sequence similarity (using the 
Gonnet PAM 250 matrix) [221, 222].   
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2.11 Respirometry  
Respirometry can be used to provide insight into mitochondrial function. 
Technology has been developed using oxygen sensors to measure oxygen flux in 
cells and tissue. Oxidative capacity can be inferred by assessing changes in 
oxygen over time. Seahorse Extracellular flux (XF) analysis provides a high 
throughput technique in response to different cellular stressors or treatments 
whereas Oroboros technology provides a high resolution analysis.    
2.11.1  Seahorse Extracellular flux (XF) analyser 
Primary and C2C12 myoblasts were seeded at 25,000 cells/well density in 24 well 
XF cell culture microplates (wells were equivalent size to those in a standard 96 
well plate). Prior to the assay an XF sensor cartridge was hydrated overnight in XF 
calibrant (Agilent Technologies, USA) at 37˚C in a non CO2 incubator. Upon 6 
days of differentiation cells were analysed using the XF Cell Mito Stress Test kit 
on the Seahorse XF analyser following the Seahorse Bioscience user guide 
(Agilent Technologies, USA). Assay medium was prepared by supplementing XF 
base medium with 1 mM pyruvate, 2 mM glutamine and 10 mM glucose at pH 7.4. 
Stock solutions of the compounds from the XF cell mitochondrial stress test kit 
were made by resuspending each compound – oligomycin, carbonyl cyanide-4 
(trifluoromethoxy) phenylhydrazone (FCCP) and rotenone/antimycin A – in assay 
medium to concentrations of 100 µM, 100 µM and 50 µM respectively. Each test 
compound was made up to its final concentration in 3 ml of assay medium 
(oligomycin (2.5 µM), FCCP (5 µM) and rotenone/antimycin A (1 µM)) and 25ul of 
each added to sensor cartridge ports A (oligomycin), B (FCCP) and C 
(rotenone/antimycin A). Following this, cell media from microplates was changed 
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to Seahorse assay media and incubated for 1 hour at 37˚C in a non-CO2 
incubator. The plate was then loaded onto the XF analyser and the assay was run 
following the software instructions. During the run, each compound from the 
mitochondrial stress kit was subsequently released from its respective cartridge 
following a pre-set programme, table 2.3 and figure 2.8 demonstrate the order the 
compounds were released and the intended effect on mitochondrial respiration 
measured by oxygen consumption rate (OCR).  
 
Compound Mitochondrial 
ETC target 
Effect 
Oligomycin 
ATP Synthase 
(complex V) 
Inhibition of ATP synthase and decrease 
OCR – indicating the cells ATP production 
to meet energy demand of the cells 
FCCP Inner membrane 
Uncoupler to give maximum OCR of the 
cells – providing the maximal respiratory 
capacity of the cell 
Rotenone/ 
antimycin A 
Complex I and III 
respectively 
Inhibit complexes and decrease OCR-  by 
shutting off mitochondrial ATP production 
Table 2.3 – Mitochondrial stress kit components – listed in order of loading with a 
description of intended effect on mitochondrial electron transport chain (ETC) 
[223].  
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Figure 2.8 Seahorse Bioscience XF Cell Mito Stress Test profile 
Graphical representation by Seahorse Biosciences (Agilent Technologies, USA), 
of mitochondrial respiration (measured by cellular OCR) over time with the XF Cell 
Mito Stress Test kit components oligomycin, FCCP and antimycin A and rotenone 
[223]. 
  
2.11.2 High resolution respirometry - Oroboros  
Excised muscles were placed in 2 ml of ice cold biopsy preservation solution 
(BIOPS) buffer (10 mM Ca-EGTA buffer, 0.1 µM free calcium, 20 mM imidazole, 
20 mM taurine, 50 mM K-MES, 0.5 mM dithiothreitol (DTT), 6.56 mM magnesium 
chloride (MgCl2), 5.77 mM ATP, 15 mM phosphocreatine, pH 7.1) and kept on ice. 
The muscles were transferred into a petri dish with 2 ml BIOPS buffer and using 
forceps and a dissecting microscope muscle fibres were separated into clusters 
with care taken not to tear fibres and damage mitochondrial membranes. Fibre 
clusters were transferred into new ice cold BIOPS buffer and 20 µl of saponin 
stock solution (at 5 mg / ml of BIOPS) was added and fibres were incubated – 
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shaking at 4 °C – for 30 mins to permeabilise. Fibres were then removed from the 
BIOPS and dried out on filter paper before 5 mg of fibres were weighed out and 
transferred into 2 ml of ice cold mitochondrial respiration medium (MiRO5) (0.5 
mM EGTA, 3 mM MgCl2-hexahydrate (MgCl2·6 H2O), 60 mM lactobionic acid, 20 
mM taurine, 10 mM potassium dihydrogen phosphate (KH2PO4), 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 110 mM D-Sucrose and 
1 g/l BSA, essentially fatty acid free) at pH 7.1. The suspended fibres were then 
transferred into the pre-cleaned and calibrated Oroboros respirometer chambers.  
Once airflow stabilised a succession of substrates were added after 5 minutes of 
stable signal from the previous substrate. Using a Hamilton syringe substrates 
were added in the following order and concentrations; 0.5 mM malate, 55 µM 
palmitoyl carnitine (for fatty acid oxidation), 10 mM glutamate, 5 mM ADP, 10 µM 
cytochrome c (to check mitochondrial integrity), 10 mM succinate, 0.5 µM FCCP 
(for maximal respiration), 0.5 µM rotenone and finally 2.5 µM antimycin A (to 
Inhibit mitochondrial respiration). Oxygen flux is measured following addition of 
each substrate to the myofibres, with a representative oxyograph trace 
demonstrated in figure 2.9.      
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Figure 2.9 Oroboros respirometry trace 
A representative Oroboros high resolution respirometry trace of myofibres treated 
sequentially with the substrates listed (added at each vertical blue line on the 
trace). Chamber oxygen is concentration is represented by the blue line and 
oxygen flux represented in red.  
 
 
2.12 Metabolomics 
Metabolomic techniques can detect and quantify metabolites. Methods can be 
specifically targeted to metabolites of interest – and with the addition of internal 
standards can provide accurate quantification – or methods can be untargeted in 
order to identify new metabolites of interest for further analysis.  
2.12.1 Primary muscle cell treatments for targeted metabolomics 
Primary myotubes were differentiated for 6 days in 175 cm3 flasks and cultures 
were either untreated or treated for 24 hours with 0.5 mM NR, 100 nM FK866 or 
both 0.5 mM NR and 100 nM FK866. Media was expelled and the myotubes were 
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washed once with ice-cold PBS. Myotubes were then detached from the surface 
using a cell scrapper in 3 ml of PBS and transferred in equal amounts into two 
new Eppendorf tubes for separate acid (A) and alkaline (B) extractions. Cells were 
pelleted by centrifugation at 4°C, supernatant was removed and pellets were 
stored at -80°C until extraction.  
2.12.2 Extraction procedure for primary muscle cells liquid 
chromatography- mass spectrometry (LC-MS) - based metabolomics 
Cell pellets were kept on dry ice and 20 µl of internal standard (IS) A or B diluted 1 
in 20 in LC-MS grade water was added to each sample. IS A (13C yeast extract) 
was used for the acid extraction and IS B (18O nicotinamide riboside (NR), 18O 
nicotinamide (Nam), D4 nicotinic acid (NA), D3, 
18O MeNam solution (60 µM of 
heavy NR, Nam, and MeNam and 240 µM of heavy NA)) was added to alkaline 
extractions. 300 µl of buffered ethanol (75 % ethanol: 25 % 10 mM HEPES pH 
7.1) pre-heated to 80°C was added to each sample and samples were placed on 
the pre-heated Eppendorf Thermomixer at 80°C for 3 minutes shaking at 1050 
rpm. Samples were then sonicated for 30 seconds in a bath sonicator (VWR, 
USA) and placed on ice. Samples were centrifuged for 10 minutes at 4°C at 
maximum speed and the supernatant was then transferred to a new Eppendorf 
tube. Both the pellet and supernatant (extract) were dried using a speed vacuum. 
Dried pellets were weighed and discarded and the dried extract was resuspended 
in 40 µl of the appropriate buffer (LC-MS grade water for acid extract and 10 mM 
ammonium acetate for alkaline extract). Extracts were then centrifuged at 
maximum speed for 10 minutes at 4°C and the supernatant was transferred to 
fresh Waters Polypropylene 0.3 ml plastic screw-top vials and analysed by LC-
MS/MS using the ACQUITY UPLC H-class system (Waters, USA). Acidic and 
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alkaline separation gradients are listed in table 2.4. Acidic solvent A was 10 mM 
ammonium acetate and 0.1% formic acid and solvent B was 0.1% formic acid in 
acetonitrile. Alkaline solvent A was 7.5 mM ammonium acetate and 0.05% (v/v) 
ammonium hydroxide and solvent B was 0.05% (v/v) ammonium hydroxide in 
acetonitrile). Detection parameters for each metabolite are provided in appendix D 
(as described by Trammell et al. [224]) and representative LC-MS raw data for 
NAD+ detection is displayed in figure 2.10. 
Acidic separation gradient. 
 
Alkaline separation gradient. 
Time 
(min) 
Solvent B 
(%) 
Column 
Volumes 
 
Time 
(min) 
Solvent B 
(%) 
Column 
Volumes 
0 5 - 
 
0 5 - 
1.8 5 1 
 
1.8 5 1.8 
11.2 35.9 5.4 
 
14 54 12.4 
11.3 90 - 
 
14.1 90 - 
13.3 90 1.2 
 
17.1 90 3 
13.4 5 - 
 
17.2 5 - 
23.4 5 5.8  
 
32.2 5 15.3  
Table 2.4 – LC-MS acidic and alkaline separation gradients  
 
Figure 2.10 Representative LC-MS raw data  
Exemplary data for detection of NAD+ using quantitative LC-MS. With traces from 
3 samples showing clear NAD+ peaks and resulting data tabulated below.       
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2.12.3 Tissue pulverisation and weighing 
Samples were kept frozen in liquid nitrogen. Liquid nitrogen was added to a 
polystyrene insulated box and all the equipment – Bessman Pulveriser, tweezers 
and spatulas – was submerged in liquid nitrogen and left until fully cooled. Cryo-
protective gloves were worn and the cooled pulveriser base was placed on foil, 
frozen tissue was immediately placed into the pulveriser base. The pulveriser pin 
was then placed into the base and pounded with a hammer until the tissue was 
powdered. The pin was removed and using a cooled spatula powdered tissue was 
transferred back into the cooled cryotube. The pulveriser was then cleaned with a 
Kimwipe (Kimtech, US) and placed back into the liquid nitrogen.  
For weighing, Eppendorf’s were pre-cooled on a rack in liquid nitrogen. A cooled 
tube was placed on the balance and 10-20 mg of frozen pulverised tissue was 
transferred using a cooled spatula, the exact weight was recorded, and 
immediately returned to the pre-cooled rack.      
2.12.4 Muscle tissue extraction for targeted metabolomics  
Pulverised muscle samples were placed on dry ice and a stock of 1 in 300 diluted 
IS A or B in LC-MS grade water was prepared to give 300 µl of IS per sample. Dry 
ice was added to a beaker of acetone to make a water bath at -4°C. Before 
starting the Branson sonifier was washed in a 50:50 water and methanol solution. 
Then 0.2 ml of ice cold LC-MS grade methanol was added to a sample, which was 
immediately returned to ice, before adding 300 µl of either IS A or B stock solution. 
Using a buoyancy aid the sample was then placed in the acetone water bath and 
sonicated for 20 seconds (with duty cycle set at 40% and output control at 4) and 
placed back on ice. This was repeated for all samples one at a time. Then all the 
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samples were placed on the Eppendorf Thermomixer pre-heated to 85°C for 5 
minutes shaking at 1050 rpm. Samples were returned to ice for 5 minutes – an 
essential step to help preserve some metabolites – before they were centrifuged 
for 10 minutes at 4°C at maximum speed. The supernatant was transferred to a 
new Eppendorf tube. Both the pellet and supernatant (extract) were dried using a 
speed vacuum. Dried pellets were weighed and discarded and the dried extract 
was resuspended in 40 µl of the appropriate buffer (LC-MS grade water for acid 
extract and 10 mM ammonium acetate for alkaline extract). Extracts were then 
centrifuged at maximum speed for 3 minutes at 4°C and the supernatant was 
transferred to fresh Waters Polypropylene 0.3 ml plastic screw-top vials and 
analysed by LC-MS/MS using the ACQUITY UPLC H-class system (Waters, 
USA). Acidic and alkaline separation gradients are listed in table 2.4. Detection 
parameters for each metabolite are provided in appendix D (as described by 
Trammell et al. [224]) and representative LC-MS raw data for NAD+ detection is 
displayed in figure 2.10. 
2.13 Mouse investigations 
All experiments and procedures involving animals were approved by and 
performed under British Home Office Guidance (Animals Scientific Procedures) 
Act 1986  
2.13.1 Nmrk2 KO mouse  
NMRK2KO mice were acquired from  The Nmrk2 
KO mutant allele was generated through the Knockout Mouse Phenotyping 
Program (KOMP2) on a C57BL/6N background. A ZEN-UB1 Velocigene cassette 
(beta-galactosidase coding sequence from E. coli lacZ gene; polyadenylation 
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signal; loxP site; promoter from the human ubiquitin C gene; neomycin 
phosphotransferase;polyadenylation signal; loxP site) was inserted through 
homologous recombination into the gene in place of all coding exons inhibiting 
transcription (figure 2.11). The construct was introduced into embryonic stem (ES) 
cells, and successfully targeted cells were injected into blastocysts and implanted 
into B6(Cg)-Tyrc-2J/J mice. After breeding, male chimeras containing the KO 
cassette were identified and bred with C57BL/6NJ females. The neo cassette and 
the cre-expressing transgene were removed following further breeding of offspring 
[225]. On receipt of heterozygous male and female mice, genotyping was 
conducted to confirm heterozygosity of the Nmrk2 gene. 
 
 
Figure 2.11 NMRK2 KO mouse construct map 
An illustration of a full insertional cassette gene ablation of the Nmrk2 gene 
through homologous recombination with a neomycin cassette.  
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2.13.2 Genotyping 
Tail or ear clippings from mice were digested by adding DNA extraction buffer (75 
µl of 25 mM sodium hydroxide (NaOH) and 0.2 mM EDTA) and heated for 1 hour 
at 98°C. Temperature was reduced to 15°C and 75 µl of 40 mM Tris-HCl (pH 5.5) 
was added. Samples were briefly centrifuged at 4000 rpm to pellet debris. 1 µl of 
extracted DNA was then aliquoted for PCR. PCR samples were made to a final 
volume of 20 µl using a mastermix with 2x BioMix Red (Bioline, UK) and the 
primers listed in table 2.5, as described in section (2.5). Samples were placed in 
the PCR thermocycler set to 5 minutes at 95 °C then 35 cycles of [30 seconds 95 
°C, 30 seconds 60 °C and 30 seconds 72 °C] followed by 5 minutes at 72 °C and 
left indefinitely at 4°C and analysed by electrophoresis on 1.8% agarose gels 
(figure 2.12) (see section 2.5).      
Primer sequence 
 
CGG TCG CTA CCA TTA CCA GT Mutant forward 
GGG ACA TGC CCT CCT ATG TA Mutant Reverse 
CCA AAT AGC AGT CGG AGA GG Wild type Forward 
GCA AAC TTG TGT GGA TCC TTC Wild type Reverse 
Table 2.5 – Wild type (WT) and mutant Nmrk2 primers 
 
Figure 2.12 Nmrk2 genotyping 
An example image from Nmrk2 genotyping with lower WT band and upper mutant 
band. A Nmrk2 heterozygous positive (+ve) control was used.  
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2.13.3 Animal breeding and care 
Heterozygous breeding of the Nmrk2 KO mouse (NMRK2KO) line was employed 
to provide litter matched WT and NMRK2KO offspring for studies. Animals were all 
kept in an enriched pathogen–free environment at 21-23°C with 12 hour light/dark 
cycles.  Unless otherwise stated standard chow and water was available ad 
libitum.   
2.13.4 Glucose tolerance test (GTT) 
GTTs were performed following 6 hours of food restriction with water remaining ad 
libitum. Mice were placed into restrainers, analgesic cream was applied to the tail 
and using a scalpel a small incision was made to the tail’s lateral superficial 
vessel. A drop of blood from the incision was collected on Accu-Chek blood 
glucose strips (Boots, UK) and read using a glucometer to provide a baseline 
blood glucose reading. Following this glucose (2g/kg) was administered by I.P 
injection into the lower left quadrant of the abdomen and blood glucose was 
measured by taking a drop of blood from the original tail incision at 15, 30, 60, 90 
and 120 minutes post glucose administration. Animals were monitored during and 
following the procedure for any signs of unexpected stress.  
2.13.5 Fasting 
Mice were single housed in clean cages with no access to food for 16 hours 
(overnight) before tissue collection. Mice had normal access to water and were 
kept in normal housing conditions.   
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2.13.6 High fat diet (HFD) 
From 10 weeks of age, mice were fed a commercially available High fat chow 
(Brogaarden, Denmark), composed of 60% Kcal fat, for 16 weeks.  The mice were 
weighed before starting the HFD and once a week until the end of the diet. 
2.13.7 In vivo metabolic phenotyping 
The PhenoMaster (TSE systems, Germany) system was used to collect indirect-
calorimetry data in vivo. The 8 house system measures the exchange of O2 and 
CO2 to give the respiratory exchange ratio (RER) and predicted heat production, 
as well as measuring food and drink intake. Mice were weighed and placed into 
the PhenoMaster with their original litter mates and in their original cages for 24 
hours to acclimate to the new environment. Following this, the mice were 
separated and housed individually for 72 hours within the PhenoMaster. The first 
24 hours allowed the mice to adapt to isolation from litter mates, and then 
metabolic data was collected during the final 48 hours. Body weight, food and 
drink intake was monitored throughout, an example metabolic trace is provided in 
figure 2.13.  
 
Figure 2.13 PhenoMaster in vivo metabolic trace 
An example trace from a mouse placed in a PhenoMaster metabolic house. RER 
(blue), drink (red), feed (green), O2 (purple) and CO2 (pink) are some of the key 
parameters that can be tracked over 72 hours.  
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2.13.8 Treadmill exercise 
To assess performance and metabolic adaptation of skeletal muscle following 
exercise a six lane mouse treadmill (TSE systems, Germany) was used for 
endurance exercise. Mice were acclimatised to the treadmill apparatus by initially 
placing them into lanes and giving them the opportunity to become familiar with 
the new environment. After this the treadmill was switched on and the treadmill 
speed and duration was gradually increased over a two-week period until mice 
were running for one hour at the full protocol speed of 0.2 m/s at a 15% incline. 
Following acclimatisation, mice were exercised for six weeks at 10am for one 
hour, three times a week at a speed of 0.2 m/s and 15% incline. Upon stopping at 
the end of the treadmill during the exercise, mice were encouraged to re-join the 
treadmill and were briefly blown with air if they failed to re-join the treadmill (up to 
a maximum of three times).    
2.13.9 Animal sacrifice and tissue collection 
Mice were sacrificed by schedule one cervical dislocation at 10 am to minimise 
circadian influence and, following cessation of circulation, tissues were excised 
immediately with muscle tissue prioritised to reduce acute signalling changes and 
metabolite degradation. Tissues were then either snap frozen in liquid nitrogen or 
placed in the required buffer or fixing agent for further analysis.   
2.14 Muscle fibre typing 
Using antibodies specific to the different myosin heavy chain (MHC) subunits 
expressed in muscle it was possible to count the different fibres and estimate the 
fibre type composition of individual muscles.  
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For fibre typing, muscles were specially snap frozen in isopentane, converting 
water within the tissue to small ice crystals and allowing effective cryostat 
sectioning. A beaker containing isopentane was lowered into liquid nitrogen and 
left until it was mostly frozen, leaving a small liquid pool in the centre of the beaker 
for tissues to freeze. Small cork discs were prepared with pins placed 
perpendicular and a drop of optimal cutting temperature compound (OCT) placed 
on the disc at the base of the pins. Muscle was excised carefully and intact to 
prevent structural damage and placed perpendicular to the cork disc alongside the 
pin. The cork disk was quickly lowered into the isopentane pool and left for 15-20 
seconds to ensure the muscle was fully frozen. On removal, the disks containing 
the tissue were immediately wrapped in foil and placed on dry ice taking care to 
prevent tissue thawing or damage and stored at -80°C.  
The frozen tissue was then analysed by Dr Gabriela Da Silva Xavier at Imperial 
College London using their established immunofluorescence staining protocol. 
Tissues were cut into 10 µm sections using a cryostat, mounted onto Superfrost 
slides and air dried for 10 minutes. Sections were washed 3 times for 5 minutes in 
PBS-T and blocked of 60 minutes in 10% goat serum in PBS-T. Sections were 
then stained using primary antibodies for different myosin heavy chain subunits 
(grouped into cocktails- see table 2.6) for 2 hours, Sections were washed in PBS-
T 3 times for 5 minutes and secondary immunofluorescent antibodies, all outlined 
in table 2.6, were then added for 60 minutes. Sections were formalin fixed and 
washed in PBS for 5 minutes before coverslips were mounted with Vectashield 
hard setting (Vector laboratories, USA). Using a Zeiss Axio Observer inverted 
microscope (Carl Zeiss, Germany) – set up with Green (470 nm LED; Excitation 
472/30; Emission 520/35), Red (540 - 580 nm LED; Excitation 534/20; Emission 
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572/28), Far Red (625 nm LED; Excitation 631/22; Emission 688/20) and 
Hammamatsu Flash4 camera – the entire section was imaged. Fibres were 
counted across the whole section manually using Image J (Fiji) software and 
recorded as positive for each fibre expressing the relevant visible colour.  
Cocktail  Primary antibodies MHC Reactivity  Secondary antibodies 
Cocktail 1a 
BA-F8 (1:50) MHC I IgG AF 647 (1:500) - Blue 
BF-F3 (1:100) MHC IIb IgM AF 555 (1:500) - Red 
Cocktail 1b 
SC-71 (1:600) MHC IIa IgG AF 488 (1:500) - Green 
BF-F3 (1:100) MHC IIb IgM AF 555 (1:500) - Red 
Cocktail 2 
SC-71 (1:600) MHC IIa IgG AF 488 (1:500) - Green 
6H1 MHC IIx IgM AF 555 (1:500) - Red 
Table 2.6 – Primary and secondary antibodies used for muscle fibre-typing 
2.15 Statistical analysis 
Statistical analysis was conducted using GraphPad Prism6 software (GraphPad 
software, USA). Unpaired Student t-test analysis was used when comparing single 
treatments or groups to a control. One way ANOVA was used for the comparison 
of multiple treatments, groups or times and two-way ANOVA was used for 
comparison of multiple groups over time. Statistical analysis of qPCR data was 
conducted using deltaCT values after normalisation with housekeeping gene 18s. 
‘n’ numbers for each experiment are noted in the related figure legend.                  
Key: * = P<0.05, ** = P<0.01, *** = P<0.001  
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Chapter 3 Characterisation of NAD
+
 
biosynthesis and salvage 
pathways in skeletal muscle. 
(For targeted NAD+ metabolomics LC-MS training and facilities were provided by 
Prof Charles Brenner at the University of Iowa and conducted during a one month 
lab placement)   
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3.1 Introduction 
Skeletal muscle plays a central role in whole body metabolism and accounts for 
approximately 30% of an adult’s total energy metabolism at rest [46]. Importantly, 
skeletal muscle also acts a major reservoir of nutrient reserves (such as glycogen 
and amino acids) that can be used upon changes to energy demand [26]. The 
complex mechanisms involved in skeletal muscle metabolic adaptation in 
response to energy stress cues are still undefined. Further understanding of these 
mechanisms is essential to determine novel molecular targets, which may play a 
central role in skeletal muscle metabolic decline, for therapeutic intervention.  
3.1.1 NAD+ signalling in skeletal muscle metabolism  
Since the discovery of NAD+ dependent sirtuin (SIRT) proteins, NAD+ has risen to 
prominence as a key regulator of cellular metabolism and mitochondrial function. 
During SIRT signalling NAD+ is consumed [90, 99] and therefore necessitates 
NAD+ re-synthesis to replenish and maintain cellular NAD+ content for continued 
signalling and unperturbed redox homeostasis.  Numerous NAD+ biosynthesis 
pathways have been identified in mammalian cells [142, 146, 226, 227]; yet it is 
still unknown how these biosynthesis pathways interact. The relative importance of 
the different NAD+ biosynthesis pathways and tissue specificity remains poorly 
understood. As metabolic decline can be both causal and consequential of muscle 
decline, this chapter aims to identify NAD+ biosynthesis pathways in skeletal 
muscle and define their relative importance to NAD+ metabolism and energy 
homeostasis.      
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3.1.2 NAD+ salvage pathways 
NAD+ can be replenished from NAD+ precursors tryptophan, nicotinic acid (NA), 
nicotinamide (NAM) and nicotinamide riboside (NR) through a number of known 
biosynthesis pathways (outlined in figure 3.1 and section 1.4). These biosynthesis 
pathways can be grouped into two distinct routes described as “amidated” or 
“deamidated” [147]. De novo synthesis from tryptophan and NA salvage are 
metabolised through multi-enzyme pathways which converge with NADsynthase1 
(NADS) – the final rate limiting “amidation” enzyme [146]. NAM and NR follow the 
“amidated” route and are metabolised to the intermediate nicotinamide 
mononucleotide (NMN) by the enzymes NAM-phosphoribosyltransferase 
(NAMPT) and nicotinamide riboside kinase (NMRK) respectively and finally NMN 
is converted to NAD+ via NMN-adenylyltransferase (NMNAT) [142, 147, 150].  
3.1.3 NAD+ biosynthesis tissue specificity  
Despite de novo biosynthesis acting as the preferred route of NAD+ biosynthesis 
in the liver [138, 139], in other tissues it is thought that the majority of cellular 
NAD+ is attributed to salvage pathways [147]; which resynthesise NAD+ from 
precursor molecules (NA, NAM and NR) found in the diet or as consumed NAD+ 
metabolites [140-142] (figure 3.1) . NAM is thought to be the preferred over NA in 
most tissues; illustrated by only transient increases in NAD+ after intraperitoneal 
(IP) injection with NA as opposed to stable increases following NAM administration 
[144]. The extent to which NMRK-mediated salvage contributes to the 
maintenance of skeletal muscle NAD+ pools is unknown. Unlike NAMPT and 
NMRK1, which are ubiquitously expressed [166, 228], NMRK2 is suggested to be 
skeletal muscle specific but has not been well characterised in this regard [171].  
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This chapter aims to establish the key NAD+ biosynthesis and salvage genes 
involved in skeletal muscle NAD+ maintenance. Skeletal muscle microarray data 
will be analysed to identify important muscle specific NAD+ biosynthesis genes. 
Further investigation of these genes will help elucidate their relative importance in 
skeletal muscle NAD+ metabolism and energy homeostasis. 
 
Figure 3.1 NAD+ de novo synthesis and salvage pathways  
A global illustration of the metabolites (blue) and enzymes (pink) involved in 
mammalian NAD+ biosynthesis and salvage pathways.  
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3.2 Materials and Methods 
3.2.1 C2C12 and Primary cell culture 
Tissue culture was performed under sterile conditions and all cells were incubated 
at 37 ˚C in 5% CO2/95% air. All culture media was refreshed every 48 hours.  
C2C12 cells were maintained in 75 cm³ tissue culture flasks in growth media (GM) 
- Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) 
foetal calf serum (FCS), 2 mM L-glutamine and 1% (v/v) penicillin/streptomycin 
(P/S) and 4.5 g/L glucose. For experiments, cells were seeded into 6 or 12 well 
plates at 60-70% confluence and left to incubate overnight. Cells were 
differentiated by replacing GM with differentiation media – DMEM supplemented 
with 5% (v/v) horse serum (HS).   
Primary muscle cells were grown from isolated satellite cells, as described in 
section 2.2, in proliferation media (DMEM with 10% (v/v) HS, 1% (v/v) P/S and 
0.5% (v/v) CEE). At 70% confluence media was changed to differentiation media 
(DMEM supplemented with 2% (v/v) HS, 0.5% (v/v) CEE and 1% (v/v) P/S).  
3.2.2 Vitamin B3 supplementation 
Unless otherwise specified, C2C12 and primary myotubes were supplemented in 
serum free media with NR, NAM, NaR and NMN at 0.5 mM for 24 hours with or 
without 100 nM FK866 (DMSO was used as a vehicle control at 0.001% (v/v) of 
final amount).   
3.2.3 RNA Extraction  
TRIzol reagent (Invitrogen, UK) was directly added to cells or to 20 mg of frozen 
tissue. Samples were homogenised and RNA was then extracted following the 
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TRIzol extraction method outlined in section 2.6. RNA concentration and quality 
was quantified using the NanoDrop (section 2.6). 
3.2.4 Reverse transcription (RT)  
1 µg of RNA sample was made in NFW with a final volume of 10 µl per sample. 
Using the High capacity cDNA reverse transcription kit (Applied Biosystems, USA) 
a RT master mix was made using the reagents listed in table 2.2. 10 µl of the 
mastermix was added to each RNA sample and samples were placed in the 
thermal cycler set to: 10 minutes at 25˚C, 120 minutes at 37˚C, 5 minutes at 85˚C 
and then continuously at 4˚C. Following RT cDNA was stored at 4˚C.   
3.2.5 PCR 
DNA was amplified using the 2x BioMix Red (Bioline) following manufacturer’s 
instructions and using the primers listed in appendix A. Samples were placed in 
the PCR machine set to 5 minutes at 95 °C then 35 cycles of [30 seconds 95 °C, 
30 seconds 60 °C and 30 seconds 72 °C] followed by 5 minutes at 72 °C and left 
indefinitely at 4 °C. Samples were analysed by electrophoresis on 1.8% Agarose 
gels.     
3.2.6 Real-time PCR (qPCR) 
For each TaqMan primer probe (Applied Biosystems, USA) a master mix was 
made as follows - 3.5 µl NFW, 0.5 µl gene primer probe and 5 µl 2x qPCR master 
mix (Applied Biosystems, USA) – per sample. 1 µl each cDNA sample was added 
to a well of a PCR plate followed by 9 µl of the gene probe master mix. All 
samples were run in duplicate or triplicate. Plates were sealed and spun briefly 
before they were loaded onto the ABI 7500 Real-time-PCR as described in section 
2.6.4.  
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3.2.7 Bioinformatics 
Bioinformatic analysis was conducted using online resources. Sequence 
alignment was performed using the software ClustalW2 and alignments were then 
scored based on sequence similarity.   
3.2.8 Immunoblotting  
10% (v/v) acrylamide gels were made using ProtoGel reagents (national 
diagnostics, UK) in Bio-Rad SDS-PAGE apparatus as described in section 2.7.  
Protein samples were made up to 20 µg/µl in distilled water and 2x Laemmli 
sample buffer was added in a 1:1 ratio. Samples were boiled for 5 minutes before 
loading. Samples were loaded into the wells and gels were electrophoresed at 120 
V for 1.5 hours or until the dye front reached the end of the gel. Gels were 
removed and transferred onto nitrocellulose membranes using the iBlot 
(Invitrogen, UK). Membranes were blocked and probed with primary and 
secondary antibodies as described in section 2.7 In darkness, (GE Healthcare Life 
Sciences, UK) was applied to the membrane following ECL treatment and then 
processed using the Xograph compact X4 developer (Xograph healthcare, UK). 
3.2.9 Targeted NAD+ metabolomics 
Primary myotubes or tissue samples were extracted in ice cold LC-MS grade 
methanol. 300 µl of internal standard (diluted 1:300 in LC-MS grade water) was 
added and samples were sonicated for 20 seconds at -4°C. Then the samples 
were incubated at 85˚C for 5 minutes, shaking at 1050 rpm. Samples were 
returned to ice for 5 minutes and centrifuged. Supernatant was transferred to a 
new tube and dried using a speed vacuum. Dried extract was resuspended in 40 
µl of either LC-MS grade water for acid extract or 10 mM ammonium acetate for 
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alkaline extract. Following a brief centrifugation, supernatants were transferred 
into Waters Polypropylene 0.3 ml plastic screw-top vials and analysed by LC-
MS/MS using the ACQUITY UPLC H-class system as described in section 
(2.12.2). 
3.2.10 NAD+ cycling assay 
NAD+ was extracted from C2C12 and primary myotubes and quantified using the 
NAD/NADH quantification colorimetric kit (BioVision, UK) as described in section 
2.8.1.  
3.2.11 Respirometry 
The Seahorse extracellular flux (XF) mitochondrial stress kit was used to measure 
cellular oxygen consumption. Differentiated C2C12 and primary myotubes were 
treated and analysed on the Seahorse XF analyser following the Seahorse 
Bioscience user guide (Agilent Technologies, USA). 
3.2.12 Cell viability 
C2C12 myotubes were differentiated and treated in a 96 well plate. Cell viability 
and apoptosis was assessed using the ApoLive-Glo™ multiplex assay (Promega) 
according to the section 2.9.  
3.2.13 Statistics 
Prism 6 (GraphPad) was used for statistical analysis with data presented as 
mean± SEM and P values <0.05 determined significant. Mean ΔCt values from the 
qPCR data was analysed using unpaired t-tests and One way ANOVA analysis for 
time course data. ‘n’ numbers for each experiment are noted in the related figure 
legend. Key: * = P<0.05, ** = P<0.01, *** = P<0.001 
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3.3 Results 
Since NAD+ was established as a key signalling molecule in energy metabolism, 
there has been a spike in research investigating NAD+ dynamics and re-synthesis 
pathways in metabolically important tissues and pathological states [66, 86, 145]. 
Yet, despite this growing interest and the clear therapeutic potential of enhancing 
NAD+ availability, NAD+ biosynthesis and salvage pathways remain ill-defined in 
skeletal muscle.   
3.3.1 NAD+ metabolism in aged skeletal muscle 
During ageing skeletal muscle typically becomes sarcopenic and manifests with 
progressively reduced muscle mass and function [182]. Perturbed NAD+ 
metabolism has previously been associated with ageing in mice and rats [89, 174, 
229]. To further investigate changes to NAD+ in aged skeletal muscle, targeted 
LC-MS metabolomics was used to provide a global view of the NAD+ metabolome. 
Tissue from young (up to 6 months) and aged (27-33 months) mice was acquired 
from the Shared Ageing Research Models (ShARM) tissue bank (Sheffield, UK) 
and analysis determined that the NAD+ metabolome was indeed changed. Total 
NAD(H) was significantly lower in aged skeletal muscle, corroborating with current 
published datasets in rats and mice [89, 174, 187]. The NAD+ signalling metabolite 
ADPr, released following NAD+ consumption, and ATP were both also significantly 
reduced in the aged skeletal muscle (figure 3.2). Other metabolites tested 
(including NAM, NADP, ADP, meNAM and NMN) were not significantly different. 
These findings show some degree of disruption to NAD+ signalling and energy 
metabolism in aged muscle that are likely to be directly associated with metabolic 
decline.   
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Figure 3.2 NAD+ metabolomics of young and aged mouse skeletal muscle 
Quantitative LC-MS analysis of total NAD(H) and related metabolites in skeletal 
muscle from young (less than 6 months) and aged (over 2 years) mice. Tissue 
was acquired from the ShARM tissue bank (Sheffield, UK), n=6. Statistical 
significance was determined by unpaired student t-test (* p<0.05, **p<0.01, 
***p<0.001).    
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3.3.2 Identification of skeletal muscle NAD+ biosynthesis pathways  
With a decline in NAD+ metabolism seen during ageing a better understanding of 
NAD+ biosynthesis in skeletal muscle is necessary to establish the best targets for 
therapeutic intervention. To initially identify NAD+ biosynthesis genes expressed in 
skeletal muscle, previous microarray data [230] was analysed; providing the 
relative mRNA expression of NAD+ biosynthesis genes in TA and soleus skeletal 
muscle. The heat map presented in figure 3.3A identifies the three main NAD+ 
biosynthesis genes expressed in both TA and soleus muscle namely; Nmrk2, 
Nampt and Nmnat1. Interestingly, Nmrk2 expression was found to be predominant 
and expressed in a muscle fibre type specific manner with a higher expression in 
fast twitch TA muscle compared to soleus muscle. 
Follow up real-time PCR analysis of TA and soleus mRNA expression confirmed 
that Nmrk2, Nampt and Nmnat1 were the most predominantly expressed NAD+ 
biosynthesis genes in skeletal muscle with comparatively low expression of Nmrk1 
and NADsyn1 (figure 3.3B). As the expression of Nmrk1 and NADsyn1 - the key 
and final rate-limiting enzyme in both NAD+ de novo synthesis and the Preiss-
Handler salvage pathway [231] - were negligible in skeletal muscle this data 
suggests that the NMRK2 and NAMPT pathways may be the most important for 
maintaining NAD+ availability in muscle.    
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Figure 3.3 Expression of rate-limiting NAD+ biosynthesis genes in skeletal 
muscle 
(A) Previous microarray data from tibialis anterior (TA) and soleus (SOL) skeletal 
muscle by Lavery et al. [230] was used to identify the expression of NAD+ 
biosynthesis genes. Follow up qPCR analysis of rate-limiting genes from NAD+ 
biosynthesis pathways in (B) TA and (C) soleus muscle. Data is presented as 
mean A.U values ± SEM, n=4.  
 
 
To determine their tissue specificity, the expression of the key rate-limiting NAD+ 
biosynthesis enzymes - Nampt, NADsyn1, Nmrk1, Nmrk2 and Nmnat1 –  from 
each of the identified pathways illustrated in figure 3.1– was assessed in a range 
of metabolically important tissues including; skeletal muscle (quadriceps, TA, 
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soleus and diaphragm), heart, liver, kidney, white adipose (gonadal) and brain 
tissue. Analysis of mRNA expression by qPCR, identified predominant Nmrk1 
expression in kidney tissue (figure 3.4A).  Expression of Nmrk2, the paralogue to 
Nmrk1, was found to be highly skeletal muscle specific, with some expression in 
cardiac muscle and white adipose tissue (figure 3.4B). In comparison Nampt 
mRNA was ubiquitously expressed across all the tissues analysed (figure 3.4C) 
with slightly lower expression in liver tissue.  NADsyn1 was predominantly 
expressed in liver and kidney tissue suggesting that de novo NAD+ biosynthesis 
and NA salvage is limited to these metabolic tissues (figure 3.4D). Conversely, 
NMNAT1, the final enzyme common to all the NAD+ biosynthesis pathways, was 
universally expressed (Figure 3.4E).  
Immunoblot analysis of NMRK1, NMRK2 and NAMPT across the same metabolic 
tissues supported these findings (Figure 3.4F). Protein expression of NMRK2 was 
muscle specific, whereas NAMPT was ubiquitously expressed and NMRK1 
expression was predominant in liver and kidney tissue. This data further supports 
the suggestion that NMRK2 and NAMPT are the main enzymes for skeletal 
muscle NAD+ biosynthesis with the alternative biosynthesis pathways potentially 
having more distinct roles in other tissues [76, 147]. Moreover, the predominant 
expression of NMRK2 in skeletal muscle identifies a unique role for NMRK2, 
specific to skeletal muscle cell regulation, compared to NAMPT which is 
ubiquitously expressed and potentially playing a more global role in NAD+ 
resynthesis.   
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Figure 3.4 NAD+ biosynthesis gene expression across metabolic tissues 
Real-time PCR analysis of key rate-limiting NAD+ biosynthesis genes – Nmrk1 (A), 
Nmrk2 (B), Nampt (C), Nadsyn1 (D) and Nmnat1 (E) – in metabolic tissues 
including quadriceps (Q), tibialis anterior (TA), soleus (Sol), liver (Liv), heart (Hrt), 
diaphragm (Dia), kidney (Kid), brain (Brn) and gonadal white adipose tissue (Wat) 
(all n=3).  (F) Protein expression of NAD+ biosynthesis enzymes identified in 
muscle tissue – NMRK1, NMRK2 and NAMPT – were examined by immunoblot 
analysis across the same metabolic tissues (representative of n=2). Real-time 
data is presented as mean A.U values ± SEM.  
 
Muscle gene expression profiles change considerably over muscle cell 
differentiation [232], and with this it is likely that there would be a shift in energy 
metabolism when muscle cells differentiate into fused myotubes from proliferating 
myoblasts. As the C2C12 muscle cell line and primary muscle cultures are used in 
this project to investigate NAD+ regulation and metabolism in vitro, understanding 
differential expression patterns of biosynthesis genes over muscle differentiation 
and development is important. Using PCR and immunoblot analysis, mRNA and 
protein expression of NAMPT, NMRK1 and NMRK2 was examined over an eight 
day C2C12 muscle cell differentiation time course. Figure 3.5A and B demonstrate 
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that Nampt mRNA and protein is constitutively expressed in C2C12 cells 
throughout muscle differentiation. In contrast, Nmrk2 mRNA and protein 
expression is switched on. In unspecialised C2C12 myoblasts (day 0) Nmrk2 
expression is negligible, then by day 2 of differentiation Nmrk2 expression is 
significantly upregulated and then peaks at day 4 before plateauing when fully 
differentiated into myotubes at days 6-8 (figure 3.5A-C). Nmrk1 mRNA expression 
remained constant throughout C2C12 differentiation, with protein expression 
exhibiting a similar pattern (figure 3.5A and B).   
Figure 3.5 NAD+ biosynthesis enzyme expression over C2C12 myotube 
differentiation 
(A) mRNA and (B) protein expression of Nmrk1, Nmrk2 and Nampt over 8 day 
C2C12 myotube differentiation and (C) qualitative PCR analysis of Nmrk2. mRNA 
data is presented as mean ± SEM A.U values (n=3) and statistical significance 
was determined by one-way ANOVA with Dunnet’s multiple comparisons test (* 
p<0.05, **p<0.01, ***p<0.001). Immunoblot and qualitative PCR analysis are 
representative of n=2. 
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3.3.3 Nmrk2 orthologue differentiation and sequence alignment  
In contrast to the results presented here, previous literature has identified 
alternative differentiation patterns for Nrmk2. Li et al. (1999) showed that muscle-
specific beta 1 Integrin binding protein (MIBP), an apparent pseudonym for Nmrk2, 
was downregulated over differentiation in C2C12 myotubes with overexpression of 
Nmrk2 preventing terminal differentiation [172].  
These differential findings were therefore further investigated using zebrafish as 
an alternative model. Due to a second genome duplication zebrafish have 4 
paralogous genes to Nmrk2 namely, nmrk1, nmrk2, mibp and mibp2 [233]. Initially, 
expression of the different zebrafish nmrk2 orthologues was examined over 
embryonic development to potentially identify alternative expression patterns of 
paralogous genes. Figure 3.6A illustrates the mRNA expression of the four 
zebrafish Nmrk paralogues over embryo development. Here, differential 
expression patterns of the 4 genes are shown with mibp and mibp2 constitutively 
expressed, nmrk2 expression switched on and nmrk1 downregulated.  
In addition, sequence alignment of mouse and zebrafish nmrk2 to the alternative 
zebrafish orthologues identified some sequence divergence although large 
portions of the sequences remained well conserved. In zebrafish nmrk2 was most 
closely conserved with mibp at 78.28%. Notably, the mouse Nmrk2 sequence was 
most conserved with zebrafish nmrk2 at 65.64%. Mouse Nmrk2 was also closely 
conserved with mibp and mibp2; further investigation of the sequences is required 
to identify the importance of the sites where the sequences are different and to 
determine the impact of this on protein structure and function. From these findings, 
the most likely explanation for the differences in expression patterns seen here to 
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those previously published is that different proteins were detected. This is 
supported by the sequence provided by Li et al. for MIBP which was 186 amino 
acids in length compared to the 195 amino acid sequence that has been 
determined for NMRK2 [172].  
Figure 3.6 Zebrafish nmrk2 orthologue gene expression and sequence 
comparison 
A. mRNA expression of the 4 zebrafish Nmrk2 paralogues – nmrk1, nmrk2, mibp 
and mibp2 – over zebrafish embryonic development. With time points of 1 cell 
(1C), 4C, 64C, 1000 cells (1K), sphere (sph.), 50% epiboly, 70% epiboly, 10 hour 
post fertilisation (hpf), 22 hpf, 28 hpf, 32 hpf, 36 hpf, 48 hpf, 72 hpf, 96 hpf and 
120 hpf. B. Sequence alignment scores determined using ClustalW2 of mouse 
(Mm) and zebrafish (Dre) Nmrk2 orthologous/paralogous genes with the score 
given as a percentage of sequence similarity.    
 
A. 
B. 
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Remarkably, this data also demonstrates that the expression of zebrafish nmrk2 is 
switched on at between 10-18 hours post fertilisation (figure 3.6A), which 
coincides with the time of initial muscle development and twitching in developing 
zebrafish embryos [234]. This supports the findings in C2C12 cells (figure 3.5) and 
suggests a conserved tissue specific role for nmrk2 in muscle development and 
differentiation across species.  
3.3.4 NR supplementation can enhance myotube NAD+ availability.  
To further understand the role of NMRK2 in skeletal muscle NAD+ salvage, C2C12 
and primary muscle cells were supplemented with its primary substrate NR for 24 
hours. NR supplementation significantly enhanced both C2C12 and primary 
myotube NAD+ content with primary muscle cells more responsive (~25% increase 
versus >100% increase following 0.5 mM NR) (figure 3.7A and B respectively). 
Figure 3.7B shows that NR enhances NAD+ in a dose dependent manner with 
levels exceeding double that of the control after 0.5 mM NR supplementation in 
primary myotubes. Nmrk2 mRNA expression consistently trends upwards 
following NR treatment yet expression of metabolic signalling genes including; 
Pdk4, Pparα, Sirt1 and Sirt3, were unchanged. Tfam, Ucp2 and Nrf1 are important 
genes involved in mitochondrial biogenesis and are often upregulated in response 
to metabolic stress [115, 235]; NR treatment did not alter the expression of these 
mitochondrial biogenesis markers (figure 3.7C). Concordantly, figure 3.7D 
illustrates that myotube NR treatment did not alter the expression of key 
mitochondrial complex proteins. Furthermore, despite an increase in NAD+ levels, 
supplementation of C2C12 myotubes with 0.5 mM NR did not alter basal or 
maximal oxygen consumption rate (figure 3.7E), indicating that an increase in 
NAD+ availability does not necessarily lead to enhanced oxidative metabolism.  
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Figure 3.7 Effects of NR supplementation on C2C12 and primary myotubes 
NAD+ content of (A) C2C12 and (B) primary myotubes following 24 hour NR 
supplementation (0.5 mM and 0.05 -1 mM respectively). (C) Corresponding mRNA 
expression of Nmrk2 and key metabolic genes previously shown to be regulated 
by NAD+ signalling. (D) Immunoblot analysis of mitochondrial complex proteins 
and (E) corresponding basal and maximal (uncoupled) mitochondrial respiration of 
C2C12 myotubes following 24 hour 0.5 mM NR treatment. All values presented as 
mean± SEM, n=3, statistical significance was determined by unpaired t-test (A) 
and one-way ANOVA with Dunnet’s multiple comparisons test (B) (* p<0.05, 
**p<0.01, ***p<0.001). 
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3.3.5 The relative contribution of NAMPT and NMRK salvage pathways 
to NAD+ availability  
Data presented in figures 3.3 and 3.4, and previously published enzyme activity 
data [147], indicates that the NAMPT and NMRK2 salvage pathways outlined in 
figure  3.8A are the main routes to NAD+ in skeletal muscle. To initially investigate 
the relative importance of NMRK2 and NAMPT for maintaining skeletal muscle 
NAD+ availability, the NAD+ boosting ability of different NAD+ precursors (NR, 
NaR, NAM and NMN) was assessed. Interestingly, figure 3.8B shows that 
exogenous supplementation of 0.5 mM NR and NMN significantly boosts NAD+ in 
primary myotubes to a similar level. Yet, 0.5 mM NAM supplementation is much 
less effective with a 10 fold dose increase required to significantly increase NAD+.  
NaR is an alternative substrate for NMRK 1 and 2 that requires NADsyn activity as 
a rate limiting step to NAD+ was used as a control [236], and did not lead to an 
increase in NAD+ following supplementation at 0.5 mM.   
Figure 3.8 Cellular NAD+ following precursor supplementation 
(A) Exogenous NAD+ precursor strategies to increasing NAD+ biosynthesis. (B) 
Primary myotube NAD+ content following 24 hour precursor supplementation at 
0.5 mM (except NAM*10 = 5 mM.) compared to vehicle treated control (Con). Data 
presented as mean ± SEM, n=4, significance determined by one-way ANOVA with 
Dunnet’s multiple comparisons test (* p<0.05). 
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NAMPT has been previously described as a vital component for NAD+ turnover in 
tissues including skeletal muscle [150, 174, 227]; thus NAD+ levels and precursor 
salvage was examined in myotubes with and without the NAMPT inhibitor FK866. 
FK866 is a potent pharmacological inhibitor of NAMPT and, although technically a 
competitive inhibitor, it’s much greater affinity for the enzyme active site compared 
to NAM means its action is classed as non-competitive [134]. Following 24 hours 
of FK866 (100 nM) treatment, NAD+ levels in the control myotubes are significantly 
depleted (by over 70%) indicating that NAMPT is indeed essential for basal NAD+ 
turnover in skeletal muscle (figure 3.9). In addition, both NR and NMN can boost 
cellular NAD+ after FK866 treatment, to the same extent as without, highlighting 
that they are both metabolised independent of NAMPT. As expected, NAM 
supplementation was unable to recover NAD+ depletion following NAMPT 
inhibition (figure 3.9).  
Figure 3.9 Cellular NAD+ following NAMPT inhibition 
Cellular NAD+ content following 24 hour primary myotube treatment with NAMPT 
inhibitor FK866 (100 nM) compared to DMSO only control, with and without 0.5 
mM NAD+ precursor supplementation. Data presented as mean ± SEM, n=4, 
significance determined by one-way ANOVA with Dunnet’s multiple comparisons 
test (with [*] significant to DMSO control (*p<0.05, **p<0.01) and [#] significant to 
FK866 control (###p<0.001).  
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Table 3.1 – Targeted LC-MS NAD+ metabolome of primary myotubes with treated 
with NR (0.5 mM) and/or FK866 (100 nM). Data presented as mean ± SEM, n=3, 
and significance determined by one-way ANOVA with Tukey’s multiple 
comparisons test (* significant to control, † significant to FK866 treatment 
(p<0.05).  
 
NAD+ metabolism is a multilevel signalling process involving a range of 
metabolites; therefore NAD+ measurements can be limited when investigating the 
impact on wider NAD+ metabolism.  To gain further insight into the potential of NR 
supplementation beyond enhanced NAD+, LC-MS based targeted NAD+ 
metabolomics was employed. This approach enabled the assessment of a range 
of NAD+ related metabolites providing a snapshot of the NAD+ metabolome in 
response to NR treatment. Table 3.1 shows quantitative levels of key NAD+ 
metabolites in primary myotubes treated with FK866 and NR. As expected, 
NAD(H) levels significantly increased following NR supplementation, and 
importantly a large increase in cellular NR from control cells was detected 24 
hours following cell treatments. NMN levels were also significantly increased 
following NR treatment. Interestingly, metabolites of NAD+ signalling NAM and 
ADPr were not altered by NR treatment but levels were reduced following FK866 
NAD+ depletion; suggesting NAD+ availability is only rate limiting to NAD+ 
signalling below normal levels (table 3.1). NA and other metabolites from the 
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Preiss handler and de novo NAD+ biosynthesis pathways (not shown) were 
undetected in the primary myotubes.         
As NAD+ is a vital co-factor for energy production, the wider cellular impact of 
depleting NAD+ was determined. Using C2C12 myotubes, mitochondrial 
respiration was assessed by myotube oxygen consumption rate (OCR). NAD+ 
depletion by FK866 resulted in a significant reduction to myotube OCR (figure 
3.10A). This effect may be attributed to limited NAD+ for energy production but 
potentially there is likely to be some degree of cell death induced from NAD+ 
depletion. Mitochondrial function was recovered by replenishing NAD+ with NR 
concomitantly with FK866 or for the final 24 hours of 72 hour FK866 treatment 
(figure 3.10A). This reinforces the criticality of NAD+ for energy production but also 
shows cell viability at least 48 hours post FK866 treatment.   
To confirm the effect of FK866 on NAD+ content (at 24 hours) is not just a direct 
result of cell death, cell viability and apoptosis was assessed. For up to 48 hours 
post FK866 treatment the number of viable cells were unchanged despite NAD+ 
depletion from 24 hours. Cell viability appears to decline between 48 and 72 hours 
(figure 3.10B and C).  A concomitant increase in apoptotic cells was also detected 
between 48 and 72 hours post FK866 treatment (figure 3.10B and D). This shows 
that myotubes can adapt to withstand low levels of NAD+ for an extended period of 
time before cell death. Interestingly NR supplementation, even after 48 hours, 
completely prevented these events (figure 3.10 B-D). NAM was also added for the 
final 24 hours of 72 hour FK866 treatment and, expectedly, it was unable to 
recover apoptotic signalling and thereby demonstrated successful inhibition of 
NAMPT. Ionomycin and hydrogen peroxide (H2O2) were used as controls to 
induce cell death by necrosis (figure 3.10C and D).   
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Figure 3.10 NR can rescue the effects of NAMPT inhibition on cell function 
(A) Primary myotube oxygen consumption rate (OCR) as a function of basal and 
maximal mitochondrial respiration following 72 hour FK866 (100 nM) treatment to 
inhibit NAMPT with or without 24 hour NR supplementation (n=3). (B) Cellular 
viability and apoptosis markers activity over 72 hour FK866 (100 nM) treatment 
with (solid line) and without (dashed line) 0.5 mM NR supplementation. (C) Cell 
viability and (D) apoptosis marker activity with controls, ionomycin (100 µM), H2O2 
(100 µM), FK866 (FK) (100 nM), NAM and NR (0.5 mM) for the time listed in hours 
(n=1, experiment quadruplet replicates). Data presented as mean ± SEM and 
significance determined by one-way ANOVA with Dunnet’s multiple comparisons 
test (* p<0.05, **p<0.01).  
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These data show that NAMPT recycling of NAM is crucial for basal NAD+ 
biosynthesis in skeletal muscle, with NAD+ depletion, mitochondrial decline and 
cell death a consequence of NAMPT inhibition. Interestingly, NR supplementation 
can completely rescue this effect, most likely through NMRK-mediated NAD+ 
salvage; suggesting that although NMRK activity is independently capable of 
maintaining cellular NAD+, NR availability may restrict this alternative pathway 
under basal conditions.  
3.3.6 Fast-twitch and slow-twitch muscle types exhibit different NAD+ 
biogenesis profiles 
It is well established that muscle tissue is heterogeneous in terms of fibre type 
composition; with slow to fast twitch fibre composition reflective of the oxidative vs 
glycolytic capacity of the muscle [20].  Data from the initial tissue screening of 
Nmrk2 indicated possible fibre-type specific expression. Further immunoblot and 
real-time qPCR analysis of different muscle beds also corroborated with the 
microarray data, demonstrating protein and mRNA expression levels were 
significantly enriched in fast-twitch TA tissue compared to slow-twitch soleus 
muscle. 
Differential expression of Nmrk2 between TA and Soleus muscle (figures 3.3 and 
3.4) demonstrates integral differences between different muscle beds. Skeletal 
muscle structure and composition is vastly dependent on the physiological 
requirement of the muscle and therefore large differences to metabolism and 
signalling in different muscle types is unsurprising [237, 238]. Consequently, 
characterisation of skeletal muscle NAD+ signalling must also account for muscle 
fibre-type specificity.  
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Analysis of total NAD+ content in different muscle beds showed significantly higher 
levels per mg of tissue in soleus muscle compared to TA (figure 3.11A), 
supporting the increased oxidative requirements of the tissue. However, in 
myotubes originating from TA and soleus muscle, basal NAD+ levels were similar 
and 24 hour NR supplementation enhanced NAD+ to the same degree (figure 
3.11B). NADH levels appeared elevated in soleus derived myotubes; thus, 
lowering the NAD/NADH ratio (figure 3.11C and D). 
The oxygen consumption rate of primary myotubes from TA and soleus muscle 
was additionally examined as a measure of mitochondrial function. As expected, 
soleus derived myotubes exhibited higher rates of oxygen consumption, indicating 
a higher oxidative capacity compared to TA derived myotubes. Following 24 hour 
NR supplementation (0.5 mM), the oxygen consumption rate significantly 
increased in soleus derived myotubes (figure 3.11E). Expression of key 
mitochondrial complex proteins was analysed and identified a differential 
expression with TA exhibiting higher levels of proteins in complex III, IV and ATP 
synthase and soleus muscle having a higher expression of proteins from complex 
I (figure 3.11F). Together these data identify important integral differences 
between different muscle beds in NAD+ metabolism which may be attributed to 
their distinct oxidative and glycolytic metabolic functions.     
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Figure 3.11 Comparison of NAD+ metabolism in TA and soleus muscle beds 
(A) NAD+ content of mouse TA and Soleus muscle tissue. (B) NAD+, (C) NADH 
and (D) NAD/NADH content of primary myotubes from TA and soleus muscle 
treated with 0.5 mM NR or vehicle control (n=6). (E) Basal mitochondrial 
respiration of myotubes from TA and soleus muscle treated for 24 hours with 0.5 
mM NR or vehicle control (n=4). (F) Immunoblot analysis of key mitochondrial 
complexes in TA and soleus tissue. Data is presented as mean ± SEM for 
significance was determined by unpaired T-test (A) and one-way ANOVA (B-E) (* 
p<0.05, **p<0.01, ***p<0.001).    
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3.4 Discussion 
The interplay between NAD+ signalling and energy metabolism acts as an 
essential homeostatic mechanism that when disrupted can be detrimental to 
metabolic health [76, 89, 227]. Skeletal muscle has long been known as a major 
site of energy metabolism and nutrient storage [26, 239]. Vast changes to energy 
demand in muscle, particularly in response to physical activity, requires robust yet 
dynamic signalling events to maintain energy homeostasis [26]. Aged mouse 
muscle examined here exhibited a declined NAD+ metabolome compared to 
muscle of young mice. With mounting evidence associating NAD+ availability and 
metabolic health it is important to identify the critical pathways in skeletal muscle 
to NAD+ metabolism [89, 169, 174, 199].     
Metabolic enzyme profiling of mouse tissue determined that the amidated route to 
NAD+ predominated in all tissues with NMNAT1 activity high and non rate-limiting, 
except in the blood [147]. The deamidated route was determined to be minor in all 
tissues, with NADS highest absolute activity in the liver and small intestine and 
notably undetectable levels in skeletal muscle [147]. This chapter aimed to further 
characterise the pathways central to NAD+ biosynthesis in skeletal muscle which 
until now has been relatively undefined. Here, following analysis of the NAD+ 
biosynthesis genes, three enzymes were identified to be predominantly expressed 
in skeletal muscle namely NMRK2, NAMPT and NMNAT1. From this it was 
determined that the NMRK and NAMPT pathways (illustrated in figure 3.1), both of 
which have NMNAT1 activity downstream, are the main routes to NAD+ 
biosynthesis in skeletal muscle. NAD+ salvage via NAMPT has been much more 
characterised than salvage via the more recently identified NMRK enzymes [157, 
227, 240]. NAMPT is ubiquitously expressed and considered essential in most 
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tissues for NAD+ regeneration [153, 158]. The data in this chapter shows that 
NMRK2, however, is highly muscle specific and is the most predominantly 
expressed NAD+ biosynthesis enzyme in skeletal muscle with expression favoured 
in fast-twitch TA muscle. This conserved expression of NMRK2 in muscle across 
species suggests an important role that has yet to be established. 
Moreover, the fast twitch fibre-type specificity of NMRK2 raises more questions 
about its importance in muscle metabolism. A higher expression in glycolytic 
muscles, like the TA, may be an important cellular redundancy mechanism to 
meet extreme changes to energy demand during high intensity exercise to allow 
muscles to maintain energy homeostasis and effectively induce metabolic 
adaptation. Soleus derived myotubes did appear to rely more on oxidative 
metabolism compared to typically glycolytic TA myotubes, yet interestingly NAD+ 
levels in soleus and TA myotubes were similar. As soleus muscle fibres are 
predominantly considered oxidative the soleus derived myotubes may have been 
expected to have a higher NAD+ content. The soleus myotubes did however have 
higher NADH levels and thus the TA and soleus myotubes had different 
NAD/NADH ratios. The importance of NAD+ content versus the NAD/NADH ratio 
has been debated for many years with no conclusive answer [241], so although 
NAD+ levels appear consistent the shift in the NAD/NADH ratio may be an 
important characteristic of their different metabolic activity. Notably, soleus tissue 
NAD+ levels were significantly higher than in TA tissue. The differences between 
tissue and primary myotubes NAD+ content highlights that although in vitro models 
are extremely useful for investigating and manipulating specific cellular systems 
there are still limitations. Therefore, it is necessary to accept the metabolic status 
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of a closed cellular system will not directly reflect a snapshot of in vivo 
metabolism, which is heavily dependent on multi-organ interplay [26].  
Further investigation of NMRK2 in skeletal muscle showed that supplementation 
with its primary substrate, the vitamin B3 precursor NR, could indeed enhance 
NAD+ content in C2C12 and primary myotubes. Although supplementation with 
NR did not appear to alter downstream metabolic signalling in the myotubes, this 
data shows the ability of muscle cells to respond to changes in substrate 
availability and adapt cellular NAD+ levels, which may prove a vital process in 
muscle to react to metabolic stress and maintain energy homeostasis. In addition, 
the ability of NR to boost muscle cell NAD+ content provides great therapeutic 
promise as an alternative vitamin B3 supplement to nicotinic acid (NA) which, 
firstly, is not likely to play an important role in muscle NAD+ biosynthesis and 
secondly, patient compliance is poor due to adverse flushing effects [195]. 
Extensive studies looking at NA (or NA derivatives) supplementation in humans 
has demonstrated numerous health benefits including lowering of total cholesterol 
and triglycerides [193, 194].This further cements a novel niche for NR, which does 
not activate the GPR109A receptor and induce flushing, in promoting metabolic 
health [199]. 
 It is not necessarily surprising that in the C2C12 and primary cell models the 
significant increase in NAD+ does not induce metabolic adaptation as these cells 
are not under metabolic stress and normal ‘healthy’ cells can already adequately 
modulate NAD+ metabolism and signalling. Most studies to date that have 
demonstrated the beneficial effects of boosting NAD+ have been in models of 
metabolic stress or pathophysiology where NAD+ homeostasis is perturbed [178, 
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179, 199, 206, 207, 229, 242]. Previously, a study using a muscle specific NAMPT 
overexpressing mouse model showed that a 50% increase in NAD+ could not 
stimulate mitochondrial biogenesis or enhance mitochondrial metabolism in 
skeletal muscle of young mice, with metabolic differences only apparent upon 
ageing [76, 240]. Our results show that when NAD+ is enhanced through NR 
supplementation NAM and ADPr levels are unchanged, whereas following NAD+ 
depletion there is a decrease (table 3.1). As NAM and ADPr are metabolites of 
NAD+ signalling (both produced from SIRT-based NAD+ consumption) [119] this 
indicates that, although a reduction to NAD+ can limit NAD+ signalling and 
ultimately hinder mitochondrial metabolism, basal NAD+ content alone is not 
limiting to NAD+ signalling.  
Interestingly, in the TA and soleus derived primary myotubes there was an 
induction of mitochondrial respiration following NR treatment unlike in C2C12 
myotubes. These differences may be attributed to the fact that the metabolic 
capacity of an immortalised cell line like C2C12 is very likely to be different to that 
of primary myotubes with C2C12 cells potentially relying on more glycolytic 
metabolism particularly in high glucose conditions [243]. In addition, figure 3.7 
highlights that NR supplementation boosts NAD+ by a smaller degree in C2C12 
myotubes compared to primary myotubes; this further demonstrates basal 
metabolic differences between the two cellular models and it may be that this 
smaller NAD+ increase in C2C12 cells is not sufficient to drive mitochondrial 
respiration.    
The findings here confirm previous studies that identified intracellular recycling of 
NAM by NAMPT as a critical process for basal NAD+ turnover in skeletal muscle 
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[76, 227, 244]. Inhibiting NAMPT activity significantly depleted NAD+, 
mitochondrial respiration and induced apoptosis. Together these data indicate that 
basally NMRK2 is unable to act as a redundancy pathway to maintain adequate 
NAD+ in response to NAMPT inhibition. As exogenous NR delivery can 
significantly enhance NAD+ levels even whilst NAMPT activity is blocked, as well 
as recover all the associated effects of NAD+ depletion, this suggests that basal 
NAD+ salvage via NMRK2 is limited by NR availability rather than enzyme activity. 
This idea is further supported by LC-MS analysis of primary myotubes that 
showed relatively low NR levels in control cells and a significant rise 24 hours 
following NR supplementation with a concomitant increase in NAD+.  
The idea that NMRK2 activity is restricted by NR availability may make NMRK2 
even more valuable as a therapeutic target for boosting NAD+ metabolism 
particularly in comparison to NAMPT. For example, blocking the NAMPT salvage 
pathway has profound consequences on the metabolic health of the cell yet NAM 
supplementation is unable to replicate the NAD+ booting effects of NR. This may 
be attributed to a low maximal rate limit for NAMPT, instability of NAM, insufficient 
cellular uptake or feedback inhibition of NAMPT. The latter of these has been 
postulated from evidence of post translational regulation of NAMPT activity in 
response to NAD+ availability suggesting NAMPT activity is regulated by its 
ultimate product in order to tightly maintain NAD+ levels [135, 244]. Studies have 
also shown that high levels of NAM are inhibitory to SIRT activity, again providing 
another mechanism for controlling NAD+ consumption via the NAMPT salvage 
pathway [152]. So, despite the NAMPT pathway being crucial for maintaining 
NAD+ turnover in healthy muscle it may be a poor target for enhancing NAD+ in 
metabolically perturbed muscle. 
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It is essential to note that NAD+ turnover and metabolic flux is continuously 
regulated and highly adaptive to countless stimuli including, physical activity, 
energy source and availability, circadian clock and pathophysiology [32, 89, 169, 
200, 245]. Thus, although snapshots of NAD+ metabolites and signalling in tissues 
and cells is extremely informative, it is still very difficult to gain conclusive insight 
into NAD+ metabolism.  
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Chapter 4 Investigating the relative 
importance of NAD
+
 biosynthesis 
genes in skeletal muscle NAD
+
 
metabolism, in vitro.  
(NMRK1KO and DKO mice were provided by Dr Carles Canto at the Nestlé 
Institute of Health Sciences and experiments involving these mice were performed 
during a one month lab placement)    
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4.1 Introduction 
NAD+ consumption is prominent in contracting muscle, due to enhanced SIRT 
activity to meet cellular energy demands [227], thus replenishment of NAD+ 
through biosynthesis and salvage pathways is a vital process. Previously, Nampt 
and Nmrk2 were identified as the key NAD+ biosynthesis genes in muscle 
suggesting that muscle relies on NAM and NR salvage to maintain NAD+ pools. 
Further research into the relative contribution of these pathways to re-synthesise 
NAD+ in resting skeletal muscle, and in response to metabolic stresses such as 
exercise, is required.  
4.1.1 Rationale for boosting cellular NAD+ 
Pharmacological inhibition of poly(ADP-Ribose polymerases (PARPs), alternative 
NAD+ consumers, in skeletal muscle can boost NAD+ levels and enhance 
mitochondrial function and oxidative metabolism [246] through increased SIRT1 
activity.  Furthermore, increasing NAD+ through microRNA-149 (miR149) inhibition 
of PARP-2 specifically in skeletal muscle can enhance mitochondrial biogenesis 
though activation of PGC-1α by increased SIRT1 expression and activity [127].   
In addition, research by Kim et al. showed that NAMPT can regulate mitochondrial 
biogenesis through NAD+ following exercise simulation by electrical stimulation 
(ES) of primary skeletal muscle fibres. They demonstrate that the increase in 
NAD+, SIRT signalling and markers of mitochondrial biogenesis induced by ES 
was inhibited following pharmacological inhibition of NAMPT with FK866 [227].  
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4.1.2 Precursor supplementation to drive NAD+ metabolism 
This latest research demonstrates the vast potential benefits associated with 
boosting NAD+ and the necessity to establish novel methods to do so that are safe 
and translatable to humans.  
Previously, the positive effects of boosting NAD+ metabolism through precursor 
supplementation have been established. For example, NA supplementation has 
been previously used to treat hypercholesterolemia [247]. In humans, the NA 
derivative acipimox has already shown promising potential for the use of NAD+ 
precursors as a new therapeutic strategy for improving the mitochondrial function 
of skeletal muscle. Treatment with acipimox increased mitochondrial respiration, 
enhanced expression of genes involved in the Krebs cycle and electron transport 
chain and increased ATP content [196]. Despite the clear therapeutic benefit, the 
use of NA and acipimox is limited by adverse flushing effects, through activation of 
the GPR109A receptor, leading to poor compliance [196].  
The positive effects of boosting NAD+ has created a new therapeutic niche for 
vitamin B3 supplementation; necessitating the need to examine the potential of 
supplementation with alternative NAD+ precursors that do not cause adverse 
effects. NAM supplementation is limited due to its inhibitory effect on SIRT activity, 
but the natural availability of NR in the diet and its ability to increase NAD+ content 
in cells makes it an ideal new therapeutic approach to treat metabolic related 
diseases [142, 152, 166, 192]. 
Canto et al. (2012) showed that NR fed mice had increased levels of NAD+ and 
enhanced SIRT1 and SIRT3 activity. High fat diet mice treated with NR had 
reduced fat mass from enhanced energy expenditure, improved insulin sensitivity 
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and enhanced skeletal muscle oxidative performance [199]. More recently, Khan 
et al. showed that NR supplemented transgenic mice manifesting with 
mitochondrial myopathy effectively delayed progression of both early and late 
stage mitochondrial disease. NR treated mice showed boosted NAD+ levels, 
mitochondrial biogenesis and induction of the unfolded protein response [207].  
4.1.3 Manipulations of skeletal muscle NAD+ metabolism. 
Gaining a better understanding of skeletal muscle NAD+ biosynthesis pathways 
can help target specific pathways with interventions, such as precursor 
supplementation, to boost NAD+ pools and drive energy metabolism.  This chapter 
will focus on the manipulation of key regulators of NAD+ metabolism in skeletal 
muscle to elucidate novel targets for enhancing NAD+ signalling and induce similar 
metabolic responses to those seen following exercise [32].  Pharmacological and 
genetic approaches will be used to inhibit and knock-out key skeletal muscle NAD+ 
biosynthesis genes (figure 4.1), Nampt and Nmrk2, previously identified – in 
section 3.3 – and determine their relative importance for skeletal muscle NAD+ 
turnover during basal metabolism. Additionally, strategies to boost skeletal muscle 
NAD+ content through targeted nutrient supplementation of NAD+ precursors will 
be examined. 
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Figure 4.1 Skeletal muscle NAD+ biosynthesis manipulations 
An outline of the main NAD+ biosynthesis pathways proposed to be important in 
skeletal muscle (left). Pharmacological and genetic manipulations (red) to be 
employed in this chapter (centre) and supplementation of substrates for the key 
NAD+ biosynthesis enzymes (right).   
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4.2 Materials and Methods 
4.2.1 Generation of NMRK loss of function mice 
NMRK2KO mice were acquired from the Jackson Laboratory. The Nmrk2 KO 
mutant allele was generated through the Knockout Mouse Phenotyping Program 
(KOMP2) on a C57BL/6N background. A ZEN-UB1 Velocigene cassette (beta-
galactosidase coding sequence from E. coli lacZ gene; polyadenylation signal; 
loxP site; promoter from the human ubiquitin C gene; neomycin 
phosphotransferase;polyadenylation signal; loxP site) was inserted through 
homologous recombination into the gene in place of all coding exons inhibiting 
transcription.  
NMRK1KO mice were provided by Carles Canto and generated on a 
C57BL/6NTac background by Taconic Biosciences, as described by Ratajczak et 
al. 2016, resulting in recombination of exons 3 to 7 and complete loss of NMRK1 
protein.  
4.2.2 Genotyping 
DNA from digested ear and tail clips was amplified using the 2x BioMix Red 
(Bioline, UK) and the primers listed in appendix A. Samples were placed in a PCR 
thermocycler - set to 5 minutes at 95 °C then 35 cycles of [30 seconds 95 °C, 30 
seconds 60 °C and 30 seconds 72 °C] followed by 5 minutes at 72 °C and left 
indefinitely at 4 °C - and analysed by electrophoresis on 1.8% Agarose gels.     
4.2.3 Primary muscle culture 
Gastrocnemius tissue was excised from hind limbs of mice and digested in DMEM 
with 0.2% collagenase and isolated myofibres were placed in tissue culture plates 
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(section 2.2). Following satellite cell migration media was replaced with 
proliferation media (DMEM with 10% (v/v) HS, 1% (v/v) P/S and 0.5% (v/v) CEE). 
Upon 70-80% confluence media was replaced with Differentiation media (DMEM 
supplemented with 2% (v/v) HS, 0.5% (v/v) CEE and 1% (v/v) P/S) and cells were 
differentiated for 6 days.    
4.2.4 Cell treatments 
Cells were treated in serum free media with 100 nM FK866 or DMSO as a vehicle 
control for 24, 48 or 72 hours. Cells were supplemented with 0.5 mM NR, 0.5 or 5 
mM NAM and 0.5 mM NMN for 24 hours.  
4.2.5 siRNA transfections – Nmrk1 knockdown 
Primary myotubes were transfected overnight in antibiotic and serum free DMEM 
on days 3 and 5 of differentiation. 0.5 µg/µl Nmrk1 siRNA (MSS212930, 
Invitrogen, UK) was transfected using OptiMem and Lipofectamine 2000 (section 
2.4). Following transfections, media was replaced with normal differentiation 
media until cells were harvested.      
4.2.6 RNA extraction  
RNA was extracted from tissue and cells using TRIzol reagent (Invitrogen, UK). 
RNA quality was determined by visualisation on a 1.5% agarose gel and 
quantified using a nanodrop. Reverse transcription was conducted using 1 µg 
RNA (see section 2.6).  
4.2.7 qPCR 
qPCR was performed in a 384-well plate in single-plex format using Assay on 
Demand primers and probes (Applied Biosystems, UK) (section 2.6.4). The real-
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time PCR reaction was performed under the following conditions: 95oC for 10 
minutes then 40 cycles of 95oC for 15 seconds and 60oC for 1 minute using an 
ABI7500 system. Data were collected as Ct values and used to obtain deltaCt 
(dCt) values.  
4.2.8 Western Blotting 
Protein lysates were extracted from tissues in RIPA buffer. Total protein 
concentration was quantified by Bio-Rad assay. Total proteins (20 μg) were 
resolved on 12% SDS-PAGE gels and transferred onto nitrocellulose membranes. 
Membranes were blocked in 5% BSA and Primary antibodies were then added 
and incubated overnight. Membranes were washed and secondary antibodies 
conjugated with HRP were added at a dilution of 1/10,000. Membranes were 
washed and bands visualised using ECL detection system (GE Healthcare, UK) 
(as described in section 2.7)  
4.2.9 NAD+ measurements 
NAD+ was extracted from primary myotubes and muscle tissue and quantified 
using the NAD/NADH quantification colorimetric kit (BioVision, UK) as described in 
section 2.8.1. 
4.2.10 Targeted NAD+ metabolomics 
20 mg of pulverised tissue samples were extracted in ice cold LC-MS grade 
methanol. 300 µl of internal standard (diluted 1:300 in LC-MS grade water) was 
added and samples were sonicated for 20 seconds at -4°C. Then the samples 
were incubated at 85˚C for 5 minutes, shaking at 1050 rpm. Samples were 
returned to ice for 5 minutes and centrifuged. Supernatant was transferred to a 
new tube and dried using a speed vacuum. Dried extract was resuspended in 40 
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µl of the appropriate buffer (LC-MS grade water for acid extract and 10 mM 
ammonium acetate for alkaline extract). Extracts were briefly centrifuged and the 
supernatant was transferred to a Waters Polypropylene 0.3 ml plastic screw-top 
vial and analysed by LC-MS/MS using the ACQUITY UPLC H-class system 
(section 2.12.4). 
4.2.11 Respirometry 
Primary myotubes were differentiated for 6 days. Following treatment with the 
relevant compounds, respiratory output (by oxygen consumption rate) of myotubes 
in Seahorse XF-Assay media (Agilent Technologies, USA) was assessed by 
Seahorse extracellular flux analysis, as described in section 2.11.1, following the 
Seahorse user guide. 
4.2.12 Statistical analysis 
Unpaired Students T-test or ANOVA statistical comparisons were made using 
GraphPad Software Inc. Prism version 6. Data are presented as mean ±SEM with 
statistical significance determined as *= P<0.05, **=P<0.01, ***=P<0.001. 
Statistical analysis of real-time PCR data was determined using dCt values. 
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4.3 Results 
In chapter 3, the NAMPT and NMRK NAD+ biosynthesis pathways were indicated 
to be the main routes to NAD+ in skeletal muscle. This chapter focusses on 
genetic and pharmacological interventions to examine the relative importance of 
these pathways and identify potential pathway redundancy when these pathways 
are compromised.  
4.3.1 Validation of NMRK2KO mouse model 
The importance of NAMPT in muscle NAD+ salvage has been previously 
described [76, 227]. However, the role of NMRKs in skeletal muscle NAD+ salvage 
and particularly the muscle specific importance of NMRK2 is yet to be defined. 
Thus, to further investigate the muscle specific role of NMRK2, a global loss of 
function mouse model was employed. Heterozygous (HET) NMRK2KO mice 
received from the Jackson Laboratory were genotyped by PCR to confirm 
heterozygosity. Primers designed for genotyping generated DNA fragments sized 
at approximately 197 base pairs (bp) for WT mice and 500 bp for NMRK2KO mice. 
Figure 4.2 shows an agarose gel of DNA extracted from ear clippings of the six 
original HET mice with a negative and positive WT control as an example of 
successful genotyping. A single lower WT band and an upper mutant band can be 
visualised to confirm all the mice as HETs. Following confirmation of Nmrk2 
heterozygosity, a breeding program was established and all subsequent litters 
were genotyped immediately after weaning and retyped following tissue collection. 
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Figure 4.2 PCR analysis of NMRK2 genotype 
DNA digested from heterozygous NMRK2 mice was analysed by generic PCR 
with a negative and WT control. WT (197 bp) and mutant (500 bp) bands were 
identified as expected.  
 
To validate genotype identification of the Nmrk2 HET, KO and WT mice, harvested 
tissues from each mouse were examined for the presence or absence of Nmrk2 
expression. qPCR analysis in figure 4.3A demonstrates the presence of Nmrk2 
mRNA in WT quadriceps and cardiac tissue and the complete absence of gene 
expression in the respective NMRK2KO mouse tissues. Qualitative PCR analysis 
was also run on an agarose gel to further validate the loss of Nmrk2 in KO tissues. 
Figure 4.3B demonstrates Nmrk2 expression in quadriceps tissue from WT, HET 
and KO mice, with bands clearly detected in WT and HET tissue and no bands in 
KO muscle - the gene G6pt was detected in all tissues and used as a PCR 
reaction and loading control. Finally, protein expression was assessed to confirm 
loss of NMRK2 protein expression in KO mice. Immunoblot analysis of NMRK2 
showed loss of protein expression across a range of muscle tissues in NMRK2KO 
mice. Liver tissue that was previously identified to not express Nmrk2 was used as 
a control, unfortunately, most likely due to non-specific protein expression bands 
were seen in a similar region to NMRK2 in KO liver tissue but Nmrk2 mRNA was 
completely undetectable in both WT and KO tissue (figure 4.3C).  
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Figure 4.3 Validation of NMRK2KO mouse model 
(A) Quantitative real-time PCR analysis of Nmrk2 mRNA expression in quadriceps 
(quad), heart and liver tissue from WT and NMRK2KO mice (n=3). (B) Qualitative 
PCR analysis of Nmrk2 mRNA (with G6PT as a loading control) in quadriceps 
muscle from WT, heterozygous (HET) and NMRK2KO mice. (C) Immunoblot 
analysis of NMRK2 protein expression in skeletal muscle beds (quadriceps, TA, 
soleus, gastrocnemius (gastroc) and diaphragm (diaphr), heart and liver tissue 
from WT and NMRK2KO mice. Real-time PCR A.U values presented as mean ± 
SEM and significance determined by unpaired t-test.(* p<0.05, ***p<0.001).    
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4.3.2 NMRK2KO mouse characterisation 
Following initial confirmation of Nmrk2 loss of function basic characterisation was 
conducted as there is currently no published data available on mammalian Nmrk2 
KO models. NMRK2KO mice were fully viable and offspring genotype ratios 
closely followed Mendelian genetics. The mice appeared healthy and behaved 
‘normally’ with no obvious physical differences in vivo between WT and KO mice. 
There was no difference between the average body weight of WT and KO mice 
and further examination of different muscle beds (quadriceps, TA, soleus and 
heart) showed that muscle weight in KO mice was similar to WT (figure 4.4A and 
B respectively). This initial macroscopic phenotyping of NMRK2KO mice highlights 
that the loss of NMRK2 function does not severely impair muscle development or 
systemic metabolism in young mice. 
Figure 4.4 Body weight and muscle bed weights of WT and NMRK2KO mice 
(A) Whole body weight and (B) skeletal (quadriceps, TA and soleus) and cardiac 
(heart) muscle weight from 12 week old WT and NMRK2KO males. All data 
presented as mean ± SEM (n=4).  
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4.3.3 NAD+ signalling mechanisms in WT and NMRK2KO muscle    
To further understand the role of NMRK2 in skeletal muscle NAD+ salvage, the 
effect of Nmrk2 gene deletion on NAD+ metabolism was investigated. Firstly, 
tissue harvested from 10 week old WT and KO mice was examined for changes to 
NAD+ salvage and signalling pathways. The data confirmed the loss of Nmrk2 
mRNA expression in TA and soleus tissue. mRNA expression of NAD+ salvage 
genes in tibialis anterior (TA) and soleus tissue (figure 4.5 A and B, respectively) 
showed mostly unperturbed expression with exception to a slight, yet significant, 
upregulation of Nmrk1 in the TA. With Nmrk2 expression predominant in TA tissue 
compared to soleus, this upregulation may be a result of redundancy signalling.  
Moreover, additional genes involved in NAD+ signalling pathways were also 
examined. These genes included purine nucleoside phosphorylase (Pnp) that can 
metabolise NR to NAM [248], nicotinamide N-methyltransferase (Nnmt1), which 
can add a methyl group to NAM [249] and prevent NAM salvage and equilibrative 
nucleoside transporters (ENT, NT5E) are believed to shuttle NR into the cell [136, 
166], as well as NAD+ consumers CD157 – an ADP-Ribosyl cyclase – and Parp1 
[98, 126, 250]. Again, NMRK2KO TA muscle exhibited more profound changes to 
expression compared to soleus tissue, with significant increases in expression of 
the genes PNP and CD157. In soleus tissue CD157 was significantly upregulated 
(~1.5 fold) but to a lesser extent than in TA (~4 fold) (figure 4.5C and D).   
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Figure 4.5 NAD+ gene expression profiling in NMRK2KO skeletal muscle 
Real-time PCR analysis of NAD+ biosynthesis genes in NMRK2KO (A) TA and (B) 
soleus skeletal muscle compared to WT. Real-time PCR analysis of key NAD+ 
signalling genes in NMRK2KO (C) TA and (D) soleus skeletal muscle compared to 
WT. All tissues were from age-matched NMRK2KO males and analysis fold 
change of ΔCT compared to WT controls (presented as solid line at y=1), n=4. 
Statistical significance was determined by unpaired t-test (*p<0.05, **p<0.01, 
***p<0.001).    
 
The direct effect of loss of NMRK2 function on basal NAD+ levels was also 
determined in muscle tissue using a number of different methods. Firstly, using the 
NAD+ colorimetric assay cellular NAD+, NADH and the NAD/NADH ratio was 
quantified in TA muscle tissue. There was no difference in NAD+ content detected 
in NMRK2KO tissue compared to WT (figure 4.6A). Due to the high turnover and 
quick degradation of NAD+ there can be difficulties in quenching metabolites and 
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accurately measuring NAD+, particularly in tissues. Thus, to confirm these findings 
alternative methods to measure NAD+ in tissue were employed. HPLC analysis of 
NAD+ content in TA muscle showed there was no significant difference in NAD+ 
levels; however, there was a potential downward trend in NMRK2KO TA muscle 
compared to WT (figure 4.6B).   
Figure 4.6 NAD+ content of WT and NMRK2KO skeletal muscle 
(A) Colorimetric analysis of NAD+, NADH and NAD/NADH in TA skeletal muscle 
from WT and NMRK2KO mice (n=4). (B) HPLC analysis of NAD+ in WT and 
NMRK2KO TA skeletal muscle (n=6). All tissues were from age-matched male 
mice and data presented as mean ± SEM. 
 
Although NAD+ levels in NMRK2KO muscle tissue were not found to be 
significantly changed from WT, the complexity of NAD+ signalling and the high rate 
of turnover means NAD+ levels alone do not necessarily uncover perturbations to 
NAD+ signalling and metabolism. Therefore, LC-MS-based targeted NAD+ 
metabolomics was employed to provide a more global quantification of NAD+ and 
its related metabolites.  In quadriceps tissue, there was no difference in NAD+ 
content following loss of NMRK2 function. Other important NAD+-related 
metabolites including NADP, NAM, NR, meNAM and ADPr were also not 
significantly different. Although both NA and NMN levels are low in comparison to 
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other metabolites, NA content was significantly reduced and NMN elevated in 
NMRK2KO mice (figure 4.7).  
Figure 4.7 NAD+ metabolome of WT and NMRK2KO skeletal muscle 
Quantitative LC-MS analysis of NAD+ and related metabolites from quadriceps 
skeletal muscle of WT and NMRK2KO mice (n=6). All tissues were collected from 
age matched males and all values in pmol/mg of dry pellet weight. Significance 
was determined by unpaired t-test (* p<0.05, **p<0.01).    
 
4.3.4 Skeletal muscle energy metabolism in WT and NMRK2KO mice 
As NAD+ is a central signalling metabolite in energy metabolism, the impact of 
NMRK2 loss of function on metabolic pathways was assessed [66, 145]. Firstly, 
expression of genes central to regulating cellular energy metabolism were 
examined in WT and NMRK2KO TA and soleus tissue by qPCR including; NAD-
dependent Sirt1 and Sirt3, and metabolic transcription factors Pgc1α, Pparα and 
Pparδ [84, 119, 127]. The expression of these major regulators of energy 
metabolism was unperturbed in both TA and soleus NMRK2KO tissue (figure 4.8A 
and B).  In addition, expression of mitochondrial genes were also examined. 
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These included mitochondrial uncoupling protein 2 (Ucp2), pyruvate 
dehydrogenase kinase 4 (Pdk4) and isocitrate dehydrogenase 2 (Idh2) – 
regulators of glucose metabolism, as well as nuclear respiratory factor 1 (Nrf1), 
and mitochondrial transcription factor A (Tfam) – key modulatory genes of 
mitochondrial biogenesis [63, 177]. Ucp2 expression in the TA was the only 
significantly altered mitochondrial gene examined ( ̴ 2 fold increase) (figure 4.8C 
and D). Together this data shows that loss of NMRK2 function does not lead to 
vast reprogramming of the metabolic genes tested.  
Induction of metabolic signalling through NAD+ dependent SIRT activation leads to 
mitochondrial biogenesis [90, 227, 251]. Gene expression is not necessarily 
reflective of enzyme activity therefore, using a mitochondrial profiling antibody, we 
examined protein expression of key components in each of the mitochondrial ETC 
complexes (complex I, II, III, IV and V (or ATP synthase)) as an indicator of 
changes to mitochondrial biogenesis. Figure 4.8E shows that, of the mitochondrial 
proteins examined, there was no change to protein expression detected in 
NMRK2KO mouse quadriceps and TA tissues compared to WT. This data 
together with the qPCR data indicates that deletion of Nmrk2 does not impede key 
mitochondrial signalling pathways under basal conditions. 
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Figure 4.8 Metabolic gene expression profiling of NMRK2KO skeletal muscle 
Real-time PCR analysis of key metabolic genes in NMRK2KO (A) TA and (B) 
soleus skeletal muscle compared to WT. Real-time PCR analysis of key 
mitochondrial genes in NMRK2KO (C) TA and (D) soleus skeletal muscle 
compared to WT. (E) Immunoblot analysis of mitochondrial complex protein 
expression in quadriceps and TA tissue from WT and NMRK2KO mice.  All tissues 
were from age-matched NMRK2KO males and analysis of ΔCT fold change (mean 
± SEM) compared to WT controls (presented as solid line at y=1), n=4. Statistical 
significance was determined by unpaired t-test (* p<0.05). 
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To more directly assess the effect of NMRK2 loss of function on energy 
metabolism, quantitative LC-MS analysis was used to identify potential changes to 
metabolite levels (ATP, ADP, inosine, cytidine, uridine, inosine monophosphate 
(IMP), uridine monophosphate (UMP) and cytidine monophosphate (CMP)) in 
muscle tissue. From the metabolites examined, figure 4.9 shows that IMP was the 
only metabolite found to be significantly different in WT and NMRK2KO muscle 
tissue.     
Figure 4.9 LC-MS analysis of energy metabolites in WT and NMRK2KO 
skeletal muscle 
Quantitative LC-MS analysis of ATP, ADP and nucleotide metabolites from 
quadriceps skeletal muscle of WT and NMRK2KO mice (n=6). All tissues were 
collected from age matched males and all values in pmol/mg of dry pellet weight. 
Statistical significance was determined by unpaired t-test (* p<0.05).    
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4.3.5 Functional analysis of NMRK2KO myotubes in vitro 
Primary myotubes from WT and KO mice were used as in vitro models of skeletal 
muscle. These allowed for higher throughput analysis and enabled the 
comparison of genetic, pharmacological and nutraceutical interventions in both 
isolation and combination.   
Using the NAD+ colorimetric assay, previously optimised in C2C12 myotubes, 
cellular NAD+, NADH and the NAD/NADH ratio were quantified in primary WT and 
NMRK2KO myotubes. Interestingly, NAD+ levels were significantly lower (35.4% ± 
8.8) in the NMRK2KO myotubes compared to WT. NADH levels were also 
reduced in the NMRK2KO myotubes; thereby resulting in an unchanged 
NAD/NADH ratio (figure 4.10 A).  
Figure 4.10 NAD+ content of primary myotubes isolated from WT and 
NMRK2KO mice 
(A) Colorimetric assay analysis of NAD+, NADH and NAD/NADH in primary 
myotubes isolated from gastrocnemius muscle of WT and NMRK2KO mice (n=5). 
(B) Preliminary LC-MS analysis of total NAD(H) in primary myotubes isolated from 
gastrocnemius muscle of WT and NMRK2KO mice (WT n=3, KO n=2). All data 
presented as mean ± SEM and statistical significance was determined by unpaired 
t-test (* p<0.05). 
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This data opposed the unchanged levels seen in tissue and highlights the notion 
that there are likely to be differences between closed cellular systems and tissue 
which are exposed to systemic regulation, particularly when examining highly 
regulated signalling events. Supporting this, preliminary LC-MS analysis of 
NMRK2KO primary myotubes showed a downward trend, albeit non-significant, in 
NAD+ content compared to WT (figure 4.10B).  
To confirm NMRK2 as a novel target enzyme for boosting NAD+ in skeletal 
muscle, through its ability to salvage NR, primary myotubes were supplemented 
with NR for 24 hours.  Surprisingly, in response to 24 hour NR treatment, NAD+ 
content significantly increased in both WT and NMRK2KO myotubes, although 
NAD+ levels were still significantly higher in the WT myotubes the percentage of 
increase from their respective untreated myotubes was similar (~55 %) (figure 
4.11A). NAM supplementation (0.5 mM for 24 hours) did not significantly change 
NAD+ levels from the untreated control myotubes however there appears to be an 
upward trend in NAD+ in the NMRK2KO myotubes (figure 4.11A). Figure 4.11B 
demonstrates that the corresponding NADH levels show a similar trend to NAD+ 
with a significant increase in NADH following NR supplementation in the WT 
myotubes only. The NAD/NADH ratio was more variable and did not significantly 
change between genotypes with or without precursor treatment (figure 4.11E).        
NAD+ and its metabolites are continuously interchanged by a range of enzymes; 
thus, it is possible NR is converted to NAM in NR supplemented NMRK2KO 
myotubes. Although exogenous NAM supplementation does not lead to enhanced 
NAD+, this may be a result of poor cellular uptake, and it is therefore feasible that 
intracellular conversion of NR to NAM by enzymes such as PNP could still result in 
increased NAD+ availability.  
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Figure 4.11 NAD+ content of WT and NMRK2KO myotubes following NAD+ 
precursor supplementation 
(A) NAD+ and (B) NADH content of WT and NMRK2KO myotubes following 24 
hour treatment with 0.5 mM NR, NAM or vehicle control for 24 hours. (C) NAD+ 
and (D) NADH content of WT and NMRK2KO myotubes following 24 hour 
treatment with NAMPT inhibitor FK866 (100 nM) and supplementation with 0.5 
mM NR, NAM or vehicle control for 24 hours. (E) NAD/NADH ratio of WT and 
myotubes with and without 24 hour 100 nM FK866 and 0.5 mM NR or NAM 
treatment. All controls and cell treatments n=5 and data presented as mean ± 
SEM, significance was determined by two-way ANOVA with Tukey’s multiple 
comparisons (* p<0.05, **p<0.01, ***p<0.001 treatment vs vehicle and # p<0.05 
WT vs NMRK2KO).    
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To test this theory and to gain further insight to the relative importance of NMRK2 
and NAMPT mediated NAD+ salvage in skeletal muscle, NAMPT was inhibited 
with FK866 thereby blocking salvage of NAM to NAD+. As previously seen in WT 
myotubes, following 24 hour FK866 treatment NAD+ levels were significantly 
depleted in both WT and NMRK2KO myotubes. However, NR supplementation 
was able the completely recover NAD+ levels following FK866 treatment in both 
WT and KO myotubes; significantly enhancing NAD+ to similar levels to those 
seen with NR treatment alone (figure 4.11C). In addition, figure 4.11C shows that 
NAM supplementation with FK866 was unable to rescue NAD+ content indicating 
that FK866 is appropriately inhibiting NAMPT. NADH levels again show a similar 
trend to NAD+ following FK866 inhibition of NAMPT (figure 4.11D).  
Together this data suggests that NR can be metabolised independently of NMRK2 
and NAMPT in skeletal muscle. Finally, although the NAD/NADH ratio did not 
significantly change following FK866 treatment it does show an upward trend in 
both the WT and KO myotubes which is reversed following NR supplementation 
(figure 4.11E); suggesting depletion in NAD+ may lead to a surge in oxidative 
metabolism.   
As this data indicates that NMRK2 and substrate NR can both independently 
regulate cellular NAD+ levels in primary myotubes, mitochondrial function was 
assessed using the Seahorse XF analyser to see whether NMRK2 or NR can 
regulate mitochondrial oxidative output. Cellular oxygen consumption rate (OCR) 
provides an indication of oxidative metabolism, and preliminary data in figure 
4.12A demonstrates that the maximal mitochondrial respiration of NMRK2KO 
myotubes may be slightly impaired compared to WT. Moreover, 24 hour NR 
 
 
141 
 
treatment appears to enhance both NMRK2KO and WT (to a larger degree) 
maximal mitochondrial respiration. The corresponding extracellular acidification 
rate (ECAR), an indicator of glycolysis, shows a downward trend in ECAR in 
NMRK2KO myotubes compared to WT (figure 4.12A - right). The figure is 
representative of n=2 and therefore this experiment will require repeating to draw 
more definitive conclusions.  
To investigate whether the potential changes in mitochondrial function in WT and 
NMRK2KO myotubes following NR treatment is a result of enhanced mitochondrial 
biogenesis, expression of key proteins from each mitochondrial complex were 
examined by immunoblot analysis using a mitochondrial profiling antibody. Protein 
expression in WT and NMRK2KO myotubes was assessed with and without 0.5 
mM NR supplementation and in either normal growth DMEM with glucose at 25 
mM or in low 6 mM glucose DMEM. This lower glucose concentration acts to 
deprive cells of glucose and inflict metabolic stress, similar to calorie restriction, 
and stimulate metabolic adaptation [84, 102]. The immunoblot data in figure 4.12B 
illustrates that protein expression of all the detected mitochondrial complex 
proteins in WT and NMRK2KO myotubes was unchanged - with or without NR in 
both high and low glucose conditions suggesting mitochondrial biogenesis was not 
induced.  
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Figure 4.12 Mitochondrial function of WT and NMRK2KO myotubes following 
NR supplementation  
(A) Mitochondrial oxygen consumption rate and extracellular acidification rate as a 
% of basal levels with in WT and NMRK2KO myotubes following 0.5 mM NR 
supplementation. (B) Immunoblot analysis of key mitochondrial electron transport 
chain subunits in WT and NMRK2KO myotubes with and without 24 hour NR 
treatment and in high and low glucose cell media.  
 
4.3.6 NMRK1 as a mediator of skeletal muscle NAD+ biosynthesis 
The data in this chapter shows that exogenous NR can be metabolised to NAD+ 
independently of both NMRK2 and NAMPT. Despite relatively low expression of 
NMRK1 in skeletal muscle, its salvage of NR is the most likely alternative route to 
NAD+. Thus, to investigate a potential role for NMRK1 in NAD+ salvage, siRNA 
based gene knockdown (KD) was employed in primary cultures. Nmrk1 KD was 
investigated in WT and NMRK2KO myotubes to determine the role of NMRK1 and 
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assess potential redundancy effects in NMRK2KO myotubes. Around 50% KD of 
Nmrk1 mRNA was achieved (figure 4.13A). NMRK1 Protein KD was not confirmed 
due to difficulties detecting NMRK1 which is expressed at low levels in myotubes. 
Nmrk1 KD in WT and NMRK2KO myotubes did not appear to significantly alter the 
gene expression profiles of NAD+ salvage genes or other genes involved in 
mitochondrial and energy metabolism (figure 4.13A and B).  
Figure 4.13 Metabolic gene profiles of WT and NMRK2KO myotubes 
following Nmrk1 knockdown 
Real-time PCR analysis of (A) NAD+ biosynthesis and (B) mitochondrial and 
energy metabolism genes in WT and NMRK2KO myotubes following transient 
Nmrk1 knockdown (KD). Data given as fold change of Nmrk1 KD WT myotubes 
compared to scrambled control treated WT myotubes or Nmrk1 KD of NMRK2KO 
myotubes compared to scrambled control treated NMRK2KO myotubes. All data 
presented as mean ± SEM. Nmrk1 KD WT, scrambled NMRK2KO and Nmrk1 KD 
NMRK2KO myotubes n= 3 and scrambled WT myotubes n=2 thus unpaired t-test 
statistical analysis on ΔCt values of NMRK2KO myotubes only (* p<0.05).       
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Due to problems with myotube isolation, WT scrambled myotubes were only n=2 
and therefore statistical analysis was only determined on ΔCT values from 
scrambled versus Nmrk1 siRNA transfected NMRK2KO myotubes. It is notable 
that, although significance could not be established, there may be some 
downregulation to Nmrk2 expression in WT Nmrk1 KD myotubes (figure 4.13A); 
potentially a result of off target knockdown.   
NAD+ was measured in primary myotubes following siRNA Nmrk1 KD. Basal 
levels of NAD+ were unchanged in Nmrk1 KD myotubes compared to those 
treated with a scrambled siRNA control (figure 4.14A). Primary myotube cultures 
were also used to investigate whether NMRK1 can use exogenous NR to boost 
NAD+ in skeletal muscle. NAMPT inhibitor FK866 was used to block NAMPT 
salvage and maximise the NAD+ boosting effect of NR. NMRK1 precursor salvage 
was assessed both alone in WT and in combination in NMRK2KO myotubes. 
Following 24 hour NR treatment, a downward trend was seen in NAD+ in WT 
Nmrk1 KD myotubes compared to scrambled treated WT myotubes (figure 4.14B). 
However, no difference was identified in NMRK2KO myotubes following Nmrk1 
KD compared to scrambled treated cells; this may be attributed to the slight 
upregulation of Nmrk1 seen in NMRK2KO tissue (figure 4.5) and thereby 50% KD 
leading to potentially WT levels of Nmrk1. 
As a downstream vitamin B3 NAD+ precursor to NAMPT and the NMRK enzymes, 
NMN was also supplemented into this model as a control to overcome all the 
pathway blocks and boost NAD+. Interestingly, despite acting downstream, NMN 
could not boost NAD+ to the same extent following Nmrk1 KD in both WT and 
NMRK2KO myotubes; indicating a possible alternative role for NMRK1 (figure 
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4.14B). Unfortunately, difficulties replicating the KD data beyond n=3 – either due 
to issues with siRNA transfection efficiency, particularly in differentiated myotubes, 
and large scale growth of primary muscle to get the required cells for multi-
intervention analysis – resulted in high variability. This data was therefore only 
used for preliminary analysis of NMRK1 in muscle with no conclusive results 
found.  
Figure 4.14 Cellular NAD+ content following Nmrk1 Knockdown 
(A) Primary myotube NAD+ content following Nmrk1 siRNA transfection compared 
to scrambled (SCR) control. (B) WT and KO myotube NAD+ content following 
Nmrk1 siRNA transfection compared to scrambled control. All myotubes were 
treated with 100 nM FK866 to inhibit NAMPT activity and supplemented with 0.5 
mM NR or NMN for 24 hours. All treatment groups were n=3 and data presented 
as mean ± SEM. 
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4.3.7 The effects of loss of NMRK function on skeletal muscle cell 
differentiation and metabolic phenotype in vitro 
As Nmrk1 KD studies proved limited for analysis of NMRK1 function, NMRK1KO 
mouse models were acquired (from the lab of Carles Canto, Nestle institute of 
health sciences, Lausanne). Following this, to assess NMRK enzyme redundancy, 
NMRK1 and 2 KO mouse breeding programs were also established to generate 
double NMRK KO (DKO) offspring.  With NMRK enzymes highly conserved [142] 
and NAD+ availability critical for energy homeostasis it was necessary to firstly 
identify any global effects loss of NMRK1 and 2 function may have on muscle 
development and metabolism. Similar to NMRK2KO mice, no gross abnormalities 
were identified, with mouse behaviour and physical characteristics seemingly 
normal. 
Furthermore, expression of myogenic genes over muscle differentiation in WT, 
NMRK1KO, NMRK2KO and DKO mouse myotubes was assessed to indicate 
normal muscle differentiation. Figure 4.15 shows that the loss of NMRK1 and 
NMRK2 function individually and combined (to eliminate potential NMRK 
redundancy) did not alter expression of key muscle differentiation markers namely; 
Acta, MyoD and MyoG (figure 4.15A-C). Myotube morphology also appeared 
consistent across the different genotypes over differentiation. Thus, this data 
combined with macroscopic in vivo assessment confirms that the NMRKs are not 
essential for muscle development in mice despite the highly muscle specific nature 
of NMRK2. This data is contrary to findings in zebrafish, whereby nrk2b was found 
to be essential for skeletal muscle morphogenesis. This effect however, was 
shown to be NAD+ specific and therefore suggests zebrafish skeletal muscle is 
more reliant of Nrk2b mediated NAD+ biosynthesis as opposed to Nampt [252].  
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Figure 4.15 NAD+ Salvage and myogenic gene expression over 
differentiation in NMRK KO myotubes 
Real-time PCR analysis of skeletal muscle myogenic markers (A-C) and NAD+ 
salvage genes (D-F) in WT, NMRK1KO, NMRK2KO and DKO isolated muscle 
cells over 8 days of differentiation to myotubes. A.U values presented as mean ± 
SEM (n=5).    
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NAD+ salvage gene expression was also examined to validate the primary 
myotube KO models and identify possible redundancy effects following loss of 
NMRK1 and NMRK2 function. As expected mRNA expression of Nmrk1 and 
Nmrk2 was absent in their respective single and double NMRK1 and 2 KO 
myotubes. Expression of NMRK1 and 2 was unchanged from WT levels in 
NMRK2 and NMRK1 KO myotubes respectively (figure 4.15D and E). Nampt 
mRNA expression was unchanged from WT levels in both the single NMRK KO 
and DKO myotubes (figure 4.15F). This data validates the genotype of the 
myotubes examined whilst indicating minimal NAD+ biosynthesis enzyme 
redundancy following loss of NMRK function over differentiation at mRNA level.  
4.3.8 NMRKs do not modulate basal skeletal muscle NAD+ but are 
essential for exogenous NR and NMN utilisation 
The data in figure 4.11 demonstrated that NMRK2KO myotubes can still 
metabolise exogenous NR to NAD+, independent of NAMPT, indicating NMRK1 
activity in myotubes. NAD+ was measured in primary myotubes from single and 
double NMRK KO mice to investigate the individual (and combined) role of 
NMRKs in basal NAD+ maintenance and precursor use; with DKO myotubes used 
to establish possible enzyme redundancy. This work was performed in the Carles 
Canto laboratory at the Nestlé Institute of Health Sciences, Lausanne, Switzerland 
with the assistance of Joanna Ratajczak for primary myotube preparation and 
analysis.  
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Figure 4.16 NAD+ content of NMRK KO myotubes 
Basal NAD+ content of primary myotubes from WT, NMRK1KO, NMRK2KO and 
NMRK1 and NMRK2 double KO (DKO) mouse skeletal muscle. All data presented 
as mean ± SEM (n=4-5).   
 
Interestingly, in contrast to previous data (figure 4.10), basal NAD+ levels were 
unchanged from control in the single and double NMRK deficient models (figure 
4.16). Although to a lesser extent than in the WT myotubes, NMRK1KO and 
NMRK2KO myotubes still exhibited enhanced NAD+ following NR supplementation 
(figure 4.17A,B left).  However, NR was completely unable to increase NAD+ in the 
DKO myotubes (Figure 4.17C left), suggesting an unbiased NMRK dependence 
for NR in muscle.   
To further understand the role of NMRKs relative to NAMPT and eliminate 
possible NAMPT redundancy, FK866 was used to inhibit NAMPT and effectively 
provide a triple loss of function system. As expected, 24 hour NAMPT inhibition by 
FK866 substantially depleted cellular NAD+ content in all the NMRK loss of 
function models (Figure 4.17A-C right). NR supplementation could recover, but not 
boost, NAD+ levels following FK866 inhibition in NMRK2KO and, to a lesser 
extent, NMRK1KO myotubes (Figure 4.17A,B right). Yet, NR supplementation 
could not rescue NAD+ depletion in NMRK DKO myotubes (Figure 4.17C right).  
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 Figure 4.17 NR and NMN salvage to NAD+ in NMRK KO myotubes 
Percent change in NAD+ content from control of (A) NMRK1KO (B) NMRK2KO 
and (C) double KO (DKO) primary myotubes following 24 hour 0.5 mM NR or 
NMN supplementation compared to WT myotubes (left) and corresponding % 
change in NAD+ content following 24 hour 100 nM FK866 treatment (right). Data 
presented as mean ± SEM and significance of actual NAD+ values between WT 
and KOs was determined by two-way ANOVA with Bonferroni post-tests (n=4-5). 
(* p<0.05, **p<0.01, ***p<0.001).     
 
 
 
151 
 
In addition, NMN is salvaged to NAD+ downstream of NAMPT and the NMRKs 
(figure 4.1) and can significantly boost NAD+ content and rescue FK866 depletion 
in WT myotubes (figure 3.9), thus it was used as a control to enhance NAD+ in all 
the NMRK loss of function models. As previously seen, NMN supplementation 
could recover and boost NAD+ with and without NAMPT inhibition in WT and 
NMRK2KO myotubes (figure 4.17B). However, and surprisingly, NMN 
supplementation could not recover NAD+ depletion in NMRK1 deficient myotubes 
(figure 4.17A,C).  
 Figure 4.18 NAM salvage to NAD+ in NMRK DKO myotubes following 
NAMPT inhibition 
Percent change in NAD+ content of NMRK DKO primary myotubes compared to 
untreated WT control (dashed line) following 24 hour 100 nM FK866 treatment and 
0.5 mM and 5 mM (NAM*10) NAM supplementation. Data presented as mean ± 
SEM (n=4).  
 
NAM supplementation was used as a further control and was unable to boost 
NAD+ at equimolar levels but could enhance NAD+ and partly overcome NAMPT 
inhibition at 5 mM (at 50,000 x FK866 concentration) in WT and DKO myotubes 
(figure 4.18). These data further confirm that NAMPT recycling of NAM is the 
principal pathway for maintaining NAD+ homeostasis in skeletal muscle. It also 
shows that the NMRKs are essential for utilising NR to enhance cellular NAD+, 
and identifies a novel role for NMRK1 in the salvage of exogenous NMN. 
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4.4 Discussion 
Skeletal muscle is a central tissue for energy homeostasis; thus loss of muscle 
mass and function with ageing and chronic disease states manifests hand in hand 
with metabolic decline [26]. As a critical signalling metabolite in energy 
metabolism, reduced NAD+ availability in ageing may compromise the plasticity of 
muscle in response to metabolic stress [89, 169, 174]. Therefore, a better 
understanding of NAD+ turnover in skeletal muscle may elucidate novel strategies 
to enhance NAD+ levels and restore metabolic function. Studies have already 
begun to outline potential muscle specific benefits of enhanced cellular NAD+ with 
strategies including, PARP inhibition to limit NAD+ consumption [92, 127] and 
supplementation with NAD+ precursors to drive biosynthesis [178, 201]. 
Following the identification of Nampt and Nmrk2 as the most predominantly 
expressed NAD+ biosynthesis genes in skeletal muscle, this chapter further 
investigated the importance of these pathways for NAD+ biosynthesis. NAMPT has 
already been well characterised as a critical regulator of basal NAD+ [76, 150, 227] 
yet little is known about the function of NMRK2. Current studies of NMRKs are 
mostly limited to yeast and zebrafish models [142, 173, 252, 253]. In yeast models 
Nmrk1-dependent metabolism of NR was shown to contribute to basal NAD+ and 
necessary for Sir2 function and life span extension seen following calorie 
restriction [253]. Whilst in zebrafish, nrk2b has been shown to regulate cell matrix 
adhesion complexes during muscle morphogenesis in an NAD+ dependent 
manner with nrk2b deficiency leading to muscle abnormalities [173]. Despite these 
studies indicating an evolutionary conserved importance for NMRK salvage of NR 
there has been little study beyond this in higher organisms.  
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Thus, to investigate the function of mammalian NMRK2, a loss of function mouse 
model was employed. As a novel mouse model with no existing published data, 
the NMRK2KO mouse was fully validated and loss of mRNA and protein was 
confirmed. Macroscopic analysis of mice identified behaviour and activity 
consistent with WT and HET litter mates. Skeletal muscle quantification of NAD+ 
and related metabolites showed mostly unchanged metabolite levels in NMRK2KO 
tissue compared to WT. Although NA was reduced in NMRK2KO muscle, the 
levels detected even in WT tissue were minimal and therefore this difference is 
unlikely to have biological relevance. Skeletal muscle NADS (protein encoded by 
NADsyn1) expression and activity is normally below detectable levels [147] but it 
is possible the decrease is a result of increased NADS activity as a redundancy 
response to loss of NMRK2 activity.   
Basic profiling of muscle tissue gene and protein expression did not identify any 
major transcriptional or translational differences in NMRK2KO muscle compared 
to WT in respect to NAD+ signalling and energy metabolism. Of the genes 
investigated, only CD157, Pnp and Ucp2 were found to be significantly changed in 
TA muscle. Soleus tissue gene expression was less affected by NMRK2 
deficiency with only CD157 significantly upregulated. Unfortunately, follow up 
immunoblot analysis of CD157 protein expression was unsuccessful largely owing 
to issues with antibody specificity (sc-7115, Santa Cruz, U.S) and its low 
expression in skeletal muscle. CD157 uses NAD+ to generate cyclic ADPribose, 
NAADP and ADPr  [98]; its role in numerous cellular signalling pathways from cell 
proliferation to immune function makes it impossible to predict the relevance of 
this upregulation [254, 255], notably it is involved in muscle contraction and 
calcium signalling [255], which may possibly be perturbed in NMRK2KOs given its 
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muscle specificity.  Interestingly, NR has been identified as a substrate for PNP 
which can dephosphorylate NR to NAM [248]. This change may be an adaptive 
response to increased NR availability in muscle in NMRK2KO. If PNP metabolism 
is enhanced this may also explain why a block to NR metabolism via NMRK2 did 
not lead to a build-up of NR in NMRK2KO muscle. Again, the importance and/or 
biological significance of changes to Ucp2 expression is difficult to deduce. UCP2 
is a mitochondrial uncoupling protein that can regulate cellular ADP:ATP ratio, 
unlike UCP1 which plays a clear role in brown adipose thermogenesis the specific 
physiological functions of UCP2 are still poorly understood; with upregulation 
associated with increased energy expenditure and protective against obesity [256-
258].  
With the NAD+ metabolome mostly unperturbed in NMRK2KO tissue, it is 
unsurprising that the loss of function mice did not present with majorly aberrant 
NAD+ signalling and metabolism. Although gene and protein expression levels are 
good indicators of changes to NAD+ signalling, they do not identify changes to 
enzyme activities and post translational signalling events. For example, despite 
unchanged gene expression to SIRT1 in NMRK2KO muscle, SIRT1 enzyme 
activity may still be different from WT. Current difficulties measuring SIRT activity 
in muscle meant that potential changes could not be directly measured in NMRK2 
deficient muscle; however, expression of metabolic genes (e.g. Pdk4, Nrf1 and 
Tfam) that are typically transcriptionally regulated by SIRT activity via PGC1α  [63, 
259] were unchanged suggesting that SIRT activity is not affected by loss of 
NMRK2 function.  
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Initial investigation of NMRK2 deficient myotubes using the colorimetric 
NAD/NADH assay identified significantly lower NAD+ levels compared to WT 
myotubes. Preliminary LC-MS analysis of NMRK2KO myotubes corroborated 
these findings. Further repetition of LC-MS is necessary to determine significance 
of this analysis and investigate NAD-related metabolites. The primary cultures 
required for LC-MS analysis required large up-scaling limiting culture success 
rates.   Thus, this analysis was treated as exploratory with further assessment 
required to draw any conclusions. The results determined in myotubes opposed 
those from NMRK2KO tissue analysis and may be attributed to myotubes existing 
in a closed system with limited substrate availability. It is possible that without 
multi-tissue and systemic interplay myotube NAD+ levels are more sensitive to 
changing.    
Furthermore, preliminary data suggests maximal mitochondrial function may be 
impaired in NMRK2KO mice. NR may enhance maximal mitochondrial function, 
following uncoupling, in WT, and to a lesser degree in NMRK2KO myotubes. This 
shows potential functional differences between WT and NMRK2KO myotubes; 
possibly indicating a diminished oxidative adaptive ability of KO myotubes during 
metabolic stress, that may be related to NAD+ availability. Normalisation difficulties 
due to the small amount of protein per well and the inability to count satellite cells 
meant data was presented as percent change from basal OCR.  Profiling of key 
mitochondrial complex proteins showed no difference between WT and KO 
myotubes with or without NR treatment, suggesting mitochondrial content is 
unchanged and not responsible for any functional differences. However, 
consistent with the other experiments performed here myotubes were treated with 
NR for just 24 hours and a longer treatment time may be required to see changes 
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at a protein level. With that said, taking into account previous literature, these 
findings in respect to NR supplementation were anticipated. The muscle specific 
NAMPT overexpressing mouse model exhibited a 50% increase in NAD+ content 
yet mitochondrial biogenesis was not induced and oxidative function was 
unchanged in young mice [240]. With the NAMPT overexpressing mice only 
demonstrating improvements to metabolic health compared to WTs upon ageing 
(2 years) [76]. 
Despite depletion of NAD+ by FK866, there is a general upward trend in the 
NAD/NADH ratio, typically thought to push oxidative metabolism. This is 
unexpected as upon NAD+ depletion it would be expected that oxidative function 
would be negatively impacted. Studies have shown that mitochondrial NAD+ is 
protected from FK866 depletion for over 24 hours [96] thereby maintaining 
mitochondrial function and it is possible the NAD/NADH ratio pushes towards 
NAD+ as an acute stress response to reduced cytosolic NAD+ availability to further 
support oxidative function. 
NR supplementation enhanced NAD+ levels in both WT and NMRK2KO myotubes. 
The NAD+ boosting effect of NR was also seen following NAMPT inhibition, thus 
ruling out potential conversion of NR to NAM and salvage to NAD+ by NAMPT. 
This indicated that NMRK1 may be able to metabolise NR in skeletal muscle 
despite low expression. NMRK1 protein was unsuccessfully detected in WT and 
NMRK2KO muscle tissue, but mRNA levels were slightly upregulated indicating a 
possible redundancy effect following loss of NMRK2 function. Initial Nmrk1 KD 
studies to investigate the potential role of NMRK1 in skeletal muscle biosynthesis 
were inconclusive due to difficulties reproducing KD efficiency in repeated 
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experiments. Muscle cells are difficult to transfect and transfections are normally 
most successful whilst cells are myoblasts. For this study, NAD+ was measured in 
fully differentiated myotubes to compare and combine with data from NMRK2KO 
myotubes and therefore this is likely the reason for inconsistent transfection 
efficiency.  
Therefore, to investigate NMRK1 function in skeletal muscle further, a 
collaboration with Dr Carles Canto at the Nestle Institute of Health Sciences was 
established, where NMRK1KO, NMRK2KO and NMRK double KO (DKO) mice 
were available for analysis. Expression of key differentiation markers showed 
levels consistent with WT myotubes in the NMRK single and double KO systems, 
indicating normal myotube differentiation. Furthermore, expression of Nampt and 
Nmrk1 and Nmrk2 mRNA was unchanged from WT in myotubes (except in 
corresponding NMRK KO myotubes), indicating a lack of redundancy at a gene 
level.      
NR supplementation of the NMRK KO models showed that NMRK1 and 2 KO 
myotubes could salvage NR and replete NAD+ following FK866 depletion, but to a 
lesser extent than WT. In DKO myotubes NR supplementation was unable to 
enhance or recover myotube NAD+, identifying NR metabolism to NAD+ as NMRK 
dependent. Despite a much lower level of expression, NMRK1 deficiency 
appeared to have a greater effect on NR metabolism compared to NMRK2 which 
may be attributed to its greater affinity for NR [164, 165]. This reinforces the notion 
that expression levels are a useful indicator but not reliable for assuming enzyme 
influence. Importantly, the relative expression of Nmrk1 in primary myotubes was 
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higher than in skeletal muscle tissue (although still considerably lower than 
Nmrk2); therefore this may have heightened the effects of Nmrk1 salvage in vitro.   
Although, NMN is metabolised to NAD+ downstream of NMRKs and NAMPT, 
exogenous NMN supplementation was unable to be used for NAD+ salvage in 
NMRK1KO primary myotubes, implicating NMRK1 in regulating exogenous NMN 
metabolism. Recent findings by Ratajczak et al. (2016), have also implicated 
NMRK1 in the regulation of exogenous NMN salvage in hepatocytes; with 
hepatocytes (which do not express Nmrk2) from NMRK1KO mice unable to use 
exogenous NMN. This work proposed a need for NMN to be extracellularly 
metabolised to NR for entry into the cell and then phosphorylated intracellularly by 
NMRK1 [166].    
This follow up analysis using NMRK1, NMRK2 and DKO myotubes failed to 
replicate the decrease in basal NAD+ levels previously seen in NMRK2KO 
myotubes. These myotubes were set up whilst in a different laboratory 
environment (Lausanne, Switzerland) and therefore there were some unavoidable 
changes to the experimental set up that may be attributed to the inconsistencies 
seen here. For example, batch numbers of horse serum, foetal bovine serum and 
chick embryo extract were different and as previously demonstrated NAD+ levels 
are highly sensitive to nutrient availability [116, 135]. Moreover, the myotube 
cultures for the single and double KO experiments had some fibroblast 
contamination that is not normally seen in primary muscle set up (although 
myotubes were still predominant). Muscle tissue consists of a mix of muscle cells 
and connective tissue and therefore, although most of the fibroblasts are 
separated from myofibres during set up, small amounts of fibroblast contamination 
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is expected in cultures [260, 261]. The increase seen was consistent across all the 
cultures (from 20 mice) done in the secondary laboratory environment and may be 
a result of differences to serums or possibly due to culture plate differences. 
Unfortunately, these culture differences were unanticipated and as both mouse 
availability and time was limiting to this part of the investigation it could not be 
repeated to determine fibroblast influence on NAD+ levels. Importantly, all the 
NMRK KO models exhibited global loss of function and therefore fibroblast 
contamination should not influence functional investigations. The inconsistencies 
in this data again highlights the highly dynamic and sensitive nature of NAD+ 
signalling and shows the difficulties faced whilst trying to accurately measure 
changes following intervention.   
This chapter presents novel findings in regards to skeletal muscle NAD+ 
biosynthesis pathways. Despite, identifying an essential role for NMRKs in NR 
salvage, initial investigations show no impairments to NAD+ signalling, muscle 
development and energy metabolism in the loss of function mouse models. 
However, the muscle specificity of NMRK2 suggests it may still be an important 
enzyme in skeletal muscle. These studies outlined the importance of different 
NAD+ biosynthesis pathways under basal conditions. Despite a minimal role for 
NMRKs under basal conditions, skeletal muscle is highly adaptive to metabolic 
stress and therefore they may have a redundancy function to support NAMPT 
salvage activity in response to stress.   
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Chapter 5 Preliminary in vivo assessment of 
NMRK2 deficient mice  
(All in vivo experiments and tissue collection were conducted at University of 
Birmingham; fibre-typing analysis was performed by Dr Gabriela da Silva Xavier 
post-collection at Imperial College London) 
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5.1 Introduction 
Skeletal muscle has a remarkable ability to adapt in response to metabolic stress 
and meet the high energy requirements for muscle contraction [31, 32, 46]. It acts 
as a critical modulator of systemic energy metabolism and adapts acutely and 
chronically to everyday stresses that threaten energy homeostasis including, 
exercise and calorie restriction [30, 46, 177]. This critical function is regulated 
through the energy sensing enzymes AMPK and SIRTs. When cellular ATP levels 
decrease, AMPK is activated and can directly phosphorylate PGC1α and 
upregulate its transcription [62]. Furthermore, AMPK can phosphorylate NAMPT 
and enhance recycling of NAM to NAD+; a surge in cellular NAD+ availability 
stimulates SIRT activity and results in deacetylation of PGC1α [244]. This post-
translational modification activates PGC1α, inducing global transcriptional 
reprogramming of metabolic genes in favour of ATP generation [63, 251].  
The importance of NAD+ biosynthesis in skeletal muscle metabolism 
NAD+ dependent SIRT-mediated metabolic signalling was classically identified in 
yeast whereby induction of Sir2 by calorie restriction enhanced lifespan [262]. 
Since then, the vast benefits of calorie restriction and induction of SIRTs have 
been elucidated [84, 263].   
In mammals, fasting and calorie restriction is associated with enhanced NAMPT 
activity and NAD+ availability to support SIRT action [84]. The dependence of 
SIRT activity on NAD+ demonstrates the importance of replenishing NAD+ 
following consumption [90, 99]. Data presented in this thesis supports previous 
research that shows NAMPT to be an essential enzyme for NAD+ biosynthesis in 
skeletal muscle [76]. Pharmacological inhibition of NAMPT leads to a severe 
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depletion of cellular NAD+ and ultimately cell death. Complete loss of NAMPT 
function in mice is incompatible with life but inducible tissue specific models have 
been generated [76, 168, 264, 265]. Surprisingly, studies of muscle specific 
NAMPT KO mice showed that young mice did not manifest with major 
abnormalities despite exhibiting a staggering 85% decrease in intramuscular NAD+ 
content [76]. However, a degenerative muscle phenotype was seen over ageing, 
with these mice manifesting with fibre degeneration, loss of muscle strength and 
endurance exercise capacity. Treatment with NR restored muscle function 
highlighting the importance of NAD+ availability to muscle health, irrespective of 
NAMPT activity [76]. The physiological relevance of loss of NAMPT function in 
terms of non-genetically altered mice has also been investigated; with a 
concomitant decline in NAMPT and NAD+ identified in aged rat muscle [89, 174].  
Exercise can increase both NAD+ and NAMPT expression in aged muscle and has 
been proposed to slow the progression of age-related metabolic decline through 
SIRT1 mediated effects [174]. Together these studies demonstrate the importance 
of maintaining NAD+ turnover in skeletal muscle and the potential metabolic 
benefits of preserving NAD+ signalling during ageing.  
NMRKs as a nutraceutical targets against metabolic decline 
Data presented here indicates that, unlike NAMPT, the NMRK enzymes have little 
influence on resting metabolism in muscle, with NMRK deficient mice presenting 
with normal NAD+ signalling and energy metabolism. However, their ability to 
exclusively metabolise exogenous NR, and dictate the use of exogenous NMN, to 
enhance NAD+ makes them valuable therapeutic targets. With NAMPT self-
limiting, and NAM excess inhibitory to SIRT activity [152], this alternative 
biosynthesis pathways has provided much research interest.  NR supplementation 
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has already been demonstrated to protect against many of the global metabolic 
consequences of HFD induced metabolic decline in mice [199]. Moreover, in 
models of muscle dystrophy NR supplementation could improve muscle function; 
with enhanced mitochondrial function and structural proteins and reduced 
inflammation, fibrosis and senescent stem cells [242, 266].  
Most of the research to date has focussed on the use of NR as a means to 
ameliorate or reverse models of metabolic impairment. However, despite its highly 
conserved and muscle specific nature, the function of NMRK2 beyond salvage of 
NR is still unknown. It is possible that it plays a supporting role for NAMPT during 
metabolic stress that is not apparent during basal metabolism. Using NMRK2KO 
mice, this chapter aims to investigate the role of NMRK2 during metabolic stress 
following in vivo interventions including fasting, HFD challenge and exercise. 
These studies will be the first to investigate the importance of NMRK2 during 
metabolic stress and the potential impact NMRK2 deficiency may have on 
metabolic adaptation.   
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5.2 Materials and Methods 
5.2.1 Animal care 
Heterozygous breeding of the NMRK2KO mouse line provided litter matched WT 
and KO cohorts. Animals were all kept in an enriched, pathogen–free environment 
at around 21-23°C with 12 hour light/dark cycles.  Unless otherwise stated 
standard chow and water was available ad libitum.   
5.2.2 High fat diet (HFD) 
From 10 weeks of age, mice were fed a commercially available high fat chow 
(Brogaarden, Denmark) for 16 weeks.  The mice were weighed before starting the 
HFD and once a week until the end of the diet. 
5.2.3 Glucose tolerance test (GTT) 
GTTs were performed following 6 hours of food restriction. Small incisions were 
made to superficial vessels on the tails of each mouse and a drop of blood 
collected on Accu-Chek blood glucose strips (Boots, UK) and read using a 
glucometer to provide a baseline blood glucose reading. Following this, glucose 
(2g/kg) was administered by I.P injection and blood glucose was measured at 15 
min, 30 min, 60 min and 120 min – post glucose administration. Animals were 
monitored during and following the procedure for any signs of unexpected stress.  
5.2.4 In vivo metabolic phenotyping 
Mice were weighed and placed into the PhenoMaster (TSE) with their original litter 
mates and in their original cages for 24 hours to acclimate to the new 
environment. Following this, the mice were separated and housed individually for 
72 hours within the PhenoMaster. The first 24 hours allowed acclimatisation to 
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isolation, and indirect calorimetry data was collected during the subsequent 48 
hours (section 2.13.7). Body weight, food and drink intake was monitored 
throughout.  
5.2.5 Fasting 
Mice were single housed in clean cages and had no access to food for 16 hours 
before tissue collection. Mice had normal access to water and were kept in normal 
housing conditions.   
5.2.6 Treadmill exercise 
Following a short acclimatisation period, mice were exercised on specialised 
treadmills for 1 hour 3 times a week at a speed of 0.2 m/s and a 15% incline. Upon 
stopping mice were encouraged to run and were briefly blown with air if they failed 
to re-join the treadmill (up to a maximum of 3 times).    
5.2.7 Tissue collection 
Tissues were collected at 10-11 AM to minimise circadian changes. Mice were 
culled by schedule 1 cervical dislocation and tissues were immediately collected 
and either snap frozen in liquid nitrogen or placed in the required buffer or fixing 
agent.   
5.2.8 Fibre-typing 
Muscle sections were fibre typed by Dr Gabriella Da Silva Xavier (Imperial College 
London), using immunofluorescence following an established protocol. Briefly, 10 
µm sections of were cut using a cryostat and mounted onto slides.  Primary 
antibodies detecting different myosin heavy chain subunits were added, followed 
by fluorescent secondary antibodies. Sections were formalin fixed, mounted and 
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then analysed using a Zeiss Axio Observer inverted microscope (Carl Zeiss, 
Germany). Fibres were manually counted across the entire section using Image J 
(Fiji) software and recorded as positive for each fibre expressing the relevant 
visible colour (section 2.14). 
5.2.9 High resolution respirometry - Oroboros  
Excised muscles were placed in ice cold BIOPS buffer and carefully separated 
into clusters. Fibre clusters were transferred into ice cold BIOPS buffer with 
saponin (at 5 mg / ml of BIOPS) and incubated at 4° C for 30 minutes on a shaker 
to permeabilise. Fibres were then dried and 5 mg of fibres were transferred into 
ice cold mitochondrial respiration medium (MiRO5) and placed into Oroboros 
respirometer chambers. Once airflow stabilised substrates were sequentially 
added as follows; 0.5 mM malate, 55 µM palmitoyl, 10 mM glutamate, 5 mM ADP, 
10 µM cytochrome, 10 mM succinate, 0.5 µM FCCP, 0.5 µM rotenone and finally 
2.5 µM antimycin A. 
5.2.10 RNA extraction  
RNA was extracted from 20 mg of tissue using TRI-reagent (Invitrogen). RNA 
quality was determined by visualisation on a 1.5% agarose gel and quantified 
using a nanodrop. 1 µg of RNA was used for reverse transcription (see section 
2.6).  
5.2.11 qPCR 
qPCR was performed in a 384-well plate in single-plex format using Assay on 
Demand primers and probes (Applied Biosystems) (section 2.6.4). The PCR 
plates were placed in the real-time ABI7500 system and amplified using the 
following protocol: 95oC for 10 minutes then 40 cycles of 95oC for 15 seconds and 
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60oC for 1 minute using an. The resulting Ct values were used to obtain deltaCt 
(dCt) values.  
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5.3 Results 
5.3.1 Regulation of NAD+ biosynthesis in fasted skeletal muscle 
Fasting is known to induce metabolic adaptation through SIRT signalling to 
reprogram energy metabolism when glucose levels are low and maintain ATP 
production [84]. To examine the effect of fasting on NAD+ biosynthesis genes in 
skeletal muscle, mice were fasted overnight and tissue was collected. qPCR 
analysis of fasted muscle tissue identified a significant increase in Nampt 
expression supporting previous evidence. Interestingly, Nmrk2 expression is 
significantly supressed in fasted muscle, although the reason for this 
downregulation is not immediately apparent. Alternative NAD+ salvage genes, 
Nmrk1 and NADsyn1 were not significantly regulated in fasting muscle (figure 5.1). 
These transcriptional changes seen in skeletal muscle following acute fasting 
highlights the dynamic nature of muscle in response to metabolic stress.  
Figure 5.1 NAD+ biosynthesis gene expression in fed and fasted skeletal 
muscle 
Real-time PCR analysis of NAD+ biosynthesis genes (Nmrk1, Nmrk2, Nampt and 
NADsyn1) from skeletal muscle of mice either fed ab libitum or following a 16 hour 
overnight fast (n=4). Data presented as mean A.U values ± SEM and significance 
determined by unpaired t-test (* p<0.05). 
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5.3.2 Metabolic phenotyping of NMRK2KO mice following High fat diet 
challenge  
HFD challenge in mice is well characterised to induce obesity and associated co-
morbidities such as insulin resistance [199, 267]. To determine whether NMRK2 
plays an important support role during perturbed metabolism, WT and NMRK2KO 
mice were subjected to HFD feeding and metabolic parameters were examined. 
On average the weight of both WT and KO mice increased by nearly 100% 
following 12 weeks of HFD with no genotype difference apparent (figure 5.2A). 
Fasting blood glucose levels were similar in WT and NMRK2KO mice at 10.7 ± 0.5 
and 11.1 ± 0.7 mmol/L respectively.  Normal chow fed WT controls exhibited 
significantly lower fasting blood glucose levels of 8.3 ± 0.3 mmol/L, suggesting 
HFD induced hyperglycaemia. Glucose tolerance tests (GTT) showed both WT 
and KO mice to have impaired glucose clearance from the blood following glucose 
I.P compared to normal chow fed mice (grey), with levels still not returned to basal 
fasting glucose after 2 hours – demonstrating high fat diet induced insulin 
resistance (figure 5.2B). Interestingly, NMRK2KO mice seemed to initially exhibit 
higher blood glucose levels following I.P injection, with an upward trend seen in 
area under the curve (AUC), indicating that NMRK2KO mice are less able to 
modulate glucose metabolism (figure 5.2C).  
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Figure 5.2 NMRK2KO mouse glucose metabolism following HFD 
(A) Total body weight of WT and NMRK2KO mice before (3 months old) and after 
(6months old) 12 weeks of high fat diet (HFD) feeding. (B) Corresponding glucose 
tolerance test curve, (with a WT chow fed GTT provided for diet comparison - 
grey) and (C) area under the curve, of HFD fed WT and NMRK2KO mice. All data 
was collected from age-matched female mice (n=9) and presented as mean ± 
SEM.      
 
Using PhenoMaster technology (TSE, Germany), mice were single housed in 
metabolic cages and gas exchange was continuously monitored over a 72 hour 
period for indirect calorimetry analysis. The respiratory exchange ratio (RER) is 
defined by the amount of CO2 produced divided by O2 used and provides an 
indication of the fuel used to support metabolism based on the degree of oxygen 
used. A respiratory quotient (RQ) of 1 is representative of pure carbohydrate 
metabolism (normally during active periods) where as an RQ of 0.7 implies pure 
fatty acid oxidation (inactive periods) [268-270]. Figure 5.3A demonstrates that 
HFD fed mice have impaired metabolic flexibility with the RER curves remaining 
relatively flat compared to normal chow fed mice. Normal chow fed mice can adapt 
metabolism throughout periods of activity and rest; with a higher use of 
carbohydrates during periods of activity (at night) and a switch to fatty acids 
metabolism during periods of rest (daytime). Here, following chronic high fat diet 
feeding NMRK2KO mice demonstrate a downward shift in RER which is more 
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prominent during night time periods of activity implying they are further 
metabolically impaired (figure 5.3B).  
Figure 5.3 In vivo metabolic phenotyping of HFD fed WT and NMRK2KO mice 
(A) Respiratory exchange ratio (RER) of WT and NMRK2KO mice fed normal 
chow (faded, upper lines) and high fat diet over 24 hours. (B) A closer look at the 
RER of HFD fed WT and NMRK2 KO mice.  (RER readings were taken every 9 
minutes and all mice were female at 6-7 months old HFD WT n=6, HFD KO n=9, 
chow fed WT and KO n=2). All data presented as mean ± SEM.  
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Figure 5.4 Food and drink consumption of WT and NMRK2KO mice in 
PhenoMaster housing 
Cumulative (left) and total (right) 24 hour food (A) and drink (B) intake of high fat 
diet fed mice placed in the PhenoMaster. (Consumption was measured every 9 
minutes and all mice were female at 6-7 months old WT n=6, KO n=9). All data 
presented as mean ± SEM, significance was determined by unpaired t-test 
analysis (* p<0.05).    
 
Food and drink intake was also monitored and surprisingly NMRK2KO mice 
appeared to eat less HFD food than WT mice (figure 5.4A). The reduced food 
intake was seen consistently over the entire experiment rather than a factor of 
delayed feeding, and feeding frequency was not affected. This difference in food 
intake likely explains the shift in RER yet the biological significance of this is still 
unknown. Water intake was also significantly reduced between genotypes (figure 
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5.4B).  Mice that did not take to the metabolic housing did not eat or drink at all 
leading to weight loss and removal from the PhenoMaster system before 
experimental readings were taken. All the mice included in the experimental 
analysis ate and drank gradually over the entire data collection period with no 
major weight loss.   This suggests the NMRK2KO did not consume less food and 
water due to distress as water intake is was not neglected. Unfortunately, mouse 
activity could not be measured using this particular set up and therefore 
differences owed to changes in physical activity could not be determined.  
Finally, the oxidative capacity of skeletal muscle from HFD fed WT and NMRK2KO 
mice was examined. Muscles were collected from mice and intact muscle fibres 
were dissociated and examined using Oroboros based high resolution 
respirometry to provide real-time analysis of mitochondrial function. A sequence of 
reagents were added to test mitochondrial output in response to substrates 
(malate, palmitoyl carnitine, glutamate, ADP, cytochrome c and succinate), 
followed by uncoupling agent FCCP, and inhibitors of mitochondrial respiration, 
rotenone and antimycin A. Mitochondrial response to Malate, palmitoyl carnitine 
and glutamate appeared blunted in NMRK2KO however maximal mitochondrial 
output of NMRK2KO muscle fibres was not significantly different from WT (figure 
5.5). This data suggests mitochondrial function is not further impaired in NMRK2 
deficient muscle following metabolic challenge.   
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Figure 5.5 High resolution respirometry of skeletal muscle from HFD fed WT 
and NMRK2KO mice 
Mitochondrial function of quadriceps muscle fibres collected from HFD fed WT and 
NMRK2KO mice was assessed by Oroboros based high resolution respirometry. A 
succession of substrates were added to the fibres including 0.5 mM malate, 55 µM 
palmitoyl carnitine (Palm.), 10 mM glutamate (Glut.), 5 mM ADP, 10 mM succinate 
(Succ.), 10 µM cytochrome c (CytC), 0.5 µM FCCP, 0.5 µM rotenone and 2.5 µM 
antimycin A (AA). Muscle was collected from females at 6-7 months old (WT n=4, 
KO n=6 and data presented as mean ± SEM).    
 
5.3.3 Fibre-typing of NMRK2KO mice following endurance exercise  
The muscle specific nature of NMRK2 and its regulation in muscle differentiation 
suggests it may have a role in muscle fibre organisation. Muscle development is 
seemingly unaffected by NMRK2 loss of function with mouse behaviour normal, 
muscle bed weights unchanged and expression of myotube differentiation markers 
consistent with WT.  Thus, to test whether NMRK2 is important following metabolic 
stress, an endurance exercise pilot study was set up using WT (n=3) and 
NMRK2KO (n=3) mice.  Endurance exercise induces metabolic adaptation and 
promotes an oxidative fibre type shift in skeletal muscle [23]. All the mice 
completed the 6 week endurance exercise protocol successfully, notes were taken 
and no obvious differences in performance was noticed. Average mouse 
bodyweight was also consistent between WT and NMRK2KO mice (figure 5.6A).  
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Following the exercise protocol, mouse tissue beds were weighed and average 
muscle weights were similar between WT and NMRK2KOs (figure 5.6B).  
Figure 5.6 NMRK2KO mouse muscle phenotyping following endurance 
exercise training 
(A) Whole body weight and (B) skeletal and cardiac muscle bed weight of WT and 
NMRK2KO mice following 6 weeks of endurance exercise training. Fibre-type 
composition of (C) soleus and (D) TA skeletal muscle from WT and NMRK2KO 
mice following 6 weeks of endurance exercise training.  (E) Corresponding 
representative images of MHC expression. Cross section (i-iv) incubated with BA-
F8 and BF-F3 (CK1a) showing MHC I (blue) and IIB (red) expressing fibres. Cross 
section (v-viii) incubated with SC-71 and BF-F3 (CK1b) showing MHC IIA (green) 
and IIB (red) expressing fibres. Cross section (ix-xii) incubated with SC-71 and 
6H1 (CK2) showing MHC IIA (green) and IIX (purple) expressing fibres. All data 
n=3, females and presented as mean ± SEM.  
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Muscle fibre typing by immunofluorescence was employed to examine potential 
differences to muscle fibre composition. As expected, TA muscle had a larger 
proportion of type 2b and 2x fibres with minimal type 1 and 2a fibres, whereas 
oxidative soleus tissue exhibited much larger proportions of type 1 and 2a fibres 
(figure 5.6C and D). NMRK2KO fibre type composition was consistent with WT 
following endurance exercise (figure 5.6 C and D); indicating that NMRK2 is not an 
essential gene in regulating fibre type composition. Representative images of WT 
and KO soleus and TA muscle fibre typing are provided (figure 5.6E).  
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5.5 Discussion 
The muscle specificity and conserved nature of NMRK2 across species implicates 
a role for it in skeletal muscle function [142]. Data presented in this thesis has 
determined its role in NAD+ biosynthesis to be minimal under basal metabolism 
with NAMPT activity crucial for maintaining NAD+ levels. Therefore, it was 
postulated that NMRK2 may function in skeletal muscle to support NAMPT activity 
during metabolic stress when NAD+ turnover is enhanced through elevated SIRT 
activity [119, 227]. Skeletal muscle is a highly metabolic tissue and, unlike liver 
tissue which has numerous routes to NAD+ [139, 166], it appears to be 
predominantly reliant on NAMPT activity. This chapter investigates the metabolic 
phenotype of NMRK2 deficient mice in vivo in response to metabolic interventions 
to evaluate a possible role for NMRK2 in NAD+ salvage when NAMPT activity is 
maximal.  
Cohorts of mice were investigated following either overnight fasting, HFD feeding 
or endurance exercise. NMRK2KO mice assumed normal activity as compared to 
WT following the interventions and showed no major signs of metabolic 
impairment. Absence of major phenotypical abnormalities in NMRK2KO mice 
following metabolic stress was unsurprising considering the lack of changes to 
mouse behaviour, NAD+ signalling and energy metabolism detected under basal 
conditions. This indicates that NAD+ signalling is sufficient during metabolic stress 
to support energy homeostasis. The robust nature of NAD+ signalling in vivo has 
been demonstrated in muscle specific NAMPT KO mouse models where young 
mice exhibit a relatively mild phenotype considering the large loss of NAD+ [76].  
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Interestingly, there were some indications NMRK2 deficient mice were more 
metabolically impaired than WT by high fat diet induced obesity. Although WT and 
NMRK2 mice were equally hyperglycaemic, NMRK2 mice appeared slower at 
clearing glucose following GTTs suggesting increased insulin resistance. An 
insulin tolerance test would be a useful follow up test to determine insulin 
sensitivity of WT and NMRK2KOs. A downward shift in RER was also seen in 
NMRK2KO mice during night time activity periods. RER is defined by the volume 
of CO2 generated divided by the volume of O2 used and can be used as an 
estimate of the respiratory quotient (RQ). A RQ of 1 indicates pure carbohydrate 
metabolism whereas a RQ of 0.7 indicates pure fatty acid oxidation. This theory is 
based on a larger amount of oxygen needed to fully metabolised fatty acids in 
comparison to glucose [269]. During wake periods glucose metabolism is normally 
favoured and fat oxidation favoured during fasted sleep periods [270]. However, 
diets with a high fat content lead to enhanced fat oxidation [271, 272]. Therefore, 
these data suggest that NMRK2KO mice are more metabolically inflexible than 
WT, and are more reliant on fat oxidation. The shift is likely to be related to the 
reduced food intake seen by NMRK2KO mice whereby fat stores are being 
mobilised for energy production. Extensive nutritional studies have shown food 
intake to have considerable impact on RQ [263, 273-275].  
The relevance of these metabolic differences in terms of NMRK2 function remains 
unclear. However, regulation of food intake by the hormone ghrelin has been 
previously shown to be UCP2 dependent with induction of mitochondrial 
respiration by UCP2 vital [258]. NMRK2KO mice exhibited upregulated Ucp2 
expression in TA muscle and thereby expression may also be altered in neurons; 
possibly providing a link between NMRK2 and food intake. Furthermore, a recent 
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study showed, by indirect–calorimetry, that metabolic flexibility was significantly 
improved in mice fed an obesogenic diet when NR (30 mg/kg) was supplemented; 
a finding that was not found in mice fed a balanced diet [276]. This again indicates 
that NMRK salvage of NR to NAD+ may be important for maintaining metabolic 
health and may also be a useful therapeutic strategy against to metabolic 
disruption.      
Previous studies have shown that exogenous NR, metabolised to NAD+ by NMRK 
activity, can protect against the effects of high fat diet induced obesity and 
diabetes [178, 199]. Although, skeletal muscle NMRK activity may be limited by 
NR availability, it is possible that endogenous NR can be generated and delivered 
from other tissues in vivo and used in muscle during metabolic decline. Thus, 
NMRK2KO mice are unable to use NR as an alternative NAD+ source leading to 
further metabolic disruption. As the HFD feeding was a pilot study the ’n’ numbers 
for each genotype were limited (WT= 6, KO= 9), and some mice were removed 
from the study before analysis due to skin sores. Consequently, statistical 
significance for GTTs and indirect calorimetry was not reached. Further biological 
replicates are now required to determine statistical significance before 
commencing new mechanistic studies to investigate the metabolic differences 
indicated here.   
Mitochondrial function of muscle fibres from NMRK2KO mice did not appear 
impaired compared to WT after HFD. However, these findings must be confirmed 
by repeated analysis. In exchange for high resolution respirometry, Oroboros 
technology is low throughput with only 2 chambers to run just 2 samples per 
experiment. Consequently, samples had to be run at different times post-harvest, 
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introducing greater amounts of variability and the possibility of diminished viability 
of the myofibres analysed after longer periods of time post collection. 
Skeletal muscle metabolic adaptation to exercise has shown to be dependent on 
NAMPT; with increased recycling of NAM to NAD+ to support SIRT activity [227]. 
In muscle specific NAMPT loss of function mice, treadmill exercise performance 
progressively deteriorated with age compared to age-matched WTs [76]. Despite, 
its high expression in muscle the impact of NMRK2 activity during exercise-
induced metabolic adaptation has not previously been investigated. Initial data 
from the pilot endurance exercise study did not determine any effects of loss of 
NMRK2 function on exercise performance, muscle size (by weight) and fibre type 
composition. This indicates that NMRK2 is not vital for exercise-induced metabolic 
adaptation and fibre type ‘shifting’, however further molecular analysis of tissues is 
required. Due to the terms of the Home Office licence, the mice here were trained 
to a set amount of exercise and not run to exhaustion. It is possible that 
performance differences may have been seen between WT and KO mice if they 
were exercised to their limits.  
Interestingly overnight fasting resulted in significant downregulation of Nmrk2; yet 
in numerous models of muscle damage and myopathy Nmrk2 expression is 
greatly upregulated [277-280]. Loss of NMRK2 function appears to have little 
effect on muscle metabolism and development; which poses new questions of why 
NMRK2 is so heavily regulated by these different scenarios and what factors are 
involved in its regulation. It may be that the sole function of NMRK2 is to salvage 
NR to NAD+, with regulation of NMRK2 expression a previously important 
response mechanism to metabolic stress to drive NAD+ biosynthesis in skeletal 
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muscle. Alternatively, changes to modern day diets and food processing may have 
led to wide spread NR deficiency, effectively making NMRK2 activity redundant 
[281].  If this was to be the case, then a major positive outcome of this 
understanding is that NR supplementation, to drive NMRK mediated NAD+ 
biosynthesis, could be an extremely useful tool for protecting against metabolic 
disease, particularly with NAMPT depletion during age-related metabolic decline 
[174]. Oral bioavailability of NR has been recently demonstrated and although 
clinical studies with NR are in their infancy currently no major adverse effects have 
been determined [201].  
Alternatively, regulation of Nmrk2 in response to muscle injury and during 
differentiation may implicate a function in muscle regeneration [277, 280]. The 
importance of this function would unlikely be noticed in young healthy mice but 
may be more apparent in aged, sarcopenic muscle. Skeletal muscle is enriched 
with satellite cells and, with the right cues, it has a great capacity to regenerate 
[11]. Zebrafish models of Nrk2b deficiency (orthologue of Nmrk2) support a role for 
Nmrk2 in muscle development. They show Nrk2b is essential for correct formation 
of cell matrix adhesion complexes and Nrk2b deficient zebrafish exhibit abnormal 
muscle development due to incorrect laminin polymerisation [252]. This phenotype 
can be rescued with exogenous NAD+ highlighting that the NAD+ salvage function 
of Nrk2b is critical [252].  Further evidence supporting an important function for 
Nrk2b in zebrafish muscle health was seen in models of dystrophy. Nrk2b 
mediated NAD+ biosynthesis following vitamin b3 supplementation led to 
repressed muscle fibre degeneration in dystrophic zebrafish embryos [173]. The 
most likely reason this more extreme phenotype is not seen in mice is because 
NAMPT salvage predominates. Again, this further implicates NMRK2 as an 
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important target to promote muscle health particularly if NAMPT function is 
compromised.    
These initial in vivo studies of NMRK2KO mice are the first to investigate the role 
of NMRK2 following metabolic challenge. Despite NMRK2 deficient mice 
displaying no gross abnormalities these studies do indicate some metabolic 
impairment. The criticality of NAD+ for energy production and metabolism 
necessitates robust signalling with immense redundancy capable of withstanding 
metabolic stress [32, 66, 86, 145]. Thus, even with metabolic challenge NAMPT 
activity, and possibly NMRK1 redundancy, are still able to maintain adequate 
NAD+ turnover. It may be the true importance of NMRK2 in skeletal muscle is 
uncovered in models of NAMPT deficiency such as during ageing [169, 174].    
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Chapter 6 Final discussion 
  
 
 
184 
 
NAD+ is now widely recognised as a central mediator of energy metabolism. 
Skeletal muscle is a highly plastic metabolic tissue that can adapt in response to 
metabolic stress to maintain energy homeostasis [1, 26, 239]. The growing global 
ageing population means sarcopenia has become a major public health issue, 
with a degenerative loss of muscle mass and function not only leading to muscle 
weakness but also negatively impacting on systemic metabolic health [182, 184].  
Aberrant NAD+ signalling has been associated with several pathophysiological 
states [76, 89, 99, 169, 170], and initial examination of young versus aged mouse 
muscle tissue identified a decline in NAD+ and ATP, supporting previous research 
associating perturbed NAD+ and energy metabolism in ageing [130, 174].  
Numerous therapeutic strategies targeting NAD+ signalling have been employed 
to prevent or improve metabolic decline [170, 178, 199, 229, 242]. The positive 
health effects of NAD+ enrichment following precursor supplementation have now 
been widely studied in disease settings [158, 169, 199, 200, 204, 205, 207, 226, 
282-284]. Treatment with NA derivative acipimox increased mitochondrial 
metabolism yet its therapeutic potential is limited due to adverse effects leading to 
poor patient compliance [196]. Recent research by Zhang et al. has already 
shown encouraging therapeutic potential of repleting NAD+ directly in skeletal 
muscle. They showed that NR treatment revitalized muscle stem cells in aged 
mice and improved mitochondrial function, and in mouse models of muscular 
dystrophy, NR increased muscle fibre regeneration through reactivation of 
senescent muscle stem cells [266].      
With the mounting evidence supporting the notion that enhancing NAD+ availability 
has health benefits in the context of the chronic diseases of ageing, and the 
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possibility of doing so by supplementation with readily available NAD+ precursor 
vitamin B3s [86, 169, 170, 229, 284]; it is necessary to determine the importance 
of the different NAD+ salvage enzymes in tissues to target NAD+ biosynthesis. 
Thus, this thesis explored NAD+ salvage and biosynthesis in skeletal muscle, as a 
major metabolic target tissue in the context of healthy ageing, and focussed in on 
identifying the role of the NMRKs as regulators of NR conversion to NAD+ [142].  
NAD+ biosynthesis in skeletal muscle appears restricted to two main salvage 
pathways involving the rate-limiting enzymes NAMPT, NMRKs and NMNAT. While 
NAMPT and, to a degree NMRK1, display ubiquitous expression; NMRK2 displays 
a muscle restricted pattern. De novo NAD+ biosynthesis and the Preiss-Handler 
NA salvage pathway play a minimal role in skeletal muscle with limited or 
undetectable levels of expression of rate limiting enzymes and metabolites. This 
supports previous metabolic enzyme activity profiling that demonstrated 
undetectable NAD synthase activity in skeletal muscle – the final rate limiting 
enzyme for both de novo biosynthesis and NA salvage [147].  
Inhibition of NAMPT enzymatic activity leads to severe NAD+ depletion that 
ultimately leads to cell death, identifying its vital role in muscle metabolism. These 
findings support recent studies by Frederick et al. (2016) that showed NAMPT to 
be vital for skeletal muscle NAD+ biosynthesis using a muscle specific loss of 
function mouse model. They found an 85% reduction in muscle NAD+, impaired 
mitochondrial function, loss of fibre integrity and muscle strength and performance 
over age; delineating the importance of NAMPT for local NAD+ turnover and 
muscle health and metabolism [76].  
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Although NAMPT is a critical regulator of basal NAD+ biosynthesis [227], 
exogenous NAM appears to be a poor precursor for NAD+ boosting in muscle cells 
compared to NR and NMN which can significantly increase NAD+ when 
supplemented even with FK866 induced NAD+ depletion.  
Considering the ability of NR to increase NAD+, the role of the NMRKs was 
examined in skeletal muscle. Despite highly specific expression of NMRK2 in 
skeletal muscle, NMRK2 loss of function has no effect on basal NAD+ turnover in 
muscle tissue. Analysis of NMRK1KO and DKO models showed there was no 
enzyme redundancy effect with basal NAD+ content unchanged in all the loss of 
function models. Characterisation of the loss of function mice did not identify 
adverse NAD+ signalling or indicate any major impairment to muscle health and 
metabolism. HFD diet induced metabolic decline did identify some possible 
metabolic impairment in NMRK2KO mice but the significance and biological 
relevance of these are yet to be determined. Together these data indicate that the 
NMRKs are not critical regulators of basal NAD+ turnover in muscle and are not 
essential for muscle development and metabolism. 
Findings from loss of function myotube models confirmed that NR is exclusively 
metabolised by the NMRK enzymes in skeletal muscle; with no change to cellular 
NAD+ levels in DKO primary myotubes following NR supplementation. The cellular 
consequences of NAD+ depletion by NAMPT fully demonstrate the criticality of 
maintaining sufficient NAD+ levels and implicate a potential supporting role by 
NMRKs to maintain NAD+ during metabolic or cellular stress. This role is however 
restricted to NR availability in skeletal muscle. Upon exogenous NR 
supplementation and thereby increasing precursor availability, NMRK-mediated 
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NAD+ biosynthesis can restore the consequences of NAD+ depletion and greatly 
enhance NAD+ content.  
The natural availability of NR in the diet [192], and its ability to restore and boost 
cellular NAD+ pools, makes NMRK salvage a promising therapeutic target 
particularly during physiological decline, such as ageing, where NAD+ content and 
NAMPT expression have been shown to be mutually reduced [89, 174]. Exercise 
studies to enhance both NAMPT and NAD+ following age-related metabolic 
decline have indicated that preserving NAD+ signalling can help prevent impaired 
energy metabolism [174]. Unlike NAMPT, basal NAD+ turnover is not reliant on 
NMRK activity and its restriction by cellular NR availability provides a great 
amount of scope for exogenous NR supplementation to drive NMRK activity and 
augment NAD+.  
Despite, the ability of NR to rescue the consequences of FK866-mediated NAD+ 
depletion and some of the effects of metabolic challenge in vivo [178, 199], data 
presented here suggests that enhancing NAD+ availability in skeletal muscle by 
NR supplementation does not stimulate NAD+ signalling or enhance oxidative 
metabolism of ‘healthy’ muscle cells. This data supports work whereby muscle 
NAD+ content was enhanced using a muscle specific NAMPT overexpressing 
mouse model; despite a 50% increase in NAD+, mitochondrial biogenesis and 
function was not found to be enhanced in young mice [240]. Nonetheless, these 
data support the notion that muscle has certain redundancy in its ability to 
metabolise NR and therefore NMN. Oral NR administration to humans has 
recently been demonstrated to be effective in boosting circulating and hepatic 
NAD+ levels, and evidence of NR exerting a greater effect than equimolar amounts 
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of NAM and NAD+ [201]. Interestingly in mice, chronic supplementation of NR in 
drinking water had minimal impact on skeletal muscle NAD+ levels despite NR 
resulting in part recovery of a loss of NAD+ phenotype [76]. Following this, acute 
oral supplementation with labelled NR (200 mg/kg) was shown to reach the liver 
and contribute to NAD+ turnover, yet in muscle tissue, only a small fraction of 
labelled NR was detectable. The label pattern indicated that the majority of 
supplemented NR was broken down and resynthesized to NAD+ rather than being 
incorporated intact. This was further supported by large increases to circulating 
NAM levels, trace levels of NR and unchanged NMN. Together this suggests poor 
delivery of NR to muscle in vivo [76]. Further work is required to determine the 
importance of effective muscle NAD+ repletion via NR and NMN in the context of 
the NMRKs.  
It was initially postulated that NMRK2 would contribute to a greater degree than 
NMRK1 in skeletal muscle NR salvage, due to its predominant muscle specific 
expression, yet the findings here showed that although NMRK2 can mediate NR 
salvage, NMRK1 may play a more prominent role. Data presented here point to 
NMRK1 being a more critical gate keeper for NR and NMN salvage and point to 
NMRK2 having an additional role in cellular metabolism involving NR 
phosphorylation. Indeed, the notion that Nmrk2 is regulated by low NAD+ may 
show it to be more important for switching to NR/NMN metabolism during stress 
responses. 
The absence of a gross NAD+ relatable phenotype in young mice may not be 
unexpected given the NAMPT MKO mice are viable and without major 
abnormalities when young despite great loses to NAD+ and ATP [76]. This does 
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pose the question as to the role of NMRK2. The highly conserved nature of the 
NMRKs across species and the greatly responsive regulation of NMRK2 during 
cellular and metabolic stress highlight an importance for NR metabolism [167, 277, 
280]. Like NAM, NR can be metabolized in the gut from NAD+ found in the food we 
eat [171]. Existence of NR in the circulation is key in terms of its use exogenously; 
with NR availability indicated by the residence of pathogens that rely on 
exogenous NR for NAD+ biosynthesis to survive in humans such as Haemophilus 
influenza [285].   
NMRK2 may have a role in NAD+ biosynthesis during metabolic decline or 
possibly an alternative role distinct from NAD+ signalling. The enriched expression 
of NMRK2 in glycolytic TA muscle again provides an interesting fibre-type 
expression pattern that may have metabolic relevance; yet fibre-typing of 
NMRK2KO muscle showed no abnormality to fibre-type distribution or 
morphology. Further mechanistic work is now required to understand the 
regulation of NMRK2 and whether its highly dynamic modulation is of biological 
importance or a result of off target regulation during muscle stress responses. 
Alternatively, this fibre-type specific expression, may implicate a wider metabolic 
role for NMRK2. Expression is highly regulated during fasting and NMRK2 null 
mice exhibit a potentially impaired metabolic phenotype following high fat diet 
induced obesity. Nmrk2 may be part of a transcriptionally regulated metabolic 
switch dictating carbohydrate (or specifically glycolytic) metabolism over lipid 
metabolism. For example, Nmrk2 is downregulated during fasting, when energy 
metabolism is predominantly sourced from lipid oxidation and [273], in keeping 
with this, HFD fed NMRK2KO mice show lower flexibility to switch from lipid to 
carbohydrate metabolism. Whereas, expression is enriched in glycolytic TA 
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muscle, during myotube fusion and injury (or possibly regeneration) [280]; with the 
latter scenarios when the cell may be more reliant on glycolytic metabolism. 
In summary, the data in this thesis demonstrates a limited set of NAD+ 
biosynthesis genes in skeletal muscle (figure 6.1). NAMPT-mediated NAD+ 
salvage in skeletal muscle is vital. Although NMRK1 and 2 can both salvage NR to 
NAD+, this process appears restricted to substrate availability with exogenous 
delivery leading to enhanced NAD+. Despite the criticality of NAMPT for 
maintaining basal NAD+ turnover, exogenous NAM delivery doesn’t not exhibit the 
same NAD+ boosting effects of NR and NMN. NAD+ levels must be tightly 
controlled for metabolic homeostasis to persist; therefore, NAMPT enzyme activity 
must be tightly regulated. High NAD+ results in inhibition of NAMPT enzyme 
activity (as an immediate regulatory response) and therefore this feedback leaves 
little scope to boost NAD+ via NAMPT overexpression or NAM supplementation.  
Although not essential to basal NAD+ metabolism, the NMRKs allow an alternative 
adaptive route to NAD+ through the salvage of NR, independent of NAMPT which 
may be important during age-related metabolic decline where a concomitant 
reduction to both NAMPT and NAD+ has been demonstrated [174]. NR can 
completely restore the effects of NAD+ depletion via NAMPT inhibition, highlighting 
that it is solely NAD+ availability that regulates signalling. Therefore, NR as a 
naturally available vitamin B3 to enhance NAD+ could be an extremely useful way 
to target metabolic decline in skeletal muscle.  
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Figure 6.1 Overview of skeletal muscle NAD+ biosynthesis pathways 
A schematic of NAD+ biosynthesis pathways in skeletal muscle. The metabolites 
detectable, and enzymes expressed, in healthy skeletal muscle are outlined in 
black and/or blue boxes. Recycling of NAM to NAD+ is vital for maintaining basal 
NAD+ availability. Although NMRK1 and 2 are expressed in muscle, their activity 
has little influence on basal NAD+ turnover due to limited NR availability. 
However,   delivery of exogenous NR or NMN (in an NMRK dependent manner) 
can increase basal NAD+ levels to a greater extent than NAM (supplementation 
strategies outlined in green).  The NAD+ biosynthesis enzymes and metabolites 
thought to play a minimal role in skeletal muscle have been presented in grey 
and/or red boxes (left). 
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Appendix A - PCR primer sequences 
The forward and reverse sequences of PCR primers used in this thesis. All 
primers were made to order from Sigma Aldrich, UK.  
 
   
   
   
   
   
   
   
    
  
Primer  Forward Reverse 
Nmrk2 (mouse) 5'-AAACTCATCATAGGCATTGGAGG-3' 5'-TTAGATGGCATGAAGTCCCCG-3' 
Nmrk2 WT (mouse) 5'-CCAAATAGCAGTCGGAGAGG-3' 5'-GCAAACTTGTGTGGATCCTTC-3' 
Nmrk2 Mutant (mouse) 5'-CGGTCGCTACCATTACCAGT-3' 5'-GGGACATGCCCTCCTATGTA-3' 
nmrk1 (zebrafish) 5’-GAAACCCACAGCATCAGAGC-3’ 5’-AGGTACATGGGCCAAACGTA-3’ 
nmrk2 (zebrafish) 5’-CCACCACATCTGACCCTGAT-3’ 5’-TCCAAGCTGCTGTTCTCCAT-3’ 
mibp (zebrafish) 5’-TAAATTTGCTCGCTCCCACG-3’ 5’-GGCCACACATGACCATCAAA-3’ 
mibp2 (zebrafish) 5’-CATTGGTATCGGAGGGGTCA-3’ 5’-CCGTGGGATCTCTCGAACTT-3’ 
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Appendix B – Assay on demand TaqMan probes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Product number 
Nmrk1 Mm00521051_m1 
Nmrk2 Mm01172895_m1  
Nampt Mm00451938_m1 
Nmnat1 Mm01257929_m1 
Nadsyn1 Mm00513448_m1 
Ucp2 Mm00627599_m1 
Tfam Mm00447485_m1 
Nrf1 Mm01135606_m1 
Pparα Mm00440939_m1 
Parp1 Mm01321084_m1 
Pdk4 Mm01166879_m1 
Sirt1 Mm01168521_m1 
Sirt3 Mm00452131_m1 
Pnp Mm00840006_m1 
Nt5e (ENT5) Mm00501910_m1 
Bst1 (CD157) Mm00477672_m1 
Nnmt Mm00447994_m1 
Idh2 Mm00612429_m1 
Pgc1α Mm01208835_m1 
Pparδ Mm00803184_m1  
MyoG Mm00446194_m1 
MyoD1 Mm00440387_m1 
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Appendix C – Immunoblotting antibodies 
NAME Supplier, product # Dilution Secondary 
Primary Antibody 
NMRK1 BioGenes (Germany)* 1:1000 Anti-Rabbit 
NMRK2 
 
BioGenes (Germany)* 1:2000 
 
Anti-Rabbit 
NAMPT (PBEF) Bethyl (USA), A300-372A 1:1000 Anti-Rabbit 
α-Tubulin (B-7) Santa Cruz Biotech. (USA), SC-5286 1:1000 Anti-Mouse 
β-Actin Cell signalling (USA), #12262 1:1000 Anti-Mouse 
Total OXPHOS (Mito-profile) Abcam (UK), ab110413 1:1000 Anti-Mouse 
GAPDH Cell signalling (USA), #2118 1:2000 Anti-Rabbit 
Secondary Antibody 
Anti-mouse-HRP Dako (Denmark), P0161 1:10000 N/A 
Anti-Rabbit-HRP Dako (Denmark), P0448 1:10000 N/A 
*Specifically generated by request 
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Appendix D – LC-MS/MS metabolite parameters 
Details of metabolite detection parameters and sensitivity for selective reaction 
monitoring (SRM) as previously established by Trammell et al. With details of ion 
transitions given as mass to charge ratio (m/z), collision energy (CE) retention 
time (RT), retention capacity (K’) and limits of quantification (LOQ) [224].  
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Appendix E – Associated Manuscript 
 
 
Nicotinamide riboside kinases display redundancy in 
mediating nicotinamide mononucleotide and nicotinamide 
riboside metabolism in skeletal muscle cells 
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ABSTRACT
Objective: Augmenting nicotinamide adenine dinucleotide (NADþ) availability may protect skeletal muscle from age-related metabolic decline.
Dietary supplementation of NADþ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) appear efﬁcacious in elevating
muscle NADþ. Here we sought to identify the pathways skeletal muscle cells utilize to synthesize NADþ from NMN and NR and provide insight into
mechanisms of muscle metabolic homeostasis.
Methods: We exploited expression proﬁling of muscle NADþ biosynthetic pathways, single and double nicotinamide riboside kinase 1/2 (NRK1/
2) loss-of-function mice, and pharmacological inhibition of muscle NADþ recycling to evaluate NMN and NR utilization.
Results: Skeletal muscle cells primarily rely on nicotinamide phosphoribosyltransferase (NAMPT), NRK1, and NRK2 for salvage biosynthesis of
NADþ. NAMPT inhibition depletes muscle NADþ availability and can be rescued by NR and NMN as the preferred precursors for elevating muscle
cell NADþ in a pathway that depends on NRK1 and NRK2. Nrk2 knockout mice develop normally and show subtle alterations to their
NADþ metabolome and expression of related genes. NRK1, NRK2, and double KO myotubes revealed redundancy in the NRK dependent
metabolism of NR to NADþ. Signiﬁcantly, these models revealed that NMN supplementation is also dependent upon NRK activity to enhance
NADþ availability.
Conclusions: These results identify skeletal muscle cells as requiring NAMPT to maintain NADþ availability and reveal that NRK1 and 2 display
overlapping function in salvage of exogenous NR and NMN to augment intracellular NADþ availability.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords Skeletal muscle; NADþ; Energy metabolism; Nicotinamide riboside
1. INTRODUCTION
Nicotinamide adenine dinucleotide (NADþ) was ﬁrst described as a
vital cofactor in cellular redox reactions important to cellular energy
metabolism [1,2]. NADþ also serves as a consumed substrate for
enzymes such as sirtuins that post translationally modify proteins by
deacetylation, yielding nicotinamide (NAM) and 20-and 3-O-aceyl-ADP
ribose in the process [3]. Sirtuins have been characterized as regu-
latory sensors that coordinate metabolic and transcriptional adapta-
tions to cellular and tissue energy requirements [4,5].
Skeletal muscle requires a high turnover of ATP to sustain contraction,
facilitated by glycolysis and oxidative phosphorylation, which depend
on the redox functions of NADþ [6]. Because of the activity of NADþ
consuming enzymes, replenishment of NADþ through biosynthesis and
salvage pathways is vital [7,8]. NADþ can be synthesized de novo from
tryptophan and by salvage of nicotinic acid (NA), a form of vitamin B3,
via the Preiss-Handler pathway [9,10]. Along with NA, nicotinamide
(NAM) is also called vitamin B3 (collectively termed niacin) and as a
nutrient or by recycling following NADþ consumption, is metabolized
by nicotinamide phosphoribosyltransferase (NAMPT) to nicotinamide
mononucleotide (NMN), which is converted to NADþ via NMN adeny-
lyltransferases (NMNAT) [11]. A ﬁnal route to NADþ is the salvage and
phosphorylation of the recently discovered form of vitamin B3 nico-
tinamide riboside (NR) to NMN, through the nicotinamide riboside
1Institute of Metabolism and Systems Research, 2nd Floor IBR Tower, University of Birmingham, Birmingham, B15 2TT, UK 2Centre for Endocrinology, Diabetes and
Metabolism, Birmingham Health Partners, Birmingham, B15 2TH, UK 3Nestlé Institute of Health Sciences (NIHS), Lausanne, CH-1015, Switzerland 4Ecole Polytechnique
Fédérale de Lausanne, Switzerland 5Section of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, London, W12 0NN, UK 6Leipzig
University, Hospital for Children and Adolescents, Center for Pediatric Research, Liebigstrasse 19-21, 04103, Leipzig, Germany 7Mitchell Cancer Institute, 1660 Springhill
Avenue, Mobile, AL, 36604, USA 8School of Sport Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK 9Department of
Biochemistry, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA
*Corresponding author. Wellcome Trust Senior Research Fellow, Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham, B15
2TT, UK. Fax: þ44 121 415 8712. E-mail: g.g.lavery@bham.ac.uk (G.G. Lavery).
Received May 5, 2017  Revision received May 22, 2017  Accepted May 24, 2017  Available online xxx
http://dx.doi.org/10.1016/j.molmet.2017.05.011
Original Article
MOLECULAR METABOLISM- (2017) 1e14  2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
1
kinase 1 and 2 (NRK1 and 2) pathway [2,12,13]. Despite mammalian
cells demonstrating pathway diversity for maintaining NADþ levels in
various tissues, the relative contribution of these pathways to NADþ
biosynthesis in skeletal muscle remained unclear. The metabolic
beneﬁts of augmenting muscle NADþ availability is being realized
through the application of NADþ precursor supplementation strategies.
Historically, NA and NAM supplementation has been used to treat
hypercholesterolemia and pellagra [14]. However, undesirable side
effects in humans have limited their utility. NA causes ﬂushing through
activation of the GPR109A receptor in a large proportion of patients,
leading to poor compliance [15]. Large doses of NAM are required to
increase NADþ leading to adverse effects and NAM mediated inhibition
of sirtuin activity [16,17]. The NA derivative Acipimox has shown the
potential of using NADþ precursors to improve and enhance mito-
chondrial function and ATP content of skeletal muscle in the context of
diabetes [15].
NMN and NR have emerged as NADþ precursors with the potential to
circumvent the adverse side effects associated with high dose niacin
and augment NADþ synthesis and sirtuin activity [18]. NMN, being an
intermediate of NADþ biosynthesis, has been used to successfully
ameliorate a number of pathological scenarios, including normalization
of glucose tolerance in diet induced diabetes [19], and is able to restore
mitochondrial function in agedmuscle [20,21]. Dietary supplementation
of NR in mice can negate the metabolic consequences of high fat diet
and increase oxidative performance [22], delay disease progression in
mice with mitochondrial myopathy, inducing sirtuin dependent mito-
chondrial biogenesis and the mitochondrial unfolded protein response
[23]. In addition, NR improves glycemic control and opposes develop-
ment of diabetic neuropathy in mice and allows rats to resist devel-
opment of chemotherapeutic neuropathy [24,25]. Importantly, NR has
been shown to safely elevate human NADþ metabolism [26].
NADþ precursor utilization pathways in muscle require further deﬁ-
nition. Naturally available NR is phosphorylated to NMN by the NR
kinases (NRKs encoded by Nmrk1 and 2) [12,27], highly conserved
enzymes, but little is known of their roles in skeletal muscle [12]. It is
unclear whether NMN is truly available to muscle as an intermediate of
NADþ biosynthesis or is dependent on NRKs as a consequence of
extracellular metabolism to NR prior to cellular uptake and incorpo-
ration into the cellular NADþ pool [28]. Here we investigate NRK
expression in skeletal muscle and deﬁne the inﬂuence of NRKs on NR
and NMN metabolism to NADþ in loss-of-function muscle cells derived
from Nmrk1 and 2 knockout mice (NRK1KO, NRK2KO). We show that
the NRKs have overlapping and redundant activity in muscle cells
critical to the conversion of exogenous NR and NMN to NADþ.
2. MATERIALS AND METHODS
Unless otherwise speciﬁed all materials and reagents were acquired
from SigmaeAldrich, UK.
2.1. Animal care
Mice were group housed in a standard temperature (22 C) and
humidity-controlled environment with 12:12- hour light:dark cycle.
Nesting material was provided and mice had ad libitum access to water
and standard chow. Mice were sacriﬁced using schedule one cervical
dislocation and tissues were immediately. All experiments were in
groups of up to 6 and conducted within the UK Home ofﬁce regulations.
2.2. Generation of NRK loss of function mice
NRK2KO mice were acquired from the Jackson Laboratory. The Nmrk2
KO mutant allele was generated on a C57BL/6NTac background
through the Knockout Mouse Phenotyping Program (KOMP2). A ZEN-
UB1 Velocigene cassette (beta-galactosidase coding sequence from
E. coli lacZ gene; polyadenylation signal; loxP site; promoter from the
human ubiquitin C gene; neomycin phosphotransferase; poly-
adenylation signal; loxP site) was inserted through homologous
recombination into the gene in place of all coding exons inhibiting
transcription. Deletion of Nmrk2 was validated by qPCR and
immunoblotting.
NRK1KO mice generated on a C57BL/6NTac background have been
previously described [28].
2.3. Exercise and ﬁbre-typing
As a preliminary experiment, mice (n ¼ 3) were acclimatized to the
treadmill environment and exercised 3 times a week for 1 h at 0.25 M/
Sec, at a 10 incline for 6 weeks.
Muscle sections were ﬁber typed using immunoﬂuorescence following
an established protocol [29e31]. Brieﬂy, 10 mm sections were cut
using a cryostat and mounted onto slides. Primary antibodies detecting
different myosin heavy chain subunits (BA-F8 e MHC1 (1:50), BF-F3
e MHC IIb (1:100), SC-71 (1:600) e MHC IIa, 6H1 e MHC IIx
(1:50)) (Developmental Studies Hybridoma Bank, University of Iowa)
were added, followed by ﬂuorescent secondary antibodies (IgG AF
647e Blue (1:500), IgM AF 555 e Red (1:500), IgG AF 488 e Green
(1:500)). Sections were formalin ﬁxed and mounted and then analyzed
using a Zeiss Axio Observer inverted microscope (Carl Zeiss, Germany).
Fibers were manually counted across the entire section using Image J
(Fiji) software and recorded as positive for each ﬁber expressing the
relevant visible color.
2.4. RNA extraction and qPCR
RNA was extracted from tissue and cells using TRI-reagent (Invi-
trogen). RNA quality was determined by visualization on a 1.5%
agarose gel and quantiﬁed using a nanodrop. Reverse transcription
was conducted using 500 ng RNA that was incubated with 250 mM
random hexamers, 5.5 mM MgCl2, 500 mM dNTPs, 20 units RNase
inhibitor 63 units multiscribe reverse transcriptase, and 1 reaction
buffer. Reverse transcription was performed using a thermocycler set
at the following conditions: 25 C for 10 min and 37 C for 120 min
before the reaction was terminated by heating to 85 C for 5 min qPCR
was performed in a 384-well plate in single-plex format. Primers and
probes were purchased as Assay on Demand (FAM) products (Applied
Biosystems). Total reaction volumes used were 10 ml containing
Taqman Universal PCR mix (Applied Biosystems). All Ct values were
normalized to 18s rRNA (VIC) (Applied Biosystems). The real-time PCR
reaction was performed under the following protocol: 95 C for 10 min,
then 40 cycles of 95 C for 15 s, and 60 C for 1 min using an ABI7500
system. Data were collected as Ct values and used to obtain deltaCt
(dCt) values.
2.5. Western blotting
Protein lysates were extracted from tissues in RIPA buffer (50 mmol/l
Tris pH 7.4, 1% NP40, 0.25% sodium deoxycholate, 150 mmol/l NaCl,
1 mmol/l EDTA) and protease/phosphatase inhibitor cocktail (Roche,
Lewes, U.K.). Total protein concentration was quantiﬁed by Bio-Rad
assay. Total proteins (25 mg) were resolved on a 12% SDS-PAGE
gel and transferred onto a nitrocellulose membrane. Primary anti-
bodies speciﬁc for NRK1/2 were generated and afﬁnity puriﬁed by
BioGenes (GmbH) Berlin, Germany and used at a 1:2000 dilution.
Primary antibodies including NAMPT (Abcam, USA), b-Actin (Cell
Signaling, USA, #12262) and a-Tubulin (Santa Cruz, USA, SC-5286)
were all commercially available and used at a 1:1000 dilution.
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Secondary anti-mouse and anti-rabbit antibodies conjugated with HRP
(Dako, Denmark) were added at a dilution of 1/10,000. Equal loading of
protein content was veriﬁed using beta-actin and alpha-tubulin and
bands visualized using ECL detection system (GE Healthcare, UK).
2.6. Preparation of tissue fractions
Muscle tissue was homogenized in sucrose buffer (0.25 M sucrose,
20 mM HEPES) and centrifuged at 1000 g for 10 min at 4 C. The
supernatant was transferred to a new tube and centrifuged at 12,000 g
for 10 min at 4 C. The mitochondrial fraction was pelleted and re-
suspended in sucrose buffer and the supernatant was transferred to
ultracentrifuge tubes and, following careful balancing, centrifuged at
100,000 g for 1 h at 4 C. The supernatant containing the cytosolic
fraction was transferred to a new tube and the pellet was re-suspended
in MOPs buffer (100 mM KCl, 20 mM NaCl, 1 mMMgCl2, 20 mMMOPs)
and washed 3 times by pelleting at 100,000 g. The microsomal pellet
was re-suspended in MOPs buffer and snap frozen.
2.7. Primary muscle culture
Gastrocnemius tissue was excised from hind limbs of mice and
digested in DMEM with 0.2% collagenase at 37 C for 2 h. Digested
tissue was washed in DMEM, and media was expelled vigorously onto
the muscle to allow single myoﬁbers to detach. Myoﬁbers were then
placed in pre-set matrigel (BD biosciences) coated wells in DMEM
supplemented with 30% (v/v) FCS, 10% (v/v) HS, 1% (v/v) P/S, 2 mM L-
glutamine, 1% (v/v) chick embryo extract (CEE) (Seralab, UK), and
0.1% of ﬁbroblast growth factor (FGF) (Peprotech). Following satellite
cell migration, media was replaced with proliferation media (DMEM
with 10% (v/v) HS, 1% (v/v) P/S and 0.5% (v/v) CEE). Upon 70e80%
conﬂuence, media was replaced with Differentiation media (DMEM
supplemented with 2% (v/v) HS, 0.5% (v/v) CE,E and 1% (v/v) P/S) and
cells were differentiated for 6 days.
2.8. Cell treatments
Cells were treated in serum free media with 1 mM FK866 or DMSO as a
vehicle control for 24, 48 or 72 h. Cells were supplemented with
0.5 mM NR (ChromaDex, USA), 0.5 mM NAR, 0.5 or 5 mM NAM and
0.5 mM NMN for 24 h. A concentration of 0.5 mM for cell treatments
was used to provide a maximal effect on cellular NADþ content
following preliminary dose response experiments and previously
published work in myotubes [22].
2.9. NADþ measurements
2.9.1. NADþ by cycling assay
NADþ was extracted from primary myotubes and quantiﬁed using
EnzyChrom NAD/NADH Assay kit (BioAssay Systems) according to the
manufacturer’s instructions.
2.9.2. NADþ by HPLC
Total NAD was measured by reversed-phase HPLC using the Chro-
master Purospher STAR RP-18 endcapped 3 mm Hibar RT 150-3 HPLC
column (Merck). Frozen mouse muscle tissue (10 mg) was lysed in
100 ml 1 M perchloric acid. Samples were incubated on ice samples
for 10 min, centrifuged and the supernatant was neutralized with 3 M
potassium carbonate. After repeated centrifugation, samples were
analyzed as previously described [32].
2.10. Targeted NADþ metabolomics
20 mg of pulverised tissue samples were placed in Eppendorf tubes on
dry ice. Metabolites were extracted in 0.2 ml of ice cold LCMS grade
methanol and kept on ice before adding 300 ml of internal standard
(diluted 1:300 in LC-MS grade water). Samples were brieﬂy sonicated
in an acetone water bath (at 4 C), returned to ice, and then incu-
bated at 85 C for 5 min, shaking at 1050 rpm. Samples were cooled
on ice for 5 min and centrifuged. Supernatant was dried using a speed
vacuum. The dried extract was resuspended in 40 ml of either LC-MS
grade water for acid extract or 10 mM ammonium acetate for alkaline
extract and transferred to a Waters Polypropylene 0.3 ml plastic screw-
top vial and analyzed by LC-MS/MS [33] using the ACQUITY UPLC H-
class system.
2.11. Respirometry
C2C12 cells were differentiated into fully fused myotubes for 5 days.
Respiratory output and mitochondrial stress tests were performed with
C2C12 myotubes in XF-Assay media (Agilent Technologies) supple-
mented with 25 mM glucose, 0.5 mM sodium pyruvate, pH 7.4,
maintained for 1 h at 37 C in 0% CO2 prior to Seahorse extracellular
ﬂux analysis. Extracellular ﬂux analysis was performed using the
Seahorse XF analyser following manufacturer’s instructions (Agilent
Technologies).
2.12. Cell viability and apoptosis
C2C12 cells were seeded in a 96 well plate and differentiated for 5
days. Cell viability and apoptosis were assessed using the ApoLive-
Glo multiplex assay (Promega) according to the manufacturer’s
instructions.
2.13. Statistical analysis
Unpaired Students t-test or ANOVA statistical comparisons were made
using GraphPad Software Inc. Prism version 6. Data are presented as
mean SEM with statistical signiﬁcance determined as *¼ P< 0.05,
** ¼ P < 0.01, *** ¼ P < 0.001. Statistical analysis of real-time PCR
data was determined using dCt values.
3. RESULTS
3.1. NRK2 expression exhibits highly conserved skeletal muscle
speciﬁcity
NAMPT and NADsyn1 act as rate limiting enzymes in the best char-
acterized mammalian NADþ biosynthesis pathways, with NADsyn1 the
common ﬁnal step in de novo synthesis and Preiss-Handler salvage
pathways (Figure 1A) [34]. NRK 1 and 2 were more recently identiﬁed
as NADþ salvage enzymes involved in a novel NR dependent route to
NADþ [12] (Figure 1A). To better understand the roles the NRKs play in
the context of the rate limiting enzymes NAMPT and NADsyn1, we
examined their expression in a range of tissues to determine tissue
speciﬁcity.
Using real-time PCR we show that Nmrk1 is ubiquitously expressed,
with particularly high expression in kidney, while Nmrk2 exhibits high
speciﬁcity to skeletal muscle (Figure 1B,C). Nampt is ubiquitously
expressed across different tissue types as previously described
(Figure 1D) [35], and NADsyn1 shows greatest expression in liver and
kidney tissue, consistent with previous data (Figure 1E) [36]. Nmnat1,
common to all NADþ biosynthetic pathways for conversion of NMN to
NADþ, is ubiquitously expressed (Figure 1F). We went on to endorse
these ﬁndings using Western blot analysis. While low levels of NRK1 are
detectable in muscle, it was prominently detected in whole kidney and
liver lysates (Figure 1G). For NRK2 we conﬁrmed its muscle speciﬁcity.
We also conﬁrmed the ubiquitous expression of NAMPT (Figure 1G).
Using previously generated microarray data for soleus and tibialis
anterior (TA) skeletal muscle [37], we further evaluated the relative
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Figure 1: NADD biosynthesis pathways in skeletal muscle. (A) An illustration of the known NADþ biosynthesis pathways identiﬁed in mammalian cells with exogenous
precursor supplementation strategies illustrated with dashed lines. NADþ can be synthesized de novo from tryptophan (Trp) and following multiple enzymatic reactions is converted
to nicotinic acid mononucleotide (NaMN) and then nicotinic acid dinucleotide (NaAD) by nicotinamide mononucleotide adenylyltransferase (NMNAT) activity, before the ﬁnal
conversion to NADþ by NAD synthase (NADSYN). NADþ can be salvaged from precursors nicotinic acid riboside (NaR) and nicotinic acid (NA) by nicotinamide riboside kinases
(NRK1/2) and nicotinic acid phosphoribosyltransferase (NAPRT) respectively to NaMN and follow the same ﬁnal steps. Finally, nicotinamide riboside (NR) and nicotinamide (NAM)
are salvaged by NRKs and nicotinamide phosphoribosyltransferase (NAMPT) respectively to nicotinamide mononucleotide (NMN) and ﬁnally to NADþ by NMNAT activity. Real-time
PCR mRNA expression of Nmrk1 (B), Nmrk2 (C), Nampt (D), Nadsyn1 (E), and Nmnat1 (F) across metabolic tissues. (G) Protein expression of NRK1, NRK2, and NAMPT across
metabolic tissues with corresponding densitometry compared to housekeeping protein (a-Tubulin for all tissues except liver and Wat which are compared to b-actin expression).
(H) Microarray of NADþ biosynthesis genes in tibialis anterior (TA) and soleus (Sol) skeletal muscle tissue (n ¼ 3). Real-time PCR mRNA expression of rate limiting NAD
biosynthesis genes in TA (I) and soleus (J) muscle (n ¼ 4). (K) NRK2 protein expression in TA and soleus muscle tissue. (L) NRK1, NRK2, and NAMPT protein expression in
cytosolic, mitochondrial and microsomal fractions of skeletal muscle. (Q ¼ quadriceps, TA ¼ tibialis anterior, Sol ¼ soleus, Liv ¼ liver, Hrt ¼ heart, Dia ¼ diaphragm,
Kid ¼ kidney, Brn ¼ brain and Wat ¼ white adipose tissue).
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expression of NADþ biosynthesis and salvage genes. We identiﬁed
Nmrk2, Nampt, and Nmnat1 as the most abundantly expressed genes
in soleus and TA muscle (Figure 1H). We used real-time PCR to conﬁrm
these ﬁndings and show that Nmrk2 is the most predominantly
expressed NADþ biosynthesis gene in fast twitch tibialis anterior
muscle compared to slow twitch ﬁbre rich soleus muscle (Figure 1I,J).
Western blots of soleus and tibialis anterior muscle lysates corrobo-
rated with the mRNA expression analysis, suggesting some muscle
beds are enriched with NRK2 (Figure 1K). Finally, we addressed
subcellular localization of the NRKs and NAMPT. Following fraction-
ation of skeletal muscle tissue enriched into microsomes, cytosol, and
mitochondria we show that NRK2, NRK1, and NAMPT are predomi-
nantly localized to cytosol (Figure 1L).
Although the role of NAMPT-mediated NADþ biosynthesis has been
characterized in skeletal muscle [38,39], the function of NRK1 and
NRK2 in particular, given its muscle restricted expression, and their
relative contribution to NADþ biosynthesis and homeostasis remained
ill deﬁned.
To further examine the speciﬁc roles of the NRKs, we investigated
mRNA and protein expression during C2C12 and primary muscle
myotube differentiation. In C2C12 cultures, NRK1 demonstrated low
level expression with respect to NRK2, rising to maximal expression
at day 8 (Figure 2A,D). In contrast, NRK2 expression was upregulated
during differentiation, peaking at day 4 around the time of myotube
fusion (Figure 2B,D). NAMPT expression remained constant
throughout differentiation (Figure 2C,D). We expanded this analysis to
examine primary cultures of muscle cells derived from hind limbs of
WT mice as a more physiologically relevant scenario. We used
Myogenin (MyoG), Myogenic differentiation 1 (MyoD), and a-actin 1
(ACTA1) as markers of differentiation in our primary system, with all
genes displaying anticipated proﬁles of expression for normal muscle
cell differentiation (Sup. 1A). Nmrk1, Nmrk2, and Nampt showed
similar patterns of differentiation as seen in C2C12s (Figure 2AeC).
In addition, we showed that Nmnat1 is constitutively expressed
during primary myotube differentiation (Sup. 1A). These data support
the notion of a highly conserved and speciﬁc function for NRK2 in
skeletal muscle.
3.2. NADþ turnover in skeletal muscle is predominantly regulated
by NAMPT salvage of NAM, yet NR proves a more valuable precursor
for augmenting NADþ
As the NA Preiss-Handler pathway is mostly restricted to liver NADþ
biosynthesis and NA treatment is limited due to adverse effects, we
aimed to establish the NADþ precursors and the pathways that could
be used to enhance NADþ content in skeletal muscle [15,34]. Meta-
bolic enzyme activity proﬁling data suggest that the amidated routes to
NADþ, mediated by the NAMPT and NRK salvage pathways, prevail as
the main biosynthetic routes to NADþ in muscle, which is corroborated
by our tissue expression data and molecular analysis [34].
To further assess this, we supplemented primary-derived myotubes
with NADþ precursors that could be utilized by NRK or NAMPT path-
ways; NAR (non-amidated version of NR), NR, NMN, and NAM
(Figure 1A) and quantiﬁed NADþ using a cycling assay. NAR, like NR, is
metabolized by NRKs to NAMN and then to NAAD by NMNATs [40].
However, NAAD requires ﬁnal amidation to NADþ via NAD synthetase
[41]. We found that NAR was unable to augment the NADþ pool in
muscle cells, whereas both NR and NMN supplementation signiﬁcantly
increased NADþ in myotubes by almost 2-fold. However equivalent
concentrations of NAM did not signiﬁcantly enhance NADþ, with 10-
fold excess NAM required to increase NADþ (Figure 3A). NAMPT is
considered the rate limiting step for NADþ salvage and synthesis in
skeletal muscle [38] but has not been explored in detail in the context
of NRKs. We examined precursor salvage and NADþ levels in myo-
tubes treated with the potent NAMPT inhibitor FK866 [42]. NAMPT is
indeed essential for basal NADþ homeostasis with NADþ levels
severely depleted (by more than 70%) following 24 h of inhibition. This
depletion was completely reversed by NR and NMN supplementation,
and both precursors were still able to boost NADþ to the same extent
as without FK866 treatment conﬁrming that NR and NMN salvage is
independent of NAMPT (Figure 3B).
To gain further insight into the activity of NR, we used LC-MS-based
targeted quantitative metabolomics. Table 1 shows levels of key
NADþ metabolites in primary myotubes treated with FK866 and NR. As
expected, NAD(H) levels signiﬁcantly increase following NR supple-
mentation, and, importantly, here we identify a large increase in cellular
NR and NMN from control cells 24 h following cell treatments. Inter-
estingly, metabolites of NADþ consumption, NAM and ADP ribose
(ADPr), were not altered by NR treatment but levels were reduced
following FK866-induced NADþ depletion, suggesting NADþ availability
is only rate limiting to NADþ signaling below normal levels (Table 1). NA
and other metabolites from the Preiss-Handler and de novo NADþ
biosynthesis pathways were undetected in primary myotubes.
NADþ is vital to mitochondrial respiration so we demonstrated the
importance of NAMPT for maintaining NADþ turnover by treating
C2C12 myotubes with FK866 for 72 h. Inhibition of NAMPT signiﬁcantly
reduced basal and maximal respiration, which was fully rescued by
treatment with NR for the ﬁnal 24 h (Figure 3C). NR alone did not
enhance mitochondrial respiration above untreated levels (Figure 3C).
Concordantly, apoptosis was stimulated in C2C12 myotubes after 48e
72 h of NAMPT inhibition. NR supplementation completely prevented
this effect (Sup. 1B).
Changes in NADþ availability and muscle cell energetics as a result of
NAMPT inhibition are known to stimulate elevated rates of NAMPT
gene transcription through AMPK activity; however, the effects on
NRKs in this context are unknown [43,44]. Using real-time PCR, we
show that cellular mRNA expression of NADþ salvage genes is tightly
regulated by NADþ availability. NADþ depletion by FK866 resulted in
upregulation of Nmrk2 and Nampt and downregulation of Nmrk1
(Figure 3D). Repletion of NADþ by NR supplementation returned mRNA
levels of all genes back to that of untreated control and NR treated cells
(Figure 3D).
These data demonstrate that NAMPT is crucial for basal NADþ
biosynthesis. NR supplementation can completely rescue NAMPT in-
hibition through NRK-mediated NADþ salvage. These data suggest that
NRK activity is independently capable of maintaining cellular NADþ and
that NR availability may restrict NRK activity under basal conditions.
3.3. Loss of NRK2 function does not impair skeletal muscle mass
or ﬁber type distribution in young mice
To further elucidate the roles of the NRKs in skeletal muscle NADþ
salvage, we focused on the muscle-speciﬁc importance of NRK2 and
have generated a model with constitutive ablation of the Nmrk2 gene
(NRK2KO). NRK2KOmice were born at anticipated Mendelian ratios and
displayed no gross abnormalities. No Nmrk2 mRNA or protein could be
detected in any NRK2KO tissue examined, which included a range of
skeletal and cardiac tissues (Figure 4AeB). 12e14 week old male and
female mice were equivalent to WT control mice in terms of total body
weight and lean mass for a range of muscle beds (Figure 4CeD). To
induce metabolic stress and examine a role for NRK2 in skeletal muscle
metabolic adaption, mice were subjected to an endurance exercise
protocol. Again, total body weight and lean mass for a range of muscle
beds were unchanged in NRK2KO mice (Figure 4EeF). Assessment of
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Figure 2: Patterns of NADD biosynthesis gene expression during skeletal muscle differentiation and muscle development. 8 day differentiation time course of Nmrk1 (A),
Nmrk2 (B), and Nampt (C) mRNA expression in C2C12 and primary myotubes (n ¼ 3e4). 8-day C2C12 myotube differentiation time course of NADþ biosynthesis enzyme protein
expression (D).
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muscle ﬁber cross-sectional area showed no signiﬁcant differences in
proportions of ﬁbre size in NRK2KO quadriceps compared to WT
(Figure 4G). Similarly, muscle ﬁber type distribution assessed for
myosin heavy chains (MHC) MHC1, MHC2a, MH2b, and MHCX in slow
twitch rich soleus, and fast twitch rich TA muscle were normal and at
expected proportions (Figure 4HeI).
3.4. NRK2 deﬁciency minimally impacts the skeletal muscle NADþ
metabolome
Recent evidence has shown that NR can elevate muscle NADþ when
administered to mice or cultured cells [22]. To ascertain the effect of
NRK2 deﬁciency on muscle levels of NADþ and related metabolites we
used LC-MS-based targeted quantitative NADþ metabolomics [33].
This method allows quantiﬁcation of NADþ as well as associated
metabolites to determine the wider effect loss of NRK2 has on NADþ
metabolism. Surprisingly, NADþ levels in quadriceps tissue from
NRK2KO mice were shown not to be deﬁcient compared to WT control
tissue (Figure 5A). The NADþ precursors NR and NAM were un-
changed, but a signiﬁcant increase in NMN was detected (Figure 5C).
Furthermore, no differences in NADP, ATP, ADP, or the NADþ
consumption product ADPr were detected (Figure 5A). To conﬁrm the
NADþ data generated by LC-MS, NADþ levels were independently
measured using a colorimetric cycling assay and by HPLC [32], which
Figure 3: Precursor availability and skeletal muscle NADD biosynthesis. (A) Primary myotube NADþ levels following 24 h 0.5 mM NADþ precursor supplementation (n ¼ 4)
determined using an NADþ cycling assay. (B) Primary myotube NADþ content following 24 h 0.5 mM NAD precursor supplementation with or without FK866 inhibition of NAMPT
(* ¼ signiﬁcant from DMSO control and # ¼ signiﬁcant from FK866 treated control) (n ¼ 4) determined using the NADþ cycling assay. (C) Basal and maximal mitochondrial
respiration following 24 h NR supplementation with or without FK866 inhibition (n ¼ 3). (D) Transcriptional regulation of NADþ biosynthesis genes, Nmrk1, Nmrk2, and Nampt
following 24 h NR supplementation with or without FK866 inhibition of NAMPT (n ¼ 3).
Table 1e Targeted LC-MS NADþmetabolome of primary myotubes treated
with NR (0.5 mM) and/or FK866 (100 nM).
Metabolites
(pmol/mg)
Control NR FK866 FK866 þ NR
NAD(H) 790.2  54.3 1968.1  518.1*y 253.8  25.7 1564.4  207.6y
NADP(H) 90.5  3.1 186.4  62.1 55.1  23.5 98.4  20.1
NR 4.9  0.6 73.6  9.5*y 9.9  2.0 112.1  11.2*y
NAM 834.2  29.8 1064.2  172.4y 354.1  43.3* 973.1  75.8y
ADPr 535.3  198.4 400.2  54.1 326.6  86 537.5  104.3
NMN ND 107.9  26.5*y 3.8  0.7 79.6  12.1*y
Na ND ND ND ND
NaR ND 1.7  0.2*y 0.1  0.1 1.9  0.2*y
NaAD ND 14.9  5.6*y ND 8.4  2
NaMN ND ND ND ND
*Signiﬁcant to control, ysigniﬁcant to FK866 treated, n ¼ 3.
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conﬁrmed that there were no signiﬁcant alterations to tissue NADþ and
NADH levels (Sup. 1CeD).
Finally, we examined the expression of key NADþ salvage and
biosynthetic genes in response to loss of Nmrk2. We did not detect any
adaptive changes in Nmrk1 or Nampt but did detect increased
expression of Pnp (2-fold) and CD157 (4-fold) (Figure 5B). Purine
Nucleoside Phosphorylase (PNP) is involved in purine metabolism and
has activity to convert NR to NAM [45]. CD157 has NADþ nucleotidase
activity liberating cADP-ribose and NAM [46]. These adaptive re-
sponses in gene expression, to compensate for loss of NRK2 in living
mice, may have more long-term consequences for NADþ salvage and
require further assessment.
Figure 4: Validation and characterization of NRK2KO mice. (A) mRNA expression of Nmrk2 in WT and NRK2KO quadriceps muscle, heart, and liver tissue. (B) Protein
expression of NRK2 across metabolic tissues from WT and NRK2KO mice. (C) Whole body weight of 12 week old WT and NRK2KO mice. (D) Tissue weight of skeletal and cardiac
muscle from 12 week old WT and NRK2KO mice. (E) Whole body weight of WT and NRK2KO mice following 6 weeks of endurance exercise training. (F) Tissue weight of skeletal
and cardiac muscle from WT and NRK2KO mice following 6 weeks of endurance exercise training. (G) Muscle ﬁber cross-sectional area as a proportion of all ﬁbers in WT and
NRK2KO quadriceps. Fiber-type composition of TA (H) and soleus (I) skeletal muscle from WT and NRK2KO mice following 6 weeks of endurance exercise training. (All data
n ¼ 3e6).
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3.5. NRKs are essential for exogenous NR and NMN utilization to
NADþ in cultured muscle cells
To better understand the interactions and contributions of muscle NRK
1, NRK2, and NAMPT to NR and NMN precursor salvage we employed
a primary muscle culture system to derive myotubes with combina-
torial single, double, and triple NRK1/2 and NAMPT loss of function.
These experiments were conducted using NRK1 and 2KO mice as
reported by Ratajczak et al. [28]. Firstly, due to the highly muscle-
speciﬁc nature of NRK2, we assessed expression of key muscle dif-
ferentiation markers and NADþ signaling genes over myotube differ-
entiation in all the NRKKO models and found that expression was not
altered, conﬁrming that the NRKs are not essential for myotube dif-
ferentiation (Sup. 2A,B).
Basal NADþ levels in NRK single or double KO (DKO) cells were
comparable to those of WT cells (Sup. 2C). Similarly, but to a lesser
extent than in the WT myotubes, single NRK1KO and NRK2KO myo-
tubes were still able to enhance NADþ levels following NR supple-
mentation, more so in NRK2KO cells compared to NRK1KO cells
(43.25% increase in NADþ versus 23.5%), suggesting functional
redundancy of the NRKs to generate NADþ from available NR.
However, NR was unable to increase NADþ in double KO cells with less
than a 1% change from untreated (Figure 6AeC, left).
In hepatocytes, extracellular NMN is converted to NR extracellularly
such that both NR and NMN require NRK1 activity to convert these
compounds to intracellular NMN and NADþ [28]. In unstressed
NADþ replete cells NMN supplementation could not augment NADþ
levels in NRK1KO, and to a lesser degree NRK2KO, such that
double KO cells are effectively unresponsive to NMN (Figure 6AeC,
left).
We then examined the ability of NR and NMN to rescue cells depleted
of NADþ following 24 h NAMPT inhibition (Figure 6AeC, right). NAMPT
inhibition substantially depleted cellular NADþ content in WT and all
the NRK loss of function cell cultures (Figure 6AeC, right). NR and
NMN were able to recover, but not boost, NADþ levels following FK866
inhibition in NRK2KO and, to a lesser extent, NRK1KO myotubes.
However, neither NR nor NMN supplementation was able to recover
NADþ depletion in DKO myotubes, again clearly indicating the NRK
dependency of NMN conversion to NADþ (Figure 6AeC, right). In all
instances, 10-fold excess NAM (5 mM) is required to overcome NAMPT
inhibition (Sup. 2D).
Figure 5: NADD availability and signaling in NRK2KO mice. (A) LCMS-based targeted NADþ metabolomics to quantify NADþ and related metabolite levels in WT and NRK2KO
skeletal muscle tissue (n ¼ 6). (B) Fold change in mRNA expression of NADþ related signaling genes in NRK2KO skeletal muscle compared to WT (at Y axis ¼ 1) (n ¼ 4).
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These data show that while NAMPT is the primary pathway for
maintaining NADþ turnover in skeletal muscle, the NRKs are essential
for utilizing exogenous NR and NMN to enhance cellular NADþ.
4. DISCUSSION
Mounting evidence supports the notion that enhancing tissue NADþ
availability has beneﬁcial effects on metabolic health in the context of
metabolic disease and physiological decline [22,23,47e49]. The
leading method to accomplish NADþ augmentation is through dietary
supplementation with NR and NMN. Although they have a similar ca-
pacity to raise NADþ and promote metabolic beneﬁt, the tissue-
speciﬁc routes of their metabolism remain obscure. Skeletal muscle
exhibits a decline in NADþ in a number of physiological, metabolic, and
genetic scenarios, all associated with defects in muscle physiology and
mitochondrial function [7,50,51]. Here we have explored NADþ
Figure 6: Manipulations to skeletal muscle NADD biosynthesis pathways. (A) NRK1KO, (B) NRK2KO, and (C) NRK double KO (DKO) primary myotubes supplemented with
0.5 mM NADþ precursors for 24 h (left) and corresponding primary myotubes supplemented with 0.5 mM NADþ precursors for 24 h following 1 mM FK866 mediated NAMPT
inhibition (right). For clarity, all data is presented as percent change in NADþ compared to DMSO only control (100%) (all groups n ¼ 4 and signiﬁcance determined between WT
and corresponding KO from actual NADþ content by two-way ANOVA using Bonferroni’s post-test).
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salvage and biosynthesis in skeletal muscle and identiﬁed NRKs as
critical to the availability of both NR and NMN to NADþ in skeletal
muscle cells.
NADþ biosynthesis in skeletal muscle appears restricted to two main
salvage pathways involving the rate-limiting enzymes NAMPT, NRKs,
and NMNAT. While basal NAMPT and, to a degree, NRK1 display
ubiquitous expression, NRK2 displays a muscle restricted pattern at
mRNA and protein level. De novo NADþ biosynthesis and the Preiss-
Handler NA salvage pathway play a minimal role in skeletal muscle
with limited or undetectable levels of expression of rate limiting
enzymes and metabolites. This supports previous metabolic enzyme
activity proﬁling data that found enzyme activity of NAD synthase e
the ﬁnal rate limiting enzyme for both de novo biosynthesis and NA
salvage e to be undetectable in skeletal muscle [34]. We endorse
this by showing that unlike NR, the acid version NaR, which is
metabolized by the NRKs and NMNATs e but also requires NAD
synthase activity for ﬁnal conversion to NADþ [40,41] e does not
appear able to act as an exogenous NADþ precursor in skeletal
muscle.
Depletion of NAMPT activity in muscle leads to a severe reduction
(85%) in muscle NADþ availability; yet, at least for young mice, no
gross NADþ relatable phenotype was observed [38]. However, with
advancing age (7 months), this chronic reduction in NADþ manifests
with impaired mitochondrial function, loss of muscle ﬁber integrity,
strength, and performance [38]. Although NAMPT is critical to basal
NADþ biosynthesis, exogenous NAM appears to be a poor precursor
for NADþ boosting in muscle compared to NR and NMN due to poor
conversion to NADþ and its inhibitory activity towards sirtuins [52]. We
found that NR supplementation could signiﬁcantly boost NADþ in the
context of reduced NADþ levels following NAMPT inhibition and rescue
concurrent defects in mitochondrial energy metabolism. Despite NR
rescuing NADþ depletion and some of the effects of metabolic chal-
lenge in vivo [22], our data suggest that increasing NADþ availability in
skeletal muscle by NR supplementation does not enhance oxidative
metabolism of ‘healthy’ NADþ replete muscle cells. Muscle-speciﬁc
NAMPT overexpressing mice showed that a 50% increase in NADþ
could not stimulate mitochondrial biogenesis or enhance mitochondrial
metabolism in young skeletal muscle [53]. Our results show that when
NADþ is enhanced through NR supplementation, NAM and ADPr levels
are unchanged, whereas there is a decrease following NADþ depletion
(Table 1). As NAM and ADPr are metabolites of NADþ signaling
(products of SIRT based NADþ consumption) [54], this indicates that
although a reduction of NADþ can limit NADþ signaling and ultimately
hinder mitochondrial metabolism, basal NADþ content alone is not
limiting to NADþ signaling, at least in healthy skeletal muscle.
Though NRK2 appears to be restricted to muscle, loss-of-function had
no effect on basic parameters of muscle physiology, perhaps reﬂecting
the unstressed nature of young muscle in this study, and in line with
the work of Frederick et al. [38]. Again, this also suggests that NAMPT
is more than sufﬁcient to match NADþ recycling to its metabolic
clearance. Measuring the quadriceps tissue NADþ related metabolome
was unremarkable other than for a 50% increase in NMN. Similarly,
NAMPT and NRK1 were unaffected at the level of gene expression and
may suggest that no overt stress response was initiated. However, we
did note elevation in the expression of Pnp and CD157. PNP can
convert NR to NAM and CD157 converts extracellular NADþ to ADPr
and NAM [45,46]. While this does not manifest as raised NAM level in
muscle, it may reﬂect raised NMN that serves to balance NADþ
availability suggesting a minor adaptation to the loss of NRK2.
We originally postulated that NRK2 would be more important than
NRK1 in skeletal muscle for NR salvage due to its predominant
expression. However, our in vivo data and work by Ratajczak et al.
showing that NRK1 controls NR and NMN metabolism in mammalian
cells [28] led us to examine more closely the dependency of NR and
NMN on each NRK. Using combinatorial muscle cultures of single and
double NRK1/2 KO cells we conﬁrmed that NR is exclusively metab-
olized by the NRK enzymes in skeletal muscle with no change to
cellular NADþ levels in DKO primary myotubes following NR supple-
mentation, which was strikingly evident in NADþ depleted cells. Both
NRK1 and NRK2 single KO cells demonstrate a level of redundancy in
their ability to respond to NR, though clearly being submaximal
compared to control cells.
NMN is metabolized to NADþ downstream of NRKs and NAMPT, yet
exogenous NMN supplementation was unable to be metabolized to
NADþ in DKO cells, again most strikingly in the context of severe NADþ
depletion. While there is a level of redundancy in the single KO cells,
the data implicate NRK1 as being more critical for regulating NMN
entry into the cell. Recent ﬁndings by Ratajczak et al. have shown that
NRK1 regulates exogenous NMN salvage in liver tissue and cells. They
identiﬁed a requirement for NMN to be metabolized extracellularly to
NR before hepatic uptake, then re-phosphorylated by NRK1 back to
NMN [28]. Similar data also have highlighted that human cells can
metabolize NMN to NR intracellularly utilizing cytosolic 50-nucleotid-
ases [40]. The data presented here in primary WT and loss-of-function
myotubes corroborate these ﬁndings and reveal the NRKs critical role
for both NR and NMN conversion to NADþ.
Positive health effects of enhancing NADþ availability have been
demonstrated in muscle [55]. Acipimox (NA analogue) treatment
improved aspects of mitochondrial physiology in type 2 diabetic
muscle. However, the effects on NADþ availability were small and the
mechanisms unclear, and the therapeutic potential of acipimox limited
due to a range of adverse effects including insulin resistance and
GPR109A receptor activation leading to ﬂushing and therefore poor
compliance [15]. The inhibition of PARPs, sparing and elevating NADþ,
leading to enhanced mitochondrial function and biogenesis through
activation of SIRT1-PGC-1a axis has been demonstrated as being
effective in muscle [56e58].
However, supplementation with NR and NMN to boost cellular NADþ
pools in a range of scenarios appears to be the most promising
strategy [19,20,22,48,51,59e63]. NR and NMN based NADþ repletion
in skeletal muscle can revitalize stem cells and augment physiological
and mitochondrial function in aged mice [49]. Furthermore, NADþ can
also act to regulate proteineprotein interactions that inﬂuence DNA
repair through control of PARP activity, and NMN or NR repletion of
NADþ in ageing could support efﬁcient DNA repair capacity while
maintaining the positive effects of sirtuin activation [64].
While NR is naturally available in the human diet, with appreciable
levels measured in milk, the main source of NR, NMN, NAM, and NA is
the NAD(P) (H) pool available through the digestion of whole, unpro-
cessed food [27]. Oral NR administration to humans has recently
demonstrated effectiveness in boosting circulating and white blood cell
NADþ levels, with further work required to determine the importance
for muscle NADþ repletion [26].
These data establish that muscle has a level of redundancy in its ability
to metabolize NR and therefore NMN. Despite NRK2 being restricted to
muscle and being highly expressed, basal NADþ turnover does not
seemingly require NRK activity. However, NRK1 and to a smaller de-
gree NRK2 are gate-keepers of NR and NMN salvage. Importantly,
NADþ depletion and energetic stress can lead to augmented NRK2
expression in a range of tissues such as neurons, cardiac, and skeletal
muscle [65e67]. Thus, beyond basal NADþ turnover, regulated NRK2
activity may serve an additional role in cellular metabolism involving
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Original ArticleNR phosphorylation, potentially more critical to stress adaptation when
there is need to enhance NR/NMN metabolism to defend metabolic
integrity.
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